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Abstract 
Objective: Expanding the original scope of the study, which was to explore the decision-making 
process of pregnant women in the uptake of invasive diagnostic tests - amniocentesis and 
Chorionic Villus Sampling (CVS) – and taking into account the latest emergence of a Non-
invasive Prenatal Testing, NIPT, the primary goal of this study was to explore factors that 
influence women’s decision to have an invasive, a non-invasive or no further testing at all.  
Design and sample: The Prenatal Decision Making Questionnaire (PDMQ) developed for the 
purposes of this study. Following a pilot test and factor analysis, it was distributed to a 
population of pregnant women (N=421) prior to them receiving their combined screening 
results. The total sample was divided into three sub-groups according to their risk status (low-
intermediate-high) for the analysis. 
Results. Logistic regression analysis using the R version 3.0.3 revealed that none of the PDMQ 
factors had a significant impact on women’s decision to have an invasive test (CVS), whereas 
the following three factors had a significant impact on the decision to have a non-invasive test 
(NIPT): negative attitude to doctors and an internal locus of control were associated with the 
uptake of NIPT, whereas a negative attitude to medicine was associated with rejection of  NIPT 
When risk status was included in the model it was found that uptake of NIPT was predicted by 
the presence of some level of risk for T21 or T13/T18. On the contrary, uptake of CVS was only 
predicted by an increased risk for T21.  
Conclusion(s): Women’s decision making process in prenatal diagnosis is affected by several 
factors with personalised risk being one of the key determinants. The findings of this study can 
be used by healthcare professionals in providing the appropriate support and information and 
facilitating an informed decision during this stage of pregnancy.  
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1. Chapter One: Literature Review  
1.1. Prenatal diagnosis in the UK 
An estimated 7.9 million infants are born each year across the world with a serious birth defect 
which is defined as “an abnormality of structure or function, which is present from birth and is 
life-threatening or has potential to result in disability” (WHO, 2006, p.1). Even though birth 
defects are a global issue, they are particularly severe in middle- and low-income countries 
where 95% of such births occur. More specifically, approximately 3.3 million children under the 
age of five die from serious genetic birth defects each year, and an equivalent number of those 
who survive may experience lifelong mental, physical, auditory and visual disabilities, causing a 
harsh human and economic toll on those affected, their families, and their communities 
(Howson & Modell, 2008). 
However, it is estimated that medical genetic services may contribute to as many as 70% of 
birth defects being prevented or treated effectively (Christianson, Howson, & Modell, 2006). 
Nevertheless, even though care can be cost-effective for some conditions such as certain 
cardiac defects and cleft lip and palate which can be diagnosed and surgically treated, they can 
also prove to be very expensive, especially for disorders that require long-term treatment such 
as the treatment of thalassaemia. For such cases, and for countries where needs and resources 
allow, it is important to emphasise on a combination of care and prevention which includes 
genetic counselling, prenatal diagnosis and the establishment of services for risk identification 
and management (Weatherall, Akinyanju, Fucharoen, Olivieri & Musgrove, 2006). This mostly 
relates to prevention strategies that can be adopted for high risk populations during family 
planning. For example, in the case of populations at high risk for thalassemia both parents can 
be genetically screened before conception to identify whether they are carriers of the gene and 
if so proceed with a pre-implantation genetic diagnosis (PGT) whereby the embryos created in 
vitro are screened for the respective condition and only those free of it are replaced into the 
womb via the method of IVF (Sermon, Van Steirteghem, & Liebaers, 2004). This would ensure 
a normal pregnancy and a healthy baby being born. It is also likely that some individuals in this 
category will still prefer to fall naturally pregnant regardless of the high risk of passing on the 
condition to the foetus. Relevant support and resources should be made available in order to 
support these families throughout their pregnancy and after the delivery of their baby. 
What is more, as a result of the social, psychological and economic consequences of caring for 
children with chromosomal or other birth defects, most pregnant women who have given birth to 
at least one child with such defects would like to receive reassurance about their unborn 
foetus’s health (Alfirevic & Walkinshaw, 2010). Access, therefore, to safe, accurate and 
affordable preventive (screening) and diagnostic methods early on in pregnancy, which provide 
the option of terminating an affected pregnancy or preparing for the birth of a child with health 
problems, is of paramount importance. 
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1.2. Current clinical practice in the UK and latest medical advancements 
At this point it is important to differentiate between prenatal diagnosis and routine antenatal 
screening. The National Institute for Health and Clinical Excellence (NICE, 2008), the UK 
National Screening Committee (UK NSC), and the Royal College of Obstetrics and 
Gynaecology (RCOG – Greentop guideline No. 8, 2008), have set the standards for antenatal 
care in the UK, recommending that all pregnant women, regardless of age, should be offered 
routine screening tests between 10 and 20 weeks of gestation. A similar view is held by the 
American College of Obstetricians and Gynaecologists (ACOG), which suggests that all women 
– regardless of their age - presenting for antenatal care prior to 20 weeks of gestation should be 
offered screening tests for foetal aneuploidy (ACOG, 2007). 
These screening tests consist of a number of different strategies for the detection of 
pregnancies at high risk of foetal chromosomal abnormalities, with current methods taking into 
consideration maternal age, ultrasound findings and maternal serum biochemistry in the first 
and second trimester of pregnancy (Nicolaides, 2003).  
The availability of non-invasive prenatal methods for the diagnosis of Down’s syndrome, for 
example, is expected to limit the number of cases that will require further invasive diagnostic 
tests; this is especially true in the case of women over the age of 35, to whom both invasive and 
non-invasive methods are typically offered. Pregnant women with a specific indication for further 
testing must receive appropriate genetic counselling regarding the various methods available to 
them, together with their pros and cons, in order to be in a position to make an informed choice 
and provide written consent for this. 
Current practices in the NHS see all pregnant women being offered a first trimester screening 
test combining maternal age, sonographic measurement of the foetal nuchal translucency and 
measurement of maternal serum screening markers (Nicolaides, 2004; Norton, Brar, & Weiss, 
2012). While these methods have improved significantly over the years they are associated with 
90-95% detection rates and also have false-positive rates of 2-3% and false-negative of ≥5% 
respectively (Sparks, Struble, Wang, Song, & Oliphant, 2012). Based on the results of this 
combined test, women identified as being at high risk for carrying a baby with a chromosomal 
abnormality are offered invasive diagnostic testing in the form of either amniocentesis or 
Chorionic Villus Sampling (CVS). Whilst these latter procedures are highly accurate (nearing 
100% detection rates) they are expensive and also entail a risk of miscarriage (1%) 
(Sundberg et al,, 1997).  
In an attempt to address these limitations, and following years of medical research and trials a 
new test, non-invasive prenatal test (NIPT), has been put forward  and has high levels of 
sensitivity and specificity (Yagel, 2013). This procedure is a blood test and aims to determine 
the chromosomal status of the foetus through the analysis of cell free foetal DNA (cffDNA) that 
is located in the maternal circulation (RCOG: Royal College of Obstetricians and 
Gynaecologists, 2014). While this test is mostly available in the private sector, it also started 
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being offered at the research site of this study as part of a trial midway our study and therefore 
our research scope (originally aiming to explore the decision making process regarding invasive 
diagnostic tests only) was expanded to include this latest medical advancement and assess its 
impact on women’s decision making process regarding prenatal testing. 
It is important to note here that with the introduction of Harmony into clinical practice, women 
are no longer classified as high (>1:300) or low (<1:300) risk but an intermediate risk group has 
also been introduced. Therefore, based on their first trimester combined screening results, 
women are subsequently classified as high (>1:100), intermediate (>1:2500), or low (<1:2500) 
risk. Those in the high-risk group are then offered the option of either an invasive test (CVS or 
amniocentesis) or NIPT, while those in the intermediate risk group are only offered the option of 
NIPT. Women falling in the low risk group are not offered any further testing.  
1.3. Screening options offered to pregnant women 
The screening options offered to all pregnant women presenting for antenatal care are 
described below (also illustrated in Table 1.1): 
1.3.1. The first trimester combined screening test (11 to 14 weeks of gestation) 
The first trimester screening test combines maternal blood serological markers with an 
ultrasound foetal assessment, in order to estimate the risk of having a specific chromosomal 
abnormality and, in particular, trisomy 21 (Down’s syndrome) or trisomy 18 (Locock, Field, 
McPherson, & Boyd, 2008). Part of this test (Nuchal Translucency - NT) can additionally help 
detect other major foetal malformations such as cardiac defects, but does not contribute to the 
diagnosis of spina bifida. 
This type of preventive prenatal testing was up until recently considered to be the most accurate 
non-invasive method for prenatal detection of either of the aforementioned abnormalities. The 
accuracy of this method is 86-90%, with a false positive rate of less than 3-5%. It is important to 
note, however, that a positive result does not necessarily mean the presence of one of these 
pathologies in the foetus but rather raises attention for further investigation to confirm or 
disconfirm the disorder. 
What is more, the first trimester screening test determines the level of risk based on ultrasound 
findings (nuchal translucency) and maternal blood biochemical markers, in conjunction with the 
mother’s age (Kirkham, Harris, & Grzybowski, 2005). Because this test is carried out relatively 
early on in pregnancy, a positive result offers women the opportunity to choose between a 
diagnostic method such as Chorionic Villus Sampling (CVS) in the first trimester or 
amniocentesis in the second trimester of the pregnancy (see Table 1.3), and NIPT (if available 
at the given clinical practice) that is not diagnostic but can provide a more accurate likelihood 
ration that can act as an intermediate step prior to an invasive procedure being performed or 
can act as a standalone informative test for those not wishing to engage in invasive testing.  
 11 
Specifically, the first trimester screening test includes: 
a) An ultrasound examination with a main emphasis on measuring the foetus’s nuchal 
translucency: a thickening of the skin around the neck (subcutaneous fluid collection) is 
associated with DS (trisomy 21) (Kirkham et al, 2005). 
The ultrasonographic examination of the first trimester, which was established in 1995, along 
with that of the second trimester, assists in the identification of morphological (structural) and 
chromosomal foetal abnormalities such as anencephaly, spina bifida, trisomy 21 (Down’s 
syndrome), trisomy 13 (Patau syndrome), trisomy 18 (Edward’s syndrome), etc. Specifically, for 
the detection of Down’s syndrome and other chromosomal abnormalities, there are a number of 
sonographic markers suggestive of further investigation, such as structural abnormalities of the 
face, heart and hands of the foetus, chorionic plexus cysts, increased nuchal translucency, 
short humerus and femur, abnormally increased echogenicity of the bowel, kidney pyelektasia, 
hypoplastic phalanx of the fifth finger, echogenic intracardiac focus (endocardiac spot), as well 
as absence of nasal bone, abnormal angle of mandible, widened iliac wing angle etc. (Ilgin-
Ruhi, Yurur-Kutlay, Tukun & Bokesoy, 2005). 
b) Maternal serum markers with the main purpose of diagnosing Down’s syndrome (DS) 
(Locock et al, 2008) as well as other chromosomal abnormalities. 
These maternal serum markers include two hormones related to pregnancy and more 
specifically to the placenta: the human Chorionic Gonadotrophin (hCG) and the Pregnancy 
Associated Placenta Protein-A (PAPP-A). 
This examination should not be confused with the triple or quadruple test which are carried out 
between the 15
th
 and 20
th
 weeks of gestation and are less reliable. The first involve the levels of 
A-foetal protein (commonly known as Alpha-Fetoprotein: AFP), human chorionic gonadotropin 
(hCG) and unconjugated estriol (UE3) (Kirkham et al, 2005). A reduced amount of AFP and 
UE3, combined with elevated hCG levels, is usually indicative of an increased risk of DS (Ilgin-
Ruhi et al, 2005). In contrast, elevated AFP levels in maternal blood are associated with open 
lesions of the central nervous system (CNS), such as spina bifida, anencephaly, 
meningomyelocele, etc. However, abnormal results may be due to testing in the incorrect week 
of gestation. 
AFP is a protein produced by the foetus, while hCG is produced by the placenta and estriol by 
both the foetus and the placenta (Reis, D’Antona & Petraglia, 2002). The triple test is a non-
invasive method with no risk to the mother and / or the foetus. The same applies to the 
Quadruple test which additionally includes the hormone "Inhibin A". 
 
 12 
Table 1.1 
Screening Options for Antenatal Testing 
Test Timing 
(Weeks) 
Detection Rate Of 
Down’s Syndrome (%) 
False-
Positive Rate 
(%) 
First Trimester    
Nuchal Translucency (NT) 10-4/7 to 13-
6/7 
70 to 71 3.5 to 5 
hCG and PAPP-A 10 to 12 53 to 58 5 
Combined Test (NT, PAPP-A, 
hCG, MA)  
11 to 14 86 to 90 Less than 3 to 
5 
NIPT 10 (and over) 99% Less than 1% 
Second Trimester    
Triple Screen (hCG, maternal 
serum AFP, unconjugated 
estriol)  
15 to 20 60 to 69 5 
Quadruple Screen (hCG, inhibin 
A, maternal serum AFP, 
unconjugated estriol)  
15 to 20 67 to 81 (up to 90 with 
ultrasonography) 
Less than 3 to 
5 
Ultrasonography 18 to 22 35 to 79 6.7 
First and second trimester    
Integrated serum screening 
(PAPP-A with NT) 
11 to 14 and 
15 to 20 
94 to 96 Less than 3 to 
5 
Integrated serum screening 
(PAPP-A without NT) 
11 to 14 and 
15 to 20 
85 to 88 Less than 3 to 
5 
PAPP-A: Pregnancy Associated Plasma Protein –A; MA: Maternal Age; NT: Nuchal 
Translucency; hCG: Human Chorionic Gonadotropin; NIIPT: Non-invasive prenatal test; AFP: 
Alphafetoprotein 
 
1.3.2. Non-invasive Prenatal Testing (NIPT) 
 
NIPT is a blood test that enables the testing of the foetus for aneuploidy through cell-free foetal 
DNA that is extracted from maternal plasma (Skirton & Jackson, 2015). 
1.3.2.1. Evidence for effectiveness and strengths of NIPT 
Most studies thus far have been conducted on a number of high-risk cohorts (Ashoor, 
Syngelaki, Wagner, Birdir, & Nicolaides, 2012) and indicate a detection rate for trisomy 21 (T21) 
(Down Syndrome) of >99% and a false positive rate of approximately <1% (Menezes, Meagher, 
& Da Silva Costa, 2013). Marginally lower detection rates have been reported for trisomy 18 
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(T18) (Edward’s Syndrome) and even though initially the performance of this test for the 
detection of trisomy 13 (T13) (Patau’s Syndrome) was less reliable, this has been evolving with 
better results being reported all the time (RCOG, 2014). Detection rates for each of these 
conditions are illustrated in Table 1.2. It is important to note that while this is still under 
investigation and trials on populations attending routine first trimester aneuploidy screening are 
still under way, recent evidence is encouraging in that the accuracy of NIPT obtained for high 
risk populations is also transferrable to the general population (Nicolaides, Syngelaki, Ashoor, 
Birdir, & Touzet, 2012). 
Table 1.2 
NIPT detection and false-positive rates for each of the three main chromosomal abnormalities 
tested  
 Detection Rate False-positive Rate 
Trisomy 21 >99% <1% 
Trisomy 18 96% <1% 
Trisomy 13 92% <1% 
Note. From Gil, Giunta, Macalli, Poon, & Nicolaides, 2014. 
a) Early performance of the test 
A key advantage of NIPT is the very early gestational age at which it can be performed, with 
foetal genetic material being detectable in the maternal blood as early as 4-5 weeks of gestation 
(Yagel, 2013). On the contrary, the widely available combined screening tests that have mostly 
been used to this day include an initial maternal blood serum screen and ultrasound between 
the 10
th
 and 14
th
 week of gestation, followed by a second serum screen between the 15
th
 and 
20
th
 week of gestation-triple test (Rosen & D’Alton, 2005). Women who are identified as being at 
high risk are then offered the option of CVS at 10-13 weeks or amniocentesis at 15-20 weeks of 
gestation. Therefore, in favour of NIPT it has been suggested that the early detection of trisomy 
without the associated risk of miscarriage could help reduce the anxiety in many pregnant 
women whether this be in the form of offering them reassurance or in terms of providing them 
with more time to consider their options regarding further testing and subsequent actions 
(Ravitsky, 2009). 
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b) Reduction in the number of healthy foetuses lost due to procedural-related 
complications  
When the combined test first came out, it helped reduce the amount of invasive diagnostic 
procedures carried out and consequently the associated financial expenses and procedural 
related miscarriages (Yagel, 2013). Therefore, NIPT is expected to contribute further towards 
this direction. 
Due to its high specificity and sensitivity compared to the combined test which has so far been 
the recommended screening method in the NHS, and if it is incorporated into first-trimester 
screening procedures, NIPT is most likely going to further reduce the number of women who 
are referred on for invasive diagnostic testing (Yagel, 2013). This will consequently be reflected 
in the amount of screen-positive healthy foetuses that are saved and is probably one of the 
strongest benefits of this new test. 
c) Important source of information for all groups of parents 
Given that the NIPT does not entail any risk of miscarriage, it offers the opportunity to even 
those who would avoid an invasive test out of fear of a procedure-related loss, to find out 
whether their baby suffers from any chromosomal abnormality and thus equip them with more 
information that may be crucial in their decisions thereafter. Such people will most probably be 
those who would not consider terminating their pregnancy regardless of the result so would not 
be willing to take the risk of an invasive test. However, the NIPT can offer them reassurance 
over their baby’s health or even if it indicates a very high possibility of Trisomy 13, 18, or 21 it 
can help them prepare for the birth of their child and seek all the support and resources they 
need to help them through. While on the one hand this may, at present, undoubtedly place more 
financial and resource demands on perinatal clinics, as more women will be continuing with 
their pregnancy being aware of their baby’s condition, on the other it may alleviate much of 
these women’s stress by helping them prepare for the upbringing of their child and feeling 
supported in doing so (Menezes et al, 2013).  
1.3.2.2. Limitations of NIPT 
d) Not a diagnostic test 
Despite the encouraging evidence so far, the overall sensitivities and specificities for NIPT are 
so far >95% with false-positive rates of <1% (Yagel, 2013). This means that while it is a test 
with high sensitivity it still does not provide a definitive result and therefore should not be used 
as a replacement for invasive testing in high-risk populations. It should instead be treated as a 
new higher-performance screening test for T21, T18, and T13 which identifies those at high-risk 
who should then be referred on for invasive diagnostic testing (amniocentesis or CVS) in order 
to verify the results (Ashoor et al, 2013). Therefore, it is important for women to understand that 
a positive result does not always mean that the baby is affected and a negative result does not 
always mean that the baby is not affected and appreciate the higher accuracy that invasive 
tests can provide. 
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e) NIPT has a 2% failed results 
It has been reported that there is an approximately 2% of total pregnancies where NIPT is 
performed fails to deliver any results due to a number of reasons (Benn, Cuckle, & Pergament, 
2013). In some studies in fact, this number has even been higher (Futch et al, 2013) drawing 
attention to several aspects that need to be taken into account when considering the pre-
requisites in order for this screening test to be effective.  
Firstly, a failed result may be associated with the test being carried out too early. In order for an 
abnormality to be reliably detected through this method, a 4-5% of foetal DNA in the maternal 
blood stream is required (RCOG, 2014; Wang et al, 2013). This is thought to correspond to the 
10
th
 week of gestation (although it is potentially detectable from the 5
th
 week of gestation) and 
therefore the test should optimally be carried out from this point onwards since the amount of 
foetal DNA earlier in pregnancy may not be sufficient (Wang et al, 2013). However, between 10 
and 21 gestational weeks the foetal DNA only marginally increases by about 0.1% on a weekly 
basis (overall 1% increase) while a greater and significant weekly increase (approximately 1%) 
can be expected after the 21
st
 week, indicating that those with a failed original result would have 
to wait until the 21
st
 week for a second blood draw to potentially produce a valid result. 
However, this entails a significant waiting and stressful period and it also does not allow 
substantial time for follow-up options (such as termination or preparation in the case of a 
positive result) to be considered carefully before a decision has to be made. Even though there 
may be some exceptional cases, current legislation allows a termination to be carried out up to 
24 weeks (RCOG, 2010) and even if it is permitted later on the procedure becomes much more 
difficult and potentially more traumatic for the woman. Therefore, in order to increase the 
possibility of an accurate result it is imperative that the exact gestational age is established 
through a scan prior to any blood being drawn.  
Another potential factor that has been linked with failed results is increased maternal weight 
which is shown to be negatively correlated with percentage of foetal DNA in the maternal serum 
(Wang et al, 2013). In other words, there is evidence to suggest that the higher a woman’s 
weight the less likely it is to obtain reliable results as per the foetus’ chromosomal status due to 
insufficient proportions of foetal DNA and this should be taken into consideration when offering 
women options for prenatal testing (Yagel, 2013). However, a threshold has not yet been 
determined for the exact maternal weight appropriate for a meaningful result and more studies 
need to explore this taking into account BMI levels so as to account for height in relation to 
weight as well.   
To sum up, in order to increase the likelihood of a reliable NIPT result, time of blood draw (10
th
 
gestational week onwards) and maternal weight need to be carefully considered as they may 
have a powerful effect on the outcome of the test.  
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f) Range of abnormalities detectable via NIPT 
NIPT currently only detects trisomies 13, 18, and 21 (and in some cases sex chromosome 
aneuploidy), whereas conventional karyotyping through amniocentesis and CVS provides 
detailed structural information on all 23 pairs of chromosomes. This means that many 
abnormalities currently being detected via invasive diagnostic tests cannot be detected via NIPT 
at least for the time being (Menezes et al, 2013). Therefore it is important for women to have a 
clear understanding of this and be appropriately supported and informed so that they can make 
a decision depending on the extent to which they wish to check their baby’s health.  
g) Ethical issues in relation to informed consent 
In terms of informed consent, it is just as important as in the case of invasive tests even despite 
the exclusion of procedure related miscarriage. Therefore, this constitutes it a necessity for 
clear guidelines and prenatal/postnatal counselling to be provided to all women who have this 
test.  
Also even though there is evidence suggesting that many women undergo the combined 
screening test because they consider it part of “routine” antenatal care (Fuchs & Peipert, 2005) 
rather than because of a rational decision they make after weighing up the pros and cons, when 
it comes to NIPT it is even more important to be clearly informed about the conditions being 
tested for and all associated information such as follow-up options (i.e. the option to terminate 
the pregnancy if Down Syndrome is diagnosed). The reason for this is mostly associated with 
the NIPT’s level of sensitivity and the critical information it may disclose to the respective 
parents.  
h) Costs  
While considering the limitations of NIPT there is a substantial financial cost that needs to be 
considered. At the moment, NIPT costs between $800 and $2000 in the USA and from $500 to 
$1500 elsewhere in the world (Benn et al, 2013). While some private insurance companies may 
cover this cost, it is important to also take into consideration those covered by public health 
insurance who have been reported to be less likely to have NIPT because they are unable to 
fund it themselves (Vahanian et al, 2014). Therefore, while NIPT may become more cost-
effective in the future and thus appeal to all populations the current financial demands place 
women who cannot afford it at a disadvantage.  
 
1.3.2.3. Conclusion – key points regarding NIPT 
Several large studies (Palomaki et al, 2012; Ashoor et al, 2013) have established NIPT as an 
effective new screening method but not one with the accuracy level of the current invasive 
diagnostic procedures, amniocentesis and CVS. Therefore, it is thus far recommended to use 
the term non-invasive prenatal testing (NIPT), rather than non-invasive prenatal diagnosis which 
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is misleading especially for those on the receiving end who are faced with an increasing number 
of options when it comes to antenatal care and testing.    
NIPT is considered as a positive development in prenatal care, mainly due to the safety of the 
procedure, the increased accuracy and sensitivity of the test in comparison to the conventional 
combined test and the subsequent decrease in procedure-related loss of foetuses. This is due 
to the fact that this new screening method has the ability to more accurately detect the 
chromosomal status of the foetus and therefore only women who are at a very high risk will be 
faced with the option of further diagnostic tests (invasive) and their associated risks and difficult 
follow-up decisions.  
However, this new development does not come without any concerns, mostly of an ethical 
nature. There are concerns that by making such a “safe” procedure so readily available, this 
may increase pressure upon women and constitute prenatal screening as a more routinised 
practice (Lewis, Silcock,  & Chitty, 2013). As a result, this is likely to jeopardise informed 
consent as it is likely that women will feel less justified in wanting to turn down a blood test that 
entails no risks and thus potentially have the test in order to avoid social stigma and being 
frowned upon for not taking all available measures in order to identify any potential defects. The 
thin lines between being responsible and being a ‘good’ mother are well acknowledged in the 
literature and it has been previously suggested that blame is often attributed to mothers who fail 
to act in what is accepted as an appropriate manner (Ehrenreich & English, 1978; Oakley, 
1984). Modern western society is very much “risk-orientated”, with the message given to women 
being that a no-risk pregnancy does not exist and therefore technological advances should be 
used in identifying potential risks to her unborn baby; these are defined by society and reflect 
what is considered to deviate from the “norm” (Beck, 1992). Considering that at the core of 
current Western belief systems lie science and technology it is perhaps not surprising that 
pregnancy and childbirth have become medicalised (Davis-Floyd, 1994). This has seen the 
focus centering on the female body as a “machine” that has to lead to a “successful” pregnancy 
and labour, diverting attention from the natural process of child-bearing and childbirth that is not 
only physical but rather involves two people, the mother and the baby. As a result of the 
expansion of medical technology, women have become more reliant on medical interventions 
as a source of information regarding the progress of their pregnancy and less trusting of their 
own maternal intuition and experience of the pregnancy (Jonsdottir, 2012). With the extensive 
use of technology, pregnancy is no longer viewed as a social process but rather becomes more 
technical with emotions of the mother often being neglected (Davis-Floyd, 2001).  
In addition, there may be further social discrimination towards the disabled community and 
individuals with any chromosomal abnormality such as Down’s syndrome may suffer from the 
effects of this and feel yet more isolated within the society (Kaposy, 2013). The more medical 
technology is used to prevent babies with any congenital abnormality being born, the less 
“normal” these people will become within the society, potentially drawing negative responses 
and attitudes from others and stripping them of their human right to equality and diversion that 
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they certainly deserve. Such concerns have previously been voiced by health care staff who 
pointed out that the continuous changes in prenatal screening are likely to have an impact on 
the mother-foetal relationship placed within the wider societal context (Rapp, 1999). Likewise, 
Dumit and Davis-Floyd (2000) have pointed out that the increasing focus on the development of 
new technologies to assess the quality of the foetus are placing a strong emphasis on the 
production of “a perfect baby”, and with new tests becoming available this is likely to further be 
reinforced. Therefore, it is suggested that in order to prevent this from happening, the 
medicalisation of pregnancy should be re-visited and medical training should step back from 
solely focusing on the physical aspect of pregnancy and child-birth but rather adopt a more 
holistic view of the process that takes into consideration both the mother and the child as 
human beings with emotions rather than physical objects (Johanson, Newburn, & MacFarlane, 
2002). 
Nonetheless, so long as there are is awareness of these risks preventative measures can be 
taken in order to ensure best practice with the least possible negative effects. A successful 
introduction of NIPT into antenatal care can be achieved, by the provision of clear guidelines 
and counselling strategies that will communicate all important information to women whilst also 
safeguarding informed consent on their behalf.  
1.4.  Invasive diagnostic testing options 
 
The result of the first trimester screening test as well as that of NIPT, however, do not provide 
an accurate prenatal diagnosis but rather determine the likelihood of finding a chromosomal 
abnormality, (Schuchter et al, 2002). Following this process, and in order to confirm and 
diagnose the foetal abnormality suspected, further prenatal tests, such as amniocentesis and 
chorionic villus sampling (CVS), are required. Therefore, prenatal diagnosis is offered to all 
women who have positive antenatal screening results (Brajenovic – Milic et al, 2008). 
These invasive tests (see Table 1.3), apart from providing a clear diagnosis, offer the couple 
several options: 
i. To explore the availability of further therapeutic intervention (i.e. surgery in the case of 
spina bifida); 
ii. To set up specific plans regarding the care of a child with special needs and to adjust 
their lifestyle accordingly; 
iii. To decide on the continuation or termination of the pregnancy. 
Any decision requires full discussion with the physician and close relatives and may require 
additional genetic specialist advice. 
Some individuals or couples may choose not to undergo preventive or other additional testing 
for various reasons, such as: 
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i. Religious, moral or other personal reasons that do not allow them the choice of 
abortion, even in the case of a non-curable disorder being diagnosed; 
ii. Personal beliefs that the initial indication of the screening test is acceptable, taking into 
consideration future implications and consequences; 
iii. Fear of harming the foetus during the process.  
 
Table 1.3 
Invasive diagnostic options for antenatal testing 
Trimester - Test Timing 
(Weeks) 
Detection Rate 
Of Down’s 
Syndrome (%) 
False-
Positive Rate 
(%) 
Sensitivity 
(%) 
Specificity
(%) 
1
st
- CVS 10-13 97.8 1 to 2 99.25 98.65 
2
nd 
- Amniocentesis 15-18 99.4 0.1 to 0.6 99.4 99.5 
 
1.4.1. Amniocentesis 
One of the main applications of cytogenetics in clinical medicine is the prenatal diagnosis of 
chromosomal and other abnormalities of the foetus. Amniocentesis is the most common 
prenatal diagnostic method that is used for this purpose and is typically performed around the 
16th week of gestation (15th- 18th). It was first applied in the 1950’s and the first official 
diagnosis of Down’s syndrome was announced in 1968. Since then its role has expanded to 
diagnose chromosomal abnormalities in general, as well as biochemical disorders, metabolic 
diseases and certain monogenic diseases (Daniilidis et al, 2008). What is more, the 
establishment of prenatal screening methods during the early stages of pregnancy (first 
trimester) has resulted in an increase in the number of amniocenteses that are being performed, 
as well as in the number of Chorionic Villus Sampling (CVS) tests, which constitute an 
alternative procedure. 
Amniocentesis is an invasive procedure and involves the trans-abdominal insertion of a thin 
hollow needle into the uterus to withdraw from the amniotic sac a sample of amniotic fluid that 
includes foetal cells. The chromosome size and banding patterns of these foetal cells are then 
analysed in the lab and the arrangement of the 24 different chromosomes (22 pairs of 
autosomes and one pair of sex chromosomes) is used as a tool for the diagnosis of genetic 
disorders (Fajnzylber, Hotz, & Sanders, 2010). The reliability of amniocentesis ranges between 
99.4 and 100% for the diagnosis of chromosomal abnormalities.  
However, as with any invasive method, amniocentesis is also associated with specific 
complications such as amniotic fluid discharge, bleeding, amnionitida, foetal injury caused by 
the needle, and miscarriage. It is important to note that attempts are made to avoid injury to the 
foetus or placenta by means of ultrasound guidance, under which the surgery is performed. 
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Nevertheless, the risk of such complications, amongst others, will, to a certain extent, influence 
a patient’s decision as to whether to accept or decline the procedure.  
Before 1984, amniocentesis was only recommended to women over 35 years of age. This 
threshold was set because at this age the risk of having a child with DS is approximately equal 
to the risk of a procedure-related miscarriage, which is usually estimated to be 1%, and 
because the cost of offering amniocentesis was considered to be outweighed by the savings 
gained from avoiding the lifelong costs associated with the birth of an infant with DS (Moyer et 
al, 1999). However, this threshold implicitly assumes that women are equally worried about 
having a child with DS and a procedure-related miscarriage, something which has previously 
been proven not to be true (Harris, Nease, & Kuppermann, 2004), and also assumes that 
women would choose to abort a child with a serious congenital abnormality such as DS.  
However, in recent years the discovery of serum and ultrasonographic markers provide ground 
for patient-specific assessment of risk level for foetal aneuploidy and allow for invasive testing to 
be more specifically targeted to high-risk women, thus leading to the avoidance of unnecessary 
invasive procedures (Geipel et al, 2003).     
First trimester amniocentesis 
First trimester amniocentesis is carried out between the 10th and 14th week of gestation. It is 
considered less secure than that of the second trimester and therefore is not as commonly used 
(Kennerknecht, Baur-Aubele, Grab, & Terende, 1992). It is technically more demanding and the 
insufficient retrieval of live embryonic cells required for the chromosomal analysis is more likely. 
In cases where an invasive diagnostic procedure is recommended for the 1
st
 trimester, CVS is 
considered more appropriate. 
1.4.2. Chorionic Villus Sampling (CVS) 
Chorionic Villus Sampling (CVS) is an alternative to amniocentesis but is carried out earlier in 
the pregnancy, typically between 10 and 13 weeks of gestation (RCOG Greentop Guideline No 
8, 2010). It is used for the prenatal diagnosis of chromosomal or genetic disorders in the foetus 
through sampling and testing of the placental tissue (chorionic villus) and always under the 
guidance of an ultrasound scan. More specifically, there are two approaches to CVS: the trans-
abdominal CVS, where a needle is inserted through the abdomen, and the trans-cervical CVS, 
where a tube is inserted through the cervix. The position of the placenta usually determines 
which of these two methods will be used in order to better access the chorionic villi (Anderson & 
Brown, 2009). Although the benefit of CVS is that it provides early and definitive chromosomal 
analysis, in comparison to amniocentesis it has a slightly higher rate of miscarriage with an 
estimated percentage of 1-2% (RCOG, 2005). 
However, according to current indications, the difference in the risk of miscarriage in relation to 
second trimester amniocentesis mostly concerns trans-cervical CVS (rather than trans-
abdominal), which is much more technically demanding. Furthermore, regarding their diagnostic 
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value, there do not seem to be major differences between second trimester amniocentesis and 
CVS. 
However, a practice that is still largely observed in some developing countries, such as India, is 
the use of such procedures for the purposes of sex selection and the abortion of female 
foetuses (Jha et al, 2006). In light of this evidence, most developed countries have established 
specific guidelines in order to ensure that the performance of such invasive procedures is in 
compliance with current medical indications (evidence-based approach). The long-term 
emotional and financial burdens that can be avoided with early diagnosis of a serious disease of 
the foetus and should the parents opt for termination of pregnancy, justify the costs associated 
with the performance of such prenatal diagnostic procedures. 
1.5. Prenatally detectable genetic disorders 
Most chromosomal abnormalities such as Down’s syndrome and Edward’s syndrome can be 
diagnosed by means of amniocentesis and CVS. It is also possible to diagnose diseases such 
as cystic fibrosis, congenital hemoglobinopathies such as thalassaemia and sickle cell disease, 
as well as Huntington and Tay-Sachs disease. Also, open lesions of the CNS such as spina 
bifida and anencephaly can be diagnosed through these methods. 
However, it is worth stressing that no form of prenatal diagnosis can guarantee the birth of a 
perfectly healthy child, because only specific congenital disorders can be ruled out prenatally. 
The method of PCR (polymerase chain reaction) is a technique that enables the creation of 
millions of copies of specific regions of the DNA molecule in a very short time and is a powerful 
tool for studying genetic material, including disease-causing genes. It has been incorporated in 
the process of amniocentesis (amnio-PCR) and provides definitive diagnosis of the most 
common chromosomal abnormalities within 24-48 hours (Baig et al, 2010). 
Some of the foetal disorders that can be detected through amniocentesis and/or CVS are listed 
below. 
1.5.1. Chromosomal disorders 
1.5.1.1. Trisomy 21 (Down’s syndrome) 
Trisomy 21 is most frequent chromosome aberration at birth and is associated with various 
physical abnormalities and diseases (Siegrist, Cousin, & Keller, 2008). More specifically, infants 
with DS suffer from general hypotonia (poor muscle strength and elasticity), are more likely to 
suffer from congenital malformations (heart problems being the most common), and are also at 
an increased risk of mental and growth retardation (Fajnzylber et al, 2010). Even though some 
therapies are available for specific malformations, there is no effective treatment for the 
cognitive problems associated with this condition, making these children dependent on their 
parents / carers for life. What is more, life expectancy for DS children in developing countries is 
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limited to approximately 35 years, although medical advances have increased this to 
approximately 55 years in the USA and other Western countries (Dick, 1996). Nevertheless, 
taking into consideration the lifelong treatments and psychological implications, which include 
maternal depression and difficulties with marital and sibling relationships, DS is a costly disease 
for a family, both on a financial and on a psychological level. Therefore, many parents are 
interested in the prenatal detection of affected foetuses in order either to adapt to the 
circumstances of having a child with a disability, to establish plans for special prenatal and post-
natal care, or to terminate the pregnancy, which is considered legal up to 24 weeks if a foetal 
abnormality is detected (France, Wyke, Ziebland, Entwistle, & Hunt, 2011). 
1.5.1.2. Trisomy 18 (Edward’s syndrome) 
Trisomy 18 is caused by the presence of an extra 18th chromosome in the infant’s cells and 
carries with it a very low life expectancy, resulting from various internal organ disorders such as 
heart abnormalities or kidney malformations (Palomaki, 2011). It is invariably characterised by 
increased foetal nuchal translucency (NT), in association with decreased maternal serum free β-
human Chorionic Gonadotropin (β-hCG) and pregnancy-associated plasma protein A (PAPP-A) 
(Sherod, Sebire, Soares, Snijders, & Nicolaides, 1997). 
1.5.1.3. Trisomy 13 (Patau syndrome) 
Trisomy 13 is characterised by the presence of an extra 13th chromosome, which disrupts the 
normal course of development by causing heart or kidney malformations and severe intellectual 
disability (Pitukkijronnakorn, Promsonthi, Panburana, Rangsiprakarn & Chittacharoen, 2008). 
Like the previous disorder, it is characterised by decreased β-hCG, PAPP-A, and increased NT 
(Spencer, Charas, Skentou, Liao, & Nicolaides, 2000). 
Other examples of chromosomal abnormalities which are prenatally detectable include: a shift 
of genetic material from chromosome to chromosome without loss or excess material, 
mosaicism (where cells within one individual have a different genetic makeup), chimerism (a 
rare condition whereby a person has more than one set of DNA), and abnormal sex 
chromosomes X and Y. The latter involves cases such as Turner syndrome, which is 
characterised by a lack of sex chromosomes (45 instead of 46, 44 XO) and whose main 
features include vrachysomia and infertility. Other sex chromosome abnormalities include the 
triple Y or X chromosome (superman, superwoman) and the syndrome 'Fragile X chromosome'. 
1.5.2. Autosomal disorders 
Autosomal disorders fall under the umbrella of single gene disorders (also called ‘monogenic 
disorders’), which are inherited genetic diseases caused by a single gene defect (Weatherall, 
2000). They are further divided into the dominant type (where the abnormal gene from only one 
parent is required in order for a child to inherit the disease) and the recessive type (where a 
copy of an abnormal gene from each parent is required for the disease to be inherited). 
Examples of autosomal dominant disorders include Huntington’s disease and Marfan’s 
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syndrome, whereas some recessive examples include congenital hemoglobinopathies (sickle 
cell disease and thalassaemia). 
1.5.2.1. Sickle cell disease (SCD) 
Sickle cell disease is an autosomal recessive genetic blood disorder which is caused by an 
abnormal type of haemoglobin. This haemoglobin – namely haemoglobin S – causes the red 
blood cells to acquire an abnormal, rigid, sickle shape and, as a result, to deliver less oxygen to 
the body’s tissues. What is more, these sickle-shaped cells are more prone to adhere to small 
blood vessels and interrupt normal blood flow (Rees, Williams & Gladwin, 2010). 
The vast majority of people with sickle cell disease will have painful episodes, which are called 
crises and have varying degrees of severity and duration (lasting from hours to whole days). 
Other conditions associated with SCD include chronic anaemia, jaundice, organ failure, 
infections, and strokes (RCOG, 2005). There is no cure for SCD, but rather patients need 
ongoing treatment in order to manage their symptoms and limit the amount of crises they 
experience. All in all, SCD may lead to various acute or chronic complications, many of which 
have a high mortality rate. Nonetheless, the life expectancy for people with this condition in the 
UK has increased from an estimated 42 years to 53-60 years, due to medical advances and 
better management of the disease (Gill, Lavin & Sim, 2010). 
With regard to diagnosis of SCD, in most parts of the world prenatal screening is offered to 
women in order to establish the parental haemoglobin gene mutation. If positive results are 
obtained, an amniocentesis or CVS is offered as an option in order to obtain a definitive 
diagnosis, which in turn, may help prevent complications and provide information for family 
planning (Steinberg, 2011).   
1.5.2.1. Thalassaemia   
Thalassaemia is another type of inherited autosomal recessive blood disorder, which is mainly 
characterised by anaemia, hence a decrease in the amount of red blood cells or in the amount 
of haemoglobin in the blood (Panomai et al,  2010).  
Unlike the qualitative nature of the implications of SCD, where an incorrect functioning of the β 
globin takes place, the problems associated with thalassaemia are of a quantitative nature, with 
an underproduction of one of the two globin chains (α or β) which make up the haemoglobin. 
Thus, there are two major forms of this disease which take their names according to which of 
the two chains of the haemoglobin molecule is affected: alpha-thalassaemia and beta-
thalassaemia respectively (Tan et al, 2010).  
In the UK, as in many other parts of the world, a blood test is offered to all pregnant women as 
part of their antenatal care in order to screen for the presence of a thalassaemia gene. If the 
result is positive, a test is subsequently offered to the father of the unborn child, and if the 
combination of the parental results indicates a risk for the foetus, further invasive diagnostic 
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tests (amniocentesis or CVS) are offered as a means of providing an accurate diagnosis for the 
baby (RCOG, 2005). Follow-up options, such as continuation or termination of an affected 
pregnancy, are discussed with the couple. 
1.5.3. Metabolic diseases 
Inherited Metabolic Diseases (IMDs), which are also autosomal recessive inherited disorders, 
include those affecting the metabolism of amino acids, organic acids, fatty acids, carbohydrate, 
and the urea cycle. Some of these may cause serious complications during pregnancy, affecting 
either the mother and/or the foetus (Preece & Green, 2002).   
 
For IMDs where the risk for serious complications is established, optimal treatment may lead to 
a better maternal and foetal outcome. One such case is that of phenylketonuria (PKU), whereby 
patients are unable to convert phenylalanine to tyrosine in the liver due to a recessively 
inherited defect in the enzyme phenylalanine hydroxylase. Symptoms of untreated PKU include 
serious developmental delay, disturbed behaviour and hyperactivity in older children. However, 
like most IMDs, phenylketonuria can be diagnosed prenatally through amniocentesis or CVS, 
and as for other conditions, a termination of pregnancy is an option in the case of an affected 
foetus. Nevertheless, even for those who do not wish to terminate a pregnancy, regardless of 
the result, a prenatal confirmation of an affected foetus may prove beneficial for the better 
management of the condition by setting up plans for specific treatments during pregnancy 
and/or at birth (Preece & Green, 2002). 
 
1.5.3.1. Disorders of the musculoskeletal system 
Muscular Dystrophies (MD) are a progressively degenerative group of inherited neuromuscular 
disorders that involve muscle weakness and the loss of muscle tissue (Sewry, 2010). Some 
types of MD cause little disability, while others are more severe and lead to a premature death. 
One such example is Duchenne Muscular Dystrophy (DMD), which affects boys and is 
characterised by progressive muscle degeneration. This leads to loss of independent 
ambulation by the age of 13 years and several other medical complications such as progressive 
arm and hand dysfunction, speech problems, respiratory insufficiency, and ultimately death in 
the late teens (Spies, Shipper, Nollet & Abma, 2010). DMD is a result of a defect in the 
dystrophin gene which is caused by mutations on the X chromosome. Invasive tests such as 
amniocentesis or CVS can be used for prenatal diagnosis of this disease, followed by the option 
of terminating an affected pregnancy (Bushby et al, 2010). 
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1.5.4. Intellectual disabilities 
1.5.4.1. Fragile X syndrome 
Fragile X is the most common inherited cause of intellectual disability involving changes in part 
of the X chromosome, and more specifically a gene called FMR1. Although both sexes can be 
affected, since males only have one X chromosome a single fragile X is likely to affect them 
more severely than females (Sherman, Pletcher & Driscoll, 2005).  
As a result of Fragile X syndrome, several cognitive and intellectual limitations manifest, 
including language delays, problems with working and short-memory, executive function, and 
mathematic and visuospatial abilities. From a behavioural aspect, autistic-like features (i.e. hand 
flapping and eye-contact avoidance) are also commonly observed, alongside impaired social 
skills and emotional problems such as anxiety and mood disorders, hyperactivity and 
aggressive behaviour (Garber, Visootsak & Warren, 2008).  
Since the specific gene responsible for this syndrome was identified in 1991, it has become 
routine clinical practice to offer screening to affected families (where the mother is a known 
carrier) and follow these up with the offer of invasive diagnostic procedures (amniocentesis or 
CVS) for those who are considered at high risk (Pesso et al,  2000). 
 
1.5.5. Neural tube defects 
Neural tube defects such as spina bifida, which is an incompletely enclosed spinal cord, and 
anencephaly, which involves the absence of a large part of the brain or skull, are two less 
common but more fatal genetic disorders. It is important to note that these can be detected 
through prenatal screening and testing, but only via amniocentesis and not CVS (Fajnzylber et 
al, 2010). 
To sum up, current guidelines from the UK RCOG and ACOG recommend that all pregnant 
women, regardless of their age, should be offered prenatal screening for congenital 
abnormalities. Those who receive positive results, and hence are considered to be at high risk 
of foetal aneuploidy, should then be given the option of undergoing an invasive prenatal 
diagnostic test – most often in the form of amniocentesis – in order to confirm or disconfirm the 
suspected pathology. However, at this point it is important to highlight the importance that is 
placed on shared decision-making when it comes to medical decisions.  
1.6. Shared decision-making 
Shared decision-making is a process in which a health-care decision is jointly made by a 
clinician and a patient, and is based on evidence-based information about choices, outcomes 
and uncertainties combined with the patient’s informed preferences (Coulter & Collins, 2011). 
While shared decision-making is mostly thought of in relation to major treatment procedures, it 
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is in fact relevant in almost every clinical encounter including screening and diagnostic tests 
such as CVS and amniocentesis. Relevant professional regulatory bodies, such as the Health 
Professions Council (HPC) and the General Medical Council (GMC), characterise shared 
decision-making as an ethical imperative in all medical decisions. According to the Good 
Medical Practice guidance for all doctors:  
“Whatever the context in which medical decisions are made, you must work in 
partnership with your patients to ensure good care. In so doing, you must listen to 
patients and respect their views about their health, discuss with patients what their 
diagnosis, prognosis, treatment and care involve; share with patients the information 
they want or need in order to make decisions; maximise patients’ opportunities, and 
their ability, to make decisions for themselves; respect patients’ decisions.” (General 
Medical Council, 2009). 
What is more, an important element of any medical decision is that it has to be an “informed 
choice” of the patient, which, according to O’Connor and O’Brien Pallas (1989), “is one that is 
based on relevant knowledge, is consistent with the decision-maker’s values and is 
behaviourally implemented” (pp.486-496).   
Understanding how to facilitate informed choices in healthcare settings is of great interest to 
those taking a psychological perspective on health behaviour, and the importance of this in 
clinical practice is evidenced in an improved patient-physician relationship and satisfaction, as 
well as better patient outcomes (Legare et al, 2011). In addition, considering that most medical 
decisions occur in an uncertain context, a shared decision-making process is considered to 
improve the quality of the patient’s decision by increasing knowledge and clarifying patient 
preferences (O’Connor et al, 2009).   
1.7.  Decision making process in prenatal testing 
1.7.1. The role of Health Psychology 
In prenatal diagnosis, the need for a decision-making process that is consistent with personal 
values is imperative as it concerns a complex and multi-faceted issue that may have lifelong 
consequences for numerous people. This includes the woman having to make the decision to 
undergo a prenatal test or not, the unborn foetus, and those of the wider family involved such as 
the partner, and other children previously born into the family. Similarly, to the aforementioned 
professional regulatory bodies, and in line with the British Medical Association’s guidelines on 
informed consent, the National Screening Committee states that all patients have a right to be 
fully informed of any testing offered to them, including any risks or alternatives, before they 
decide whether to agree to the proposed test or not (Marteau, Dormandy & Michie, 2001). This 
means that women who are offered the option of amniocentesis, CVS or NIPT should be fully 
informed of the purpose of the tests, the accuracy of the findings, the risks and uncertainties 
attached to the process – such as the risk of miscarriage with invasive tests - and any follow-up 
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plans which involve a choice of terminating or continuing with the pregnancy (GMC, 1999). 
However, despite these rules and regulations that -theoretically at least- guide clinical practice, 
there is evidence to suggest that pregnant women do not always possess the required 
knowledge and understanding of the tests being offered to them, putting into question the extent 
to which they are actually in a position to make an informed choice (Green, Hewison, Bekker, 
Bryant, & Cuckle, 2004).  
Nevertheless, regardless of the complexity of the process and its stakes, NIPT as well as 
invasive diagnostic tests may offer benefits to women who participate, and therefore it is 
important to look into the specific factors that are implicated in the decision-making process, 
which may contribute to test use, benefiting both individuals and medical science in general 
(Tercyak, Johnson, Roberts, & Cruz, 2001). 
Health psychology can undoubtedly play an important role in this field. First of all, the theoretical 
models, such as Social Learning Theory (Bandura, 1977), combined with the extensive 
research capacity within this discipline, may offer the foundations for identifying the variables 
that influence women’s decisions. For example, in the past the Theory of Planned Behaviour 
(TPB; Ajzen, 1991) has been successfully used to explain and predict a range of behaviours 
including the uptake of prenatal screening (Sapp et al, 2010). Furthermore, health psychologists 
may also contribute on a more practical level by developing interventions aimed either directly 
at women or at doctors in order to maximise informed decision-making when it comes to 
deciding whether or not to undergo an invasive prenatal diagnostic procedure. 
1.7.2. An overview of factors involved in the decision-making process 
A review of the literature suggests that the uptake of prenatal tests, such as amniocentesis, 
CVS, and NIPT is related to both rational variables, such as knowledge about the specific 
procedure, and emotional variables, such as anxiety levels, social norms, and other internalised 
values which are reflected in an individual’s attitudes. The latter can be defined as a person’s 
favourableness or unfavourableness towards a specific concept (Lesser & Rabinowitz, 2001). 
To be more specific, previous studies have stated that knowledge is a prerequisite for any 
woman making an informed decision about taking up any of the prenatal tests that are being 
offered to her. This encompasses knowledge of: the purpose of a given test, the likelihood of a 
positive or negative outcome, the risks attached to the diagnostic procedure, and follow-up 
plans including the offer of abortion in the case of an affected foetus (Marteau, Johnston & 
Plenicar, 1988). Within the context of prenatal tests, and since uptake is voluntary, the purpose 
of the information provided to women faced with this decision is to facilitate informed decisions 
(Shoonen et al, 2011). However, regarding its predictive validity, there have been conflicting 
findings in the literature. Hence, some studies have found that women who had an elective 
amniocentesis were more knowledgeable about the diagnostic test than those who chose not to 
have the procedure (Lesser & Rabinowitz, 2001), while others have found that knowledge was 
not predictive of women’s decision outcome (Michie, Dormandy, & Marteau, 2002). As far as 
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NIPT is concerned, whilst most women have been found to have good knowledge of the main 
properties of this test, several misunderstandings have also been reported, such as that NIPT is 
100%, that it can detect conditions such as spina bifida and that the turnaround time for the 
results is shorter than that for invasive diagnostic tests (Lewis et al, 2016). Lower levels of 
knowledge regarding NIPT have been associated to women declining the test (Farrell, Hawkins, 
Barragan, Hudgins, & Taylor, 2015). 
The second set of variables that has been implicated in the decision-making process regarding 
uptake of invasive and non-invasive tests includes intrinsic values as reflected in women’s 
attitudes towards specific concepts. Attitudes can be divided into two broad categories: attitudes 
towards specific targets, which in the current context might involve attitudes towards having a 
baby with Down’s syndrome, and attitudes towards behaviours that are directed towards 
specific targets, which in this instance may consist of attitudes towards having NIPT or a 
diagnostic test for Down’s syndrome (Bryant, Green & Hewison, 2010). Prior studies have 
suggested an overwhelmingly positive attitude of women towards prenatal testing in general 
and a tendency of women to report a positive attitude even towards having the recently 
developed NIPT (Sahlin et al, 2016). Nonetheless, further research is required to establish 
these findings, considering that NIPT has only been recently introduced into clinical practice. 
In health psychology, rational expectancy-value models such as the Theory of Reasoned Action 
(TRA; Ajzen & Fishbein, 1980) and The Theory of Planned Behaviour (Ajzen, 1991), which have 
been mostly used in order to explore the relationship between attitudes and behaviour, focus on 
predicting behaviour via attitudes toward the specific behaviour (i.e. undergoing a prenatal test) 
rather than attitudes towards the behavioural target (i.e. having a child with DS). However, a 
study by Bryant et al (2010) demonstrated that understanding an individual’s attitudes towards a 
tested-for condition, such as Down’s syndrome, alongside the burden attached to having a baby 
with such a condition, may help predict their intentions of using prenatal diagnostic tests. 
Therefore, when considering influences on amniocentesis/CVS or NIPT uptake it is important to 
explore not only attitudes towards having the actual test, but also attitudes towards having a 
baby with DS. 
A further attitude that has been associated with the rejection of amniocentesis/CVS is the 
attitude towards miscarriage as a result of the diagnostic procedure, with women who are more 
concerned over the possible risk of miscarriage being more likely to decline the diagnostic test 
(Santalahti, P., Hemminki, E., Latikka, A.M., & Ryynanen, 1997). Conversely, the absence of 
risk when it comes to NIPT has been found to influence women’s positive attitude towards this 
testing method (Lewis et al, 2016) and has been associated with uptake of this testing approach 
(Barrett, Advani, Chitty, & Choolani, 2016). 
Quite relevant to this is the suggestion by Marteau (1990) that patients’ attitudes towards 
doctors and medicine (which she categorised as positive versus negative) may prove useful in 
predicting health-related behaviours, such as attending for screening. However, later studies 
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reported that refusal of prenatal screening did not necessarily signify rejection of medical 
science and technology; it was observed that while women who declined amniocentesis/CVS 
tended to distrust biomedicine and place more trust in experiential sources of information – such 
as feeling “normal” movements of the baby in the womb – and vice versa for those accepting 
the diagnostic test, neither of the two groups placed authoritative power solely in one source or 
the other. Rather, they both drew on the biomedical model to account for their decision, simply 
focusing on different elements of it whilst also taking into account experiential information, to 
either a greater or lesser extent (Lippman, 1999; Markens, Browner & Press, 1999). That said, a 
recent study found that trust in doctors and medicine was fundamental in shaping women’s 
decisions to accept or decline amniocentesis, drawing attention back to the suggestion initially 
raised by Marteau (Markens, Browner & Preloran, 2010).  
Another independent factor that has been positively associated with amniocentesis/CVS and 
NIPT uptake is women’s perception of being at an increased risk of having a baby with Down 
syndrome, regardless of their actual risk level (Lewis et al, 2016; Marteau et al, 1991). However, 
this finding has not been consistent across studies, with Tercyak et al (2001) reporting that 
neither actual nor perceived risk was related to test uptake. 
Moreover, although less documented in the literature, it has been proposed that the notion of 
“anticipated decision regret” might play an important role in the choice of having a prenatal test 
(Tymstra, 2007). The reasoning behind this construct is that people will choose to have a test 
done in order to avoid being confronted later on with negative feelings that may result from what 
proves to have been a wrong choice; for instance, expectant mothers might feel responsible for 
giving birth to a child with a congenital abnormality if this could have been prevented by her 
accepting an invasive test when it was offered to her. 
Another factor that is possibly implicated in the amniocentesis/CVS decision-making process is 
health locus of control (HLOC), which, according to Rotter’s Social Learning Theory (1966), is 
classified as internal, when an individual’s appraisal of an outcome is perceived as a direct 
result of their own behaviour, or external, when a person believes that the outcome of a 
situation is under the control of powerful others (i.e. doctors), or is determined by random 
forces, such as chance (Sanders, 1989). HLOC is a construct that has received much research 
attention by health psychologists, who have highlighted its importance by associating beliefs 
about internal versus external control with various health-related behaviours (Strickland, 1978). 
With regard to amniocentesis, an internal or medical profession/external locus of control has 
been associated with acceptance of the test, whereas a chance/external locus of control has 
been associated with refusal of the procedure (Lumley, Zamerowski, Jackson, Dukes & 
Sullivan, 2006; Punales, 2005); this suggests that women who believe themselves or their 
doctors to be in control are more likely to undergo invasive testing, as opposed to women who 
attribute outcomes to chance.  
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Relevant to this is the concept of “subjective norms”, which has also been reported in previous 
studies, whereby a woman will choose to have a prenatal test regardless of her own attitude 
towards it simply because she feels pressured into it by her social environment (Michie et al, 
2002). The most influential sources reported in the literature are partners, doctors in antenatal 
care and to a slightly lesser extent family and friends (Georgsson et al, 2016). Yet, the evidence 
is not clear, with some studies reporting that the majority of women are not affected by others 
and that the decision to undergo NIPT or not is their own (Sahlin et al, 2016). The term 
“technological imperative” which is widely spread throughout Westernised parts of the world 
also mirrors this tendency of people to worship technology and to conform to societal pressure 
of considering normative the acceptance of any technological intervention that becomes 
available (Gillick, 2007). And even though the choice to undergo a prenatal test such as 
amniocentesis/CVS or NIPT is up to the woman herself, it appears that nowadays the maternal 
and medical norms are such that any such recommendations are perceived as orders to be 
followed. Nevertheless, the possible implications of technological interventions need to be 
addressed and alternatives, such as non-use, be considered if a truly informed decision is to be 
made (McCoyd, 2010).  
Finally, anxiety is a factor that has been implicated in numerous studies regarding prenatal 
screening and diagnostic tests. However, the results have been conflicting with some studies 
reporting it as a factor contributing to the uptake of amniocentesis in order for the woman to 
gain reassurance about her baby’s health (Lesser & Rabinowitz, 2001), while others associate 
elevated anxiety levels with rejection of amniocentesis, as a result of concern over the 
possibility of foetal injury, anticipated pain during the procedure, or the outcome of the test 
(Ilgin-Ruhi et al., 2005; Karasahin, Gezginc & Alanbay, 2008). As far as NIPT is concerned, 
anxiety over foetal health and women’s own coping abilities has been associated with uptake of 
this testing method (Lewis et al, 2016). Understanding how anxiety interacts with other 
psychosocial factors is relevant to the objective of this study.  
 
1.8. Aim of the study 
Although all the aforementioned variables have been identified through various studies that 
have been carried out regarding the uptake of prenatal screening and amniocentesis, the vast 
majority of these studies lack a theoretical framework, focusing instead on isolated variables. 
Also, it has been suggested that due to similarities in key constructs between the leading 
models of health behaviour, an integrative approach using a combination of several models may 
better explain specific health behaviours (Shiloh, 2006). Therefore, the aim of this study will be 
to take a more holistic approach and use a combination of psychological models in developing a 
questionnaire aimed at identifying those variables that are most significant in a woman’s 
decision to have NIPT, an invasive test or no further testing following the routine first trimester 
combined screening test. 
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1.9. Study hypotheses 
 Women who perceive themselves to be at an increased risk of having a baby with a 
chromosomal abnormality will be more likely to have an invasive test or NIPT. 
 Women who feel pressured by their social environment into having an invasive test or 
NIPT will be more likely to opt in for one of these tests. 
 Women who have an increased awareness of NIPT and invasive diagnostic tests will be 
more likely to have one of these tests. 
 Women with a positive attitude towards undergoing an invasive test or NIPT will be 
more likely to have one of these tests. 
 Women who attach a greater burden to having a child with a chromosomal abnormality 
will be more likely to have an invasive diagnostic test and/or NIPT. 
 Women with a positive attitude towards doctors and medicine will be more likely to 
choose to have an invasive diagnostic test or NIPT. 
 Women with an internal or medical professional/external locus of control will be more 
likely to have an invasive test or NIPT. 
 Women who are concerned over losing their baby as a result of a diagnostic procedure 
will be less likely to undergo an invasive diagnostic test and more likely to have NIPT.  
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2. Chapter Two: Methods – Pilot Study and Validation of Questionnaire 
2.1. Development of questionnaire  
2.1.1. Theoretical framework  
Following the literature findings described in Chapter 1, a questionnaire was developed for the 
purposes of this study. Adopting a holistic approach, this was informed by a combination of the 
following theoretical models: 
a) The “subjective expected utility model” (SEU; Savage, 1954) which is the leading decision-
making model in the presence of risk, according to which an optimal decision maximises 
expected utility (Shiloh, 2006); 
b)  Ley’s Cognitive Hypothesis (1989), according to which, in order to improve compliance, a 
certain level of awareness regarding the specific situation is required;  
c) The Health Belief Model (Rosenstock, 1966), which is used to describe behaviour or 
decision-making under the circumstances of uncertainty, and according to which, health 
behaviour is determined by beliefs regarding: perceived susceptibility, perceived severity, 
costs, and benefits; in other words, a person is considered more likely to carry out a health 
behaviour if they perceive the threat of the disease to be relevant to them and if the 
benefits of this behaviour are perceived to outweigh the costs (Armitage & Conner, 2000); 
d) The Theory of Planned Behaviour (Ajzen, 1988), which predicts a person’s intention to 
perform a specific behaviour based on their attitudes towards this behaviour, their 
perceived behavioural control over the final outcome, and the influence of subjective 
norms, which is a term used to describe a person’s beliefs about what salient others think 
he/she should do;  
And finally, 
Other factors that were also addressed in the questionnaire and have been earlier described 
(see Chapter 1) include: the construct of anticipated decision regret, Health Locus of Control, 
anxiety, and women’s socio-demographic and medical backgrounds. 
2.1.2. Study variables measured 
Based on the theoretical framework described in the section above, all variables to be included 
in the study were identified (see Table 2.1).  
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Table 2.1 
Variables to be studied and their respective theoretical frameworks 
  
Each of the identified variables presented in Table 2.1 were then explored in relation to existing 
measures and their psychometric properties and a comprehensive questionnaire was 
developed including the following sections: 
 
a) Section A: Knowledge  
This section consisted of four items that examined women’s knowledge in relation to the 
purpose and reliability of amniocentesis, the risk for miscarriage associated with invasive tests, 
and follow-up options. Two of the items were multiple choices and two were ‘true’ or ‘false’. The 
score scale ranges from zero (no correct answers) to 4 (all correct answers) with higher scores 
indicating greater awareness in relation to invasive tests. Similar scales to this have previously 
been used to assess knowledge of prenatal screening tests in general rather than focusing on 
invasive tests (Brajenovic-Millic et al, 2008; Marteau et al, 1988). 
b) Section B: You and amniocentesis / CVS 
This section involved the measurement of the following internalised variables: 
i. Attitudes towards having amniocentesis/CVS was measured by a scale that consisted 
of four 5-point semantic differentials as follows: “For me, having amniocentesis/CVS 
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would be… not at all beneficial-very beneficial / extremely unpleasant-not at all 
unpleasant / not at all reassuring-very reassuring / not at all frightening-very 
frightening”. Participants’ responses were measured on a five point Likert scale ranging 
from 1(very negative attitude) to 5 (very positive attitude). 
ii. Attitudes towards amniocentesis/CVS was measured by two items using a 5-point Likert 
scale ranging from 1(=strongly disagree) to 5(=strongly agree). Higher scores indicate a 
more negative attitude towards amniocentesis/CVS.  
iii. Attitude towards miscarriage as a result of amniocentesis/CVS was measured using a 
5-point Likert scale ranging from 1(=extremely bad) to 5(=not at all bad). Higher scores 
indicate a more negative attitude towards miscarriage. 
iv. Perceived severity was measured using a 5-point Likert scale ranging from 1(=strongly 
disagree) to 5(=strongly agree). Higher scores indicate a higher perceived severity of 
chromosomal disorders such as Down’s syndrome. 
v. Anticipated decision regret was measured using a 5-point Likert scale ranging from 
1(=strongly disagree) to 5(=strongly agree). Higher scores indicate higher intentions to 
use any tests available. 
vi. Burden attached to having a child with a serious abnormality was measured using a 5-
point Likert scale ranging from 1(=“very good”) to 5(=”very bad”), with higher scores 
indicating greater burden attached. 
vii. Perceived risk of having a child with a serious abnormality was measured using a 5-
point Likert scale ranging from 1(“not at all likely”) to 5(“very likely”). Higher scores 
indicate greater perceived risk. 
viii. Perceived behavioural control was measured using a short version of a scale used in a 
previous study (Berkenstadt et al, 1999). This consisted of three items rated on a 5-
point Likert scale and ranging from 1(=strongly disagree) to 5(=strongly agree). Higher 
scores indicate greater perceived behavioural control. 
For all the items above a sixth option (“Don’t know”) was also provided. 
 
c) Section C: Others and amniocentesis / CVS 
This section included a scale adapted from a previous study on prenatal screening (van der 
Berg, 2008) and measured subjective norms by assessing normative beliefs and weighing 
them for motivation to comply (Ajzen, 1991). Normative beliefs were assessed for the 
woman’s partner and her midwife/obstetrician by two 5-point items. For example:  “If it is 
offered to me, I think my partner will want me to…” with answer options ranging from 
“certainly decline amniocentesis/CVS” to “certainly accept amniocentesis/CVS”. The 
respondent’s motivation to comply with each of these normative beliefs was measured by a 
5-point item as follows: “I find my partner’s opinion about accepting or declining the test…” 
and answer options ranging from “very important” to “not at all important”. An overall 
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subjective norm scale of the two referents together is estimated by calculating the mean of 
the two products of normative beliefs with motivation to comply and the scale ranging from 
1 (=strong subjective norm to decline amniocentesis/CVS) to 5 (=strong subjective norm to 
accept amniocentesis/CVS) 
d) Section D: How you are feeling 
This section measured anxiety using the anxiety scale from the Hospital and Anxiety Scale 
(HADS; Zigmond & Snaith, 1983). This includes 7 items rated on a 4-point likert scale with 
scores for each item ranging from 0 to 3. A mean score is then calculated across all items, 
meaning that a respondent can score between 0 and 21, with higher scores indicating 
greater levels of anxiety. A cut off score of 8 has been established across numerous 
studies indicating that individuals scoring above this score are clinically anxious (Bjelland, 
Dahl, Haug, & Neckelmann, 2002).  
e) Section E: Attitudes towards doctors and medicine 
This is a scale developed by Marteau (1990) and aims to specifically measure attitudes 
towards effectiveness of medicine in promoting health and attitudes towards the 
effectiveness of doctors in promoting health. It consists of 19 items rated on a scale from 
1(=strongly disagree) to 5(=strongly agree). 
f) Section F: Beliefs about illness: 
This section consists of the Health Locus of Control Scale (Walston & Walston, 1981) 
which is formed by the following three 6-item subscales: internality; powerful others 
externality; and chance externality. Each of these scales is rated on a 5-point likert scale 
ranging from 1(=strongly disagree) to 5(=strongly agree) and they are scored 
independently from one another.  
g) Section G: You and your family  
This section covered demographic information (i.e. age, ethnicity, religion), socio-economic 
status (i.e. marital status, level of education, occupation, household annual income) and 
medical history information (i.e. prior miscarriages or termination of pregnancy, prior history 
of amniocentesis, etc.). This information is important in order to be able to control for 
external factors and be able to focus on the specific psycho-social variables under study. 
However, the demographics section was strategically placed at the end of the 
questionnaire so as to ensure that participants gave priority to the actual questionnaire 
should they return it incomplete. 
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h) Screening measure 
At the end of the demographics section a brief screening measure for mental health issues 
was included. This includes a mixture of ten health-related issues covering both, mental 
health, such as depression and schizophrenia, and common health problems, such as 
migraine and allergies. The aim of the common health problems was to slightly mask the 
emphasis on asking questions just about mental health. Participants were also asked to 
state any medication they were taking at the time. The purpose of this screening tool was 
to allow for exclusion of those who were suffering from any sort of mental health issue, 
which may have impacted on their responses to the other scales of the questionnaire.     
See Appendix 1 for a copy of the original questionnaire. 
2.1.3. Procedure  
Following ethical approval from the NHS REC committee and the King’s College Hospital R&D, 
women were invited to participate in the study through the post. The questionnaire and the 
accompanying documents (consent form - see Appendix 2, information sheet – see Appendix 3, 
debrief form – see Appendix 4) were sent together with the appointment letters that were posted 
for their first trimester scan. Participants were given the option to either post back the completed 
questionnaire and consent form (using a pre-stamped envelope enclosed) or bring them in 
themselves to hand over to a member of staff when they attended their scan appointment. 
In an attempt to increase the response rate, after an initial trial, incentives were added to the 
study after ethical approval was sought from the aforementioned ethical committees. The 
incentives comprised of: 
a) A voucher (see Appendix 5) for respondents to complete their preferred method of contact 
and return with their questionnaire so as to be entered into a prize draw for a £200 voucher 
to spend at a big maternity chain-store. and, 
b) A sample of Pregnacare folic acid & vitamin supplements that was included as a token of 
gratitude with every questionnaire sent out to candidates through the post.   
Upon return of the completed questionnaires, these were securely stored –unopened- at KCH 
and the chief investigator collected them for analysis and safe storage. Following the analysis of 
the data, the questionnaires (which were anonymous) were stored in locked cabinets and kept 
separately from the consent forms to which they could only be linked via a participant ID 
number allocated by the chief investigator. This ensured that all responses were unidentifiable 
and only the chief investigator could have access to the questionnaires and personal 
information if required. 
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2.1.4. Participants 
Participants were all patients of King’s College Hospital (KCH), who were in the first trimester of 
their pregnancy and had not yet attended for their first scan. In line with the inclusion criteria 
they were all above 18 years of age, they could speak and write English, and were not suffering 
from any kind of mental health issues. A total of 58 valid questionnaires were collected and 
included in the analysis. 
2.2. Principal Component Analysis (PCA) on pilot study questionnaire 
2.2.1. Background and main goals 
As mentioned above, the questionnaire administered during the pilot study consisted of some 
already established and validated scales (the Health Locus of Control Scale; the HADS – 
anxiety scale; and, the attitudes towards doctors and medicine questionnaire) whilst other 
questions were also included in an attempt to explore additional variables that may potentially 
influence women’s decision making process regarding uptake of amniocentesis/CVS. The latter 
however, were not part of a previously standardised questionnaire so it was considered 
plausible to subject them to further statistical assessment through conducting a factor analysis.  
The main goal for this was to reduce the number of items into clusters of variables or otherwise 
named ‘factors’ that will be stronger statistically and more meaningful. This process would 
hopefully lead to a shorter and more efficient questionnaire but not at the cost of any important 
information, whilst also facilitating analysis and interpretation of the findings. The newly revised 
version is planned to be used for the main study in order to retrieve all the necessary data from 
participants without being overly exhausting and time-consuming.  
In terms of factor analysis there are many different types involving a multitude of different 
techniques, but for the purposes of this study a PCA was carried out. PCA has its roots back to 
Pearson (1901) making it the oldest but also the most popular multivariate statistical technique 
which is used in almost all scientific disciplines (Abdi & Williams, 2010). Its wide use has led to it 
being characterised as a well-established technique for dimensionality reduction (Tipping & 
Bishop, 1999) thus justifying its use in this pilot study. 
As summarised by Abdi &Williams (2010) the goals of PCA are: 
a) To extract the most important information from the data table; 
b) To compress the size of the data set by keeping only this important information; 
c) To simplify the description of the data set; and 
d) To analyse the structure of the observations and the variables. 
The PCA was carried out using the statistical software SPSS and the results are considered 
below in order to validate the suitability of this method for our specific data-set and extract 
suitable factors for interpretation. It is important to note here that the process of PCA in SPSS 
was repeated until all weak variables were removed and only those suitable for interpretation 
were retained. 
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2.2.2. Key findings 
Key points based on the final PCA carried out are presented below: 
a) Sample size  
Throughout the years many different propositions have been made in relation to what an 
appropriate sample size would be for a factor analysis leading to various “rules of thumb” being 
established. For example, 300 cases have been suggested as a probably adequate sampling 
size while others have recommended 100 cases as a minimum or on a ratio scale 5 to 10 cases 
per each variable to be measured (Field, 2000). In this pilot study there were 58 cases which is 
in line with the absolute minimum of 50 cases recommended by Hair (1998) and Habing (2003).  
Nevertheless, being aware that this is still quite a small number of cases, the adequacy of the 
sampling size was also examined by various other methods that have been established and are 
easily measured in SPSS: 
i. Kaiser-Meyer-Olkin (KMO or else MSA) measures the sampling adequacy and even 
though ideally a value of 0.7 or above would be desired, the sample is considered 
adequate if KMO is above 0.5 (Field, 2000). In the present analysis, the final KMO was 
0.627 thus meeting this criterion (Table 2.2). 
 
ii. Bartlett’s Test of Sphericity is another measure of the strength of the relationship 
between variables and compares the correlation matrix with a matrix of zero 
correlations (Beaumont, 2012). As reported by Field (2000, p.457) “it tests the null 
hypothesis that the original correlation matrix is an identity matrix”, which would mean 
that there are no correlations between the variables and therefore a significant p value 
is required in order to be able to reject the null hypothesis. From the current analysis we 
can see that Bartlett’s test of Sphericity is significant (Table 2.2) thereby justifying the 
conduct of a PCA. 
 
Table 2.2 
KMO and Bartlet’s Test 
b) Correlation Matrix  
This is the starting point for all types of factor analysis and is consulted in order to assess 
whether we have appropriate correlations that would justify a factor analysis. In essence, PCA – 
like all other types of factor analysis – tries to combine variables together into factors (or 
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components) based on their correlations and therefore it is possible to form a first impression of 
what the factors will be by looking at the correlation matrix and identifying clusters of variables 
that are highly correlated between them. As a rule of thumb a substantial number of correlations 
is >0.3 otherwise there is no point in carrying on with the analysis since the variables are 
unrelated between them and thus cannot be modelled so as to form overarching factors 
(Tabachnick & Fidell, 2001). 
Looking at the correlation matrix of this study (see Appendix 6) there are over 10 variables with 
a correlation above 0.3 thereby justifying continuation with the analysis. 
b) Communalities   
These figures show how much of the variance in each single variable has been accounted for 
by the extracted factors. The value ranges from zero to 1, where zero indicates that the variable 
cannot be predicted at all from any of the factors and 1 indicates that the variable can be fully 
defined by the extracted factors (Beaumont, 2012). Given that when carrying out a factor 
analysis it is hoped that the observed dataset will be reflected in the model being tested, a 
highest possible value is desired and the nearer to one it is, the better. In general it is accepted 
that the factor solution should explain at least half of each original variable’s variance, so the 
communality value for each variable should be 0.50 or greater. 
Looking at Table 2.3 below, we can see that for this study, all communalities were above 0.50 
and 10 out of 16 were even above 0.7 indicating that they represent a significant amount of 
variability in the model. 
According to Field (2000, p.43) communalities are also related to sample size and the lower 
they become the more important sample size is. Thus, if the communality is high the extracted 
factors account for a big proportion of the variable’s variance and the sample size can be 
considered to be adequate, but if the communality is low, the sample size would have to be 
bigger in order to compensate for this.  In terms of this study, there are many high 
communalities thus providing a further confirmation for the appropriateness of our sample size. 
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Table 2.3 
Communalities 
 
c) Initial number of components (factors) extracted 
The number of components that is initially extracted in PCA is exactly the same number as 
variables being analysed. In this case we had 16 variables being analysed and therefore 16 
components were initially extracted. However, in general only the first one or two components 
can be expected to account for a fairly large amount of the total variance and each succeeding 
component will account for a progressively smaller amount of variance. Therefore, out of all the 
components initially extracted only the first few can be expected to be meaningful enough to be 
retained. The exact number can be assessed through various criteria discussed in the following 
section.  
d) Determining the number of meaningful components (factors) to be retained 
In PCA this decision can be facilitated through the following criteria: 
i. The eigenvalue-one criterion: This is also known as the Kaiser criterion (Kaiser, 1960) 
and is the most commonly used method in PCA in determining the number of factors 
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important enough to be retained for interpretation. The rationale is quite straightforward 
and begins from the assumption that each variable contributes one unit of variance to 
the total amount of variance.  
According to this approach, any component with an eigenvalue over 1.00 is suitable to 
be retained and interpreted as this implies that it accounts for a greater amount of 
variance that has been contributed by one variable. On the contrary, any component 
with an eigenvalue that is less than 1.00 accounts for less variance that has been 
contributed by one variable and therefore should be ignored. To sum it up, the goal of 
PCA is to reduce the number of variables into a smaller amount of retained components 
which have an eigenvalue above 1.00. 
 
Looking at Table 2.4, for this study there are 6 components with an eigenvalue over 
1.00 and therefore these are the ones indicated for retention and interpretation. The 
Cumulative % is less than 100% because not all of the variance is explained when only 
some of the factors are retained in the final analysis. Components 7 through 16 were 
eliminated. Even though together they represent over 30% of the variance explained, 
any one of the factors accounts for very little variance and therefore is not considered 
significant enough to be retained. 
 
The eigenvalue-one criterion is well-suited for the current study since it has been 
established as a reliable way of retaining the correct amount of components particularly 
when a small to moderate amount of variables are being analysed (<30) and 
communalities are above 0.70 (Stevens, 1986).    
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Table 2.4 
Total variance explained 
 
 
ii. Proportion of variance accounted for: this indicates how much of the variability in the 
data can be accounted for by the extracted components. Most often researchers retain 
the amount of components that cumulatively account for a minimum accepted value, 
which is usually set to 60%, meaning that all the respective components put together 
explain 60% of the total variance (Beaumont, 2012). As observed in Table 2.4, the first 
6 components in this study account for the 69.998% of variance and therefore are the 
ones that should be retained. 
 
e) Summary of basic criteria confirming the appropriateness of PCA 
As illustrated in Table 2.5, PCA is justified for our data-set and a total of 6 major components 
were identified. 
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Table 2.5 
Summary of fulfilled criteria, confirming appropriateness of PCA for this study 
  
f) Giving meaning to the factors 
The next stage is to examine the variables that are grouped together under each of the 
extracted components in order to identify common themes.  
One method that facilitates the process of interpretation is ‘rotation’, which aims to further 
analyse the extracted factors and make the factor loadings more transparent (Bountziouka & 
Panagiotakos, 2012). It is generally recommended as it simplifies the component structure and 
makes interpretation more reliable (Cattell, 1978).  There are two types of rotation available in 
SPSS, but for the purposes of this study an oblique rotation was performed. Contrary to its 
alternative (orthogonal rotation), this method does not require components to be orthogonal to 
each other and thus allows variables to be correlated (Vogt, 1998). 
Based on the results from the oblique rotation (see Appendix 7) the questions that load onto 
each of the six components are shown in Table 2.6. 
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Table 2.6 
Breakdown of all extracted components 
  
Looking at the breakdown of each of the above components (Table 2.6), it is clear that 
components 2, 3, and 5 are coherent and thus may represent a real-world construct. 
Components 1 and 4 however, include items that cannot logically be grouped together in order 
to form a coherent factor and thus should be removed from the questionnaire. Finally 
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component 6 only includes one question and will therefore also be removed as it is not strong 
enough to form a factor on its own.  
This interpretation seems to reveal that, in reality, the original questionnaire (or at least the part 
that was subject to PCA) is composed of three subscales: perceived behavioural control, 
benefits of amniocentesis, and attitudes towards chromosomal abnormalities.  
2.3. Internal reliability – Cronbach alpha 
2.3.1. Background 
Having decided to retain three components from the PCA based on a logical assessment of 
their respective items, a further statistical analysis – in the form of Cronbach α - was performed 
using SPSS, in order to confirm or challenge these conclusions.  
Looking at the output generated in SPSS, the following three tables need to be consulted in 
order to draw conclusions: 
a) “Reliability Statistics” 
According to this table, a minimum value of α = 0.7 – 0.8 is required in order for the respective 
scale to be considered to have a good internal reliability, thus indicating that all questions are 
measuring the same thing. 
b) “Item-Total statistics: Corrected item – total correlations” 
These values illustrate the correlations between each item and the total score retrieved from the 
questionnaire. In order for a scale to be considered reliable, all items must correlate with the 
total. Otherwise, if any of the items has a value less than 0.3 it might need to be dropped. 
c) “Item-Total statistics: Alpha if item is deleted” 
These values indicate the overall alpha value if each given question were to be removed from 
the calculation. Therefore, when reading this table we are looking for values that are greater 
than the overall alpha, because if the deletion of an item increases Cronbach alpha that means 
it improves the scale’s reliability.  
2.3.2. Internal reliability for each individual sub-scale produced by PCA 
2.3.2.1. Subscale 1: Perceived behavioural control 
This subscale appeared to have good internal consistency with α = .804. In addition, all items 
are sufficiently correlated with the total (values greater than 0.6), while none of them would 
substantially affect reliability if they were removed (see Appendix 8). Therefore, all three items 
appear to be worthy of retention. 
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2.3.2.2. Subscale 2: Benefits of amniocentesis / CVS 
Similarly this subscale had good internal consistency with α = .738. All items were correlated 
with the total (values greater than 0.5) and none of them would increase reliability if they were to 
be removed (see Appendix 8). Therefore, all three items were suitable to be retained. 
2.3.2.3. Subscale 3: Attitudes towards chromosomal abnormalities 
Contrary to the other two constructs this subscale had a low internal reliability score with α=.466 
(see Appendix 8). This may be due to the fact that the specific sub-scale only consisted of two 
items which may not have been sufficient enough to measure what they set out to measure. 
According to Tavakol & Dennick (2011) “if the test length is short, the value of alpha is reduced”. 
Therefore, they recommend that in an attempt to increase internal reliability, more items testing 
the same concept can be added to the test. This is a good point to be explored by future 
studies. 
However, despite the low alpha score both items correlated with the total, meeting the threshold 
criterion of 0.3 and therefore at least for the purposes of this study this subscale will be retained 
as it is though results will be interpreted with cautiousness. 
2.3.3. Internal reliability for other subscales included in the questionnaire 
As previously mentioned, PCA was only performed on those sections of the questionnaire that 
were developed for the purposes of this study and needed to be assessed for their 
psychometric properties. However, there were other scales also included in the questionnaire 
that have previously been validated through other studies. Nevertheless, as it has been 
suggested to be good practice (Streiner, 2003) it was decided that a reliability test would also be 
applied to these individually in order to test for their suitability for this particular population 
(Streiner, 2003) (see Appendix 9). 
a) Hospital Anxiety and Depression Scale (HADS) – Anxiety scale 
This subscale seemed to have a lower level of internal reliability than expected, with α=.577.  
b) Attitude towards doctors and medicine 
This subscale also had a low internal reliability based on this sample, with α=.601 
c) Health Locus of Control (HLOC) 
Finally, this subscale also demonstrated low internal reliability for our sample, with α=.563. 
However, despite the low internal reliability scores for all three above scales, they will be 
retained in the questionnaire for the main study. Several previous studies have validated their 
psychometric properties and therefore the low alpha scores observed in this study may be more 
related to the size of the sample but may not be an issue in the main study where the sample 
will be significantly larger.  
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It is important to note here that the main purpose of this pilot study was mainly to assess those 
sections of the questionnaire that were newly developed, through the use of PCA and Cronbach 
alpha and thus the reliability of the latter three scales will again be assessed in the main study. 
2.3.4. Questionnaire amendment based on PCA findings and cronbach alpha 
All in all, based on the PCA the following factors will form part of the amended version of the 
questionnaire (see Appendix 10) to be used in the main study together with the previously 
validated scales mentioned in 2.3.2 above. 
A detailed account of all factors included in the original and the amended questionnaire is 
illustrated in Table 2.7. The amended questionnaire will be referred to as Prenatal Decision 
Making Questionnaire (PDMQ) for the remainder of the study. 
  Table 2.7 
Factors included in the original and the amended questionnaire
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2.4. Preliminary findings based on pilot study sample 
Basic statistical tests were conducted on the pilot study population in order to get some more 
information on the sample and gauge women’s responses thus far on the variables being 
measured. 
2.4.1. Sample characteristics 
The vast majority of participants were white (75.7%) while various minority groups made up the 
rest of the sample (see Table 2.8). In terms of religion, 58.6% of the total sample was Christian 
while quite a large amount was of ‘no religion’ (36.2%). This is in line with national data that 
indicate a steady increase in the amount of adults who are living in the UK and reporting they 
have ‘no religion’, with numbers rising from 47% in 2001 to 59% in 2009 (Office for National 
Statistics, 2013). The sample was almost equally divided into women under the age of 35 
(55.2%) and women aged 35 or over (49.8%), while the mean age for the total sample was 
33.67 (minimum: 23; maximum: 45; SD: 4.940). This is slightly higher than the national average 
that was reported to be 30 years of age in 2013 (Office for National Statistics, 2013). However, 
looking back at previous years, there has been a steady increase in the mean age of women at 
childbirth rising from 27.9 in 1993, to 28.8 in 2003 and 29.3 in 2008, suggesting that the last 
reported figures from 2013 may have increased as well reaching more towards our own sample 
characteristics. What is more striking, however, is the division in age groups with national 
averages reporting that 78.99% of live births in 2013 were to women aged 20-34 and the 
remaining 21.01% to women aged 35 or over (Office for National Statistics, 2013). This is 
something worth keeping in mind when considering the more equal distribution in our sample.  
The vast majority of women (94.8 %) in our sample were either married or living with their 
partner at the time of the survey which also contradicts the reported national average of 52.6% 
of live births being to married couples. However, it must be noted that we included couples 
living together regardless of being married or not in this category and therefore this may justify 
the seemingly big difference between our and the national findings without necessarily 
representing a true difference. The majority of the sample (67.2%) had an annual household 
income of £35.001-150.000 and overall the participants were of a varied educational 
background (see Table 2.9) with 81.1% having a university degree of some level. 
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Table 2.8 
Breakdown of participants’ ethnic origins 
 
For the 84.5% of the sample this was a planned pregnancy. This is in line with reports from the 
NATSAL study (Mercer et al, 2013) whereby 1 in 6 pregnancies in Britain are unplanned, 
translating into 84% being planned. Out of the total sample, the 15% reported having difficulties 
in getting pregnant with the 3.4% having had to be assisted by IVF in order to conceive. The 
25.9% of the sample had had a previous miscarriage whereas the 20.7% reported having had a 
termination of pregnancy in the past. Finally, only 3.4% of the participants reported having had 
an invasive test in the past and 32.8% reported that they knew of someone close to them 
having undergone such a procedure. 
 
Table 2.9  
Participants’ level of education 
  
2.4.2. Preliminary findings for the variables being studied 
In an attempt to get a first impression on how women scored in the variables that were retained 
following the Principal Component Analysis, descriptive statistics were conducted appropriately. 
The total sample consisted of participants that showed varying degrees of anxiety levels 
according to the HADS-anxiety scale measurements (see Table 2.10). It is important to note 
that almost half of the sample (48.3%) reported quite elevated anxiety levels indicating that they 
may be in need of support at this point in order to help alleviate their stress and not interfere 
with a healthy pregnancy. This is in line with previous studies reporting elevated levels of 
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anxiety in approximately 1 in 2 women, and this being the case during the first and third 
trimester as opposed to the second trimester which seems to be less stressful (Lee, Lam, Lau, 
Chong, & Fong, 2007). 
Table 2.10 
Assessment of anxiety levels based on the HADS scale 
In terms of attitudes towards doctors and medicine, the findings were contradictory. Participants 
demonstrated a slightly more negative attitude towards doctors but appeared to be more 
positively inclined towards medicine (see Table 2.11). While this was not further explored, it 
may be due to women’s past experiences with doctors or even simply down to associating their 
doctors with the communication of potentially painful information and thus creating a negative 
feeling. On the other hand, medicine and any relevant medical test may be viewed as a useful 
source of information / intervention thus creating a more positive attitude.  
Table 2.11  
Scores for attitudes towards doctors and medicine scales 
According to the Health Locus of Control Scale, 70.7% of the total sample indicated a greater 
internal locus of control, with 13.8% scoring high on the chance locus of control, and 8.6% 
scoring high on the powerful others dimension. This is an encouraging finding as it is thought 
that those who believe they have some degree of control are more likely to take responsibility 
for their actions and make more informed choices. 
Likewise, 91.4% of the sample demonstrated high levels of perceived behavioural control which 
again leads to the assumption that they feel they are in a position to take control of their and 
their baby’s health and any decisions related to it. 
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With regards to attitudes towards chromosomal abnormalities the majority of the sample 
(58.6%) reported these to be negative compared to the 39.7% that reported a more positive 
attitude towards chromosomal abnormalities. 
Finally, 69% of participants scored high on the perceived benefits of amniocentesis / CVS scale, 
indicating a potentially strong factor that would influence them towards having the test.  
2.5. Power analysis – calculating the sample size for the main study  
2.5.1. Background 
The starting point for any research is setting a null hypothesis and subsequently performing the 
relevant statistical tests in order to determine whether this can be accepted or not. For example, 
in this particular study the null hypothesis could be that “there is no difference in the mean 
outcome measure for all variables under study between women who decide to have 
amniocentesis and women who decide not to”. Ideally, we would like to be able to reject the null 
hypothesis and to show through statistical procedures that the different outcome decision 
between the two groups of women is not a result of chance. Once the null hypothesis has been 
determined, it is important to look at other constructs that will enable this process along the way.  
The Central Office for Research Ethics Committees (2007) has proposed some guidelines 
emphasising the importance of calculating the appropriate sample size, according to which ‘the 
number should be sufficient to achieve worthwhile results, but should not be so high as to 
involve unnecessary recruitment and burdens for participants’. Therefore, in order to maintain a 
balance and for studies to neither be underpowered (too few participants) nor overpowered (too 
many participants), it has become common practice for researchers to calculate the sample size 
that will be sufficient to achieve adequate power to carry out planned hypothesis testing 
(MacCallum, 1996). 
2.5.2. Calculating the sample size 
Sample size (n) is in essence a function of three factors – the significance level, power, and 
effect size. Thus, in prospective studies the most common practice is to calculate n, using a 
conventional level of significance, effect size and a desirable power (McCrum-Gardner, 2010).  
a) Significance level (p value).  
This is the probability cut-off which is chosen prior to performing the test, and usually a value of 
p=0.05 (or p=0.01) is used (Erdfelder, Faul, & Buchner, 1996). However, this is not absolute 
and it depends on how much safeguard is required against accidentally rejecting the null 
hypothesis when it is actually true. 
b) Effect size.  
This is a measure of the difference in the outcomes between two or more groups, and is the 
smallest difference that is considered to be clinically relevant (Prajapati, Dunne, & Armstrong, 
2010; McCrum-Gardner, 2010). While there are numerous ways for this to be calculated, Cohen 
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(1962) through his work on the power of statistical tests in behavioural research, established 
some standardised effect sizes which he characterised as ‘small’, ‘medium’, and ‘large’. 
Following an extensive study on effect size in social psychological research, and Cooper & 
Findley’s (1982) conclusion that it is reasonable to assume a medium effect size in power 
analysis, the majority of power studies observed in the literature have indeed used Cohen’s 
definitions as a guide (Sedlmeier & Gigerenzer, 1989). 
c) Power. 
This represents the type II or beta error probability of falsely retaining an incorrect Ho (Faul, 
Erdfelder, Buchner, & Lang, 2009).  In other words, the statistical power of a test (1-β) 
measures its ability to reject the null hypothesis when it should actually be rejected. As a rule of 
thumb, 80% is considered as the minimum accepted level meaning that there is a 20% chance 
of accepting the Ho in error (beta=20%). It is easily assumed that studies that lack statistical 
power are of limited use as they do not allow safe conclusions to be drawn in relation to the 
discrimination of the Ho from the alternative hypothesis (H1). 
2.6. G power 3.1 – Analysis and results 
The importance of statistical power analysis for every research study in the social, behavioural, 
and biomedical sciences is widely reported in the literature and several authors have provided 
extensive tables of power and relevant sample sizes (Erdfelder et al, 1996). However, it was not 
until the late 1980’s that power charts (Scheffe, 1959) and power tables (Cohen, 1962) were 
replaced by more precise, efficient, and user-friendly computerised power analysis programs 
(Goldstein, 1989).  
One such application that was also used for the purposes of the present pilot study is the 
programme Gpower (version 3.1) which is freely available online (http://www.psycho.uni-
duesseldorf.de/abteilungen/aap/gpower3/download-and-register) and is commonly used for 
numerous statistical tests in the social, behavioural, and biomedical sciences (Faul et al, 2009).  
All in all, there are three steps in this application: 
a) Selection of statistical test to be used  
G power 3.1 offers a wide variety of statistical tests including: one sample correlation tests; 
statistical tests comparing both dependent and independent Pearson correlations; simple linear 
regression coefficients; multiple linear regression coefficients for both fixed- and random- 
predictor models; logistic regression coefficients; and, Poisson regression coefficients (Faul et 
al, 2009).  
In this case t-tests were computed using the statistical software Gpower 3.1 in order to 
determine the required sample size for the comparison between three independent groups: 
women choosing to have an invasive diagnostic test, women choosing NIPT, and women 
choosing to have no further testing at all.  
b) Specification of the desired type of power analysis  
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Depending on the phase of the research and the research question, G power 3.1 offers the 
following five types of power analysis: A priori analysis; Post hoc analysis; Compromise 
analysis; Criterion analysis; and, Sensitivity analysis.  
For the purposes of the current study an a priori type of analysis was performed as this is the 
most relevant and efficient method for sample size calculation (Prajapati et al, 2010). One of its 
strongest points is that it allows for statistical power, alpha level and effect size to be controlled 
prior to the study being conducted (Hager, 2006) while the respective values can be determined 
by the researcher without any restrictions.  
c) Selection of the accuracy level of the calculations  
In line with conventional values found across the literature, for the present analysis a power of 
0.80 was used, alongside a medium effect size (0.5) according to Cohen’s measurement 
standards, and a significance level of .05. A two-tailed test was also selected as it is unknown 
towards which direction the two groups will differ between them. 
Based on the aforementioned specifications it was found that a sample size of 159 participants 
will be required for the main study in order to have sufficient statistical power and draw safe 
conclusions about the decision-making factors that influence women in having an invasive test 
or not (see Figure 1). 
 
 
Figure 1. G power analysis parameters for calculation of sample size for the main study 
 
2.7. Target population for the main study 
As with the pilot study, the target population for the main study will consist of pregnant women 
attending King’s College Hospital (KCH) for their first trimester combined screening test. Prior to 
receiving their screening results women will be given the questionnaire to complete if they wish 
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to participate in the study. Other inclusion criteria involve age 18 or over, ability to read and 
write English, and absence of any mental illness at the point of data collection.  
2.8. Conclusion 
Adopting a holistic approach and through a comprehensive combination of key psychological 
models and literature evidence, a questionnaire was developed aiming to explore pregnant 
women’s decision making factors when it comes to the uptake of invasive testing.  
Overall, the questionnaire consisted of some scales that have previously been validated through 
several studies and have been reported to have good psychometric properties. However, for a 
number of factors to be explored no measures were identified in the literature and thus new 
scales were developed for the purposes of this study.  Therefore, the present pilot study was 
conducted with a main goal to validate these scales before proceeding to the main study. 
A Principal Component Analysis (PCA) was performed using SPSS and this was followed by a 
reliability test, namely Cronbach alpha using the same statistical software. As a result, the 
following three valid components were formed: perceived behavioural control, attitude towards 
chromosomal abnormalities, and benefits of amniocentesis / CVS. Therefore only their 
respective questions were retained and the rest were dropped as there was no evidence of their 
contribution to the questionnaire.  
This lends support to the initial assumption that a combination of different variables from 
different theoretical models can actually be construed into an integrative approach to predicting 
one’s decision (Shiloh, 2006) although it was still disappointing to not be able to measure the 
role of all the variables we set out to explore. Out of the different psychological models that 
informed the development of the questionnaire it can be seen that some constructs were not 
supported, leading to various interpretations on how clear-cut each of the models used is and 
offering encouraging evidence for the flexibility in which these can be used in order to formulate 
a more efficient predictive model.  
More specifically, Ley’s Cognitive Hypothesis (1989) whereby those deciding to have a 
procedure (i.e. amniocentesis / CVS) will have greater knowledge of the test than those not 
undergoing it, was not supported by this questionnaire, adding more controversy to the current 
literature findings (French, Kurczynski, Weaver, & Pituch, 1992). In terms of this specific 
variable a possible explanation may be that actually the group of participants in this pilot study 
were mostly low-risk women and thereby were not actually faced with a decision to have an 
invasive test or not, so knowledge about it may not have been that relevant to their responses 
as they may have not felt the need to find out about the test before they actually “have” to 
consider it. Another potential explanation is that there were not enough items exploring 
‘knowledge’ about the test and therefore, if more questions were added this could have led to a 
different outcome. 
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Likewise, the subjective expected utility model (Savage, 1954) was not fully supported by this 
questionnaire. This model posits that an individual will base their decision on an assessment of 
their subjective outcomes of a behaviour (in this case weighing costs and benefits of 
amniocentesis / CVS) and their own subjective risks associated with that behaviour (i.e. how 
likely they are to have a baby with a chromosomal abnormality such as Down’s syndrome). In 
other words, similarly to the Health Belief Model (Rosenstock, 1966) it is hypothesised that one 
will weigh up the costs and benefits of undergoing a diagnostic procedure (i.e. amniocentesis / 
CVS) in relation to their perceived susceptibility to conditions tested for by that procedure (i.e. 
Down’s syndrome) (Mongin, 1997). However, based on the principal component analysis results 
for this questionnaire it appears that while benefits of amniocentesis / CVS were significant 
enough to form an influential factor in women’s decision making process, the costs associated 
with it and women’s perceived susceptibility to certain conditions were not prominent enough to 
form distinct factors in this process. Furthermore, perceived severity of chromosomal 
abnormalities such as Down’s syndrome was not relevant to this questionnaire, meaning that 
the only variable retained from the HBM were ‘benefits of amniocentesis / CVS’. This again, can 
possibly be interpreted as women mainly focusing on the benefits of amniocentesis / CVS when 
considering a hypothetical scenario of them being faced with such a decision. However, as 
these women were mostly low risk it is not possible to draw any further conclusions as to 
whether this indeed leads them to have the test or whether they can acknowledge the value of 
the test regardless of whether they decide to undergo it or not. This is a point for further 
exploration with a population where women of medium to high risk are actually faced with this 
decision, but is beyond the scope of this study.  
Another model that was partially supported by this questionnaire was the Theory of Planned 
Behaviour (TPB; Ajzen, 1988). In line with this theory, it seems that women’s attitudes towards 
chromosomal abnormalities such as Down’s syndrome were quite prominent in this 
questionnaire and the items generated were powerful enough to form a factor. It is interesting 
that attitudes towards the actual behaviour of undergoing invasive testing were not reflected as 
a valid factor in this questionnaire but this may have been due to the limited number of items 
referring to this variable rather than it not being influential in women’s decision. Likewise, 
‘subjective norms’ were not supported by this questionnaire, although once again it is uncertain 
whether this is because women are not that influenced by others in their decision or whether the 
addition of further items might have led to the formation of such a factor. However, upon 
reflection, a similar scale that was used in an earlier study (Van den Berg, 2008) had a low 
internal reliability (α=0.59) suggesting that indeed the influence of others may not be that central 
in the decision making process of invasive testing. However, ‘perceived behavioural control’ 
was sufficiently represented in this questionnaire indicating the importance of empowering 
women to make their own decisions and take control of their lives and wellbeing. This is 
supported by previous findings whereby perceived behavioural control predicted participation in 
cancer screening (Devellis, Blalock, & Sandler, 1990), and other health protective behaviours 
such as attending routine health screening (Conner & Norman, 1994) and condom use (Fisher, 
1984). However, even though a methodological limitation of most previous studies is that they 
 56 
measure intentions of performing a behaviour that has been previously performed and thus the 
prior experience of performing this act is indeed the strongest predictor of intention and 
behaviour (Sutton, 1994), a study exploring a novel behaviour also reported perceived 
behavioural control to be a significant predictor of women’s intentions to take hormone 
replacement therapy for the first time (Quine & Rubin, 1997). This strengthens the findings of 
our study where women may not have necessarily had a previous pregnancy and therefore are 
more likely to be faced with prenatal diagnostic decisions for the first time yet this not 
compromising the role of perceived behavioural control.  
Interestingly, contrary to prior evidence the previously validated scales included in the 
questionnaire – HLOC, Attitudes towards doctors and medicine, and HADS (anxiety scale) – 
were found to have low internal reliability for this specific sample. However, this is likely to be 
due to the rather limited sample size and thus will not affect their inclusion in the main study 
where the sample size will significantly be increased. 
To sum up, the final questionnaire (PDMQ) that will be used in the main study consists of a 
combination of various theoretical constructs examining the following factors for their 
contribution to women’s decision making process regarding the uptake of invasive testing: 
benefits of amniocentesis / CVS, perceived behavioural control, attitudes towards chromosomal 
abnormalities, Health Locus of Control, attitudes towards doctors and medicine, and anxiety.  
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3. Chapter Three: Main Study 
3.1. Background and current practices 
According to guidelines by the National Screening Committee, the current standard screening 
procedure in the National Health System (NHS) in the UK is the first trimester combined test 
which incorporates fetal ultrasound and maternal serum biomarkers (NSC, 2015). The benefit of 
this test is that it detects approximately 90% of foetuses with trisomy 21 (T12) and 95% of 
fetuses with trisomies 18 and 13 (T18/T13), although its limitation is that it entails a 5% false 
positive rate (FPR) (Nicolaides, 2011). This combined test is typically offered to all pregnant 
women and provides an individualized risk estimate. Women who are identified as high risk 
(≥1:150) are then offered the option of an invasive diagnostic test either in the form of Chorionic 
Villus Sampling (CVS) from 11 weeks of gestation or amniocentesis from 15 weeks (Alfirevic, 
Gosden, & Neilson, 2000). However, while both these tests provide a definitive diagnosis, they 
also entail up to 1% risk of miscarriage (Tabor & Alfirevic, 2010). 
An alternative, non-invasive method for risk assessment (NIPT) was first suggested in the late 
‘90s following the discovery of cell-free foetal DNA (cffDNA) in the maternal blood stream (Lo et 
al, 1997). While there were initial difficulties in distinguishing the foetus-specific genetic 
information from the maternal cell-free DNA, recent advances in technologies have helped 
overcome this obstacle and large clinical trials have validated the ability of non-invasive 
prenatal testing (NIPT) in detecting foetuses affected by Down’s syndrome (T21) as early as 10 
weeks into the pregnancy with a detection rate of 99% and a low FPR of 0.1%.Detection rates 
are also high for T18 (96%) and T13 (92%) (Gil, Akolekar, Quezada, Bregant, & Nicolaides, 
2014).While NIPT is more accurate than the conventional combined screening test, it still 
entails a small percentage of false positive (FP) and false negative (FN) results and is therefore 
considered a highly sensitive screening tool rather than a diagnostic test (Nicolaides et al, 
2012), with results requiring confirmation via invasive tests that provide a definitive diagnosis 
(ACOG, 2012). 
When considering the advantages of NIPT, the two most frequently cited are the absence of 
procedure-related risk of miscarriage and the attainment of results early on in pregnancy 
(Lewis, Choudhury, & Chitty, 2014). While these are undoubtedly of clinical significance, the 
limitations of NIPT should also be taken into account when comparing to invasive testing (IT). 
Firstly, in its current form NIPT is only accurate in detecting the three main chromosomal 
abnormalities, T13, T18, and T21 whilst failing to detect the majority of other genetic conditions 
that are identified through invasive testing (Nicolaides, Syngelaki, Gil, Atanasova, & Markova, 
2013). Even though efforts to expand the range of detectable conditions via NIPT, including 
sub-chromosomal abnormalities, are already being reported (Srinivasan, Bianchi, Huang, 
Sehnert, & Rava, 2013) these are in their early stages and large clinical trials remain to be 
conducted before further conclusions can be drawn (Vora, & O’Brien, 2014). In addition, there is 
a margin of 5% out of the total NIPT cases that produce inconclusive results; while this may be 
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due to a number of reasons it is most often due to a low foetal fraction (Gil, Giunta, Macalli, 
Poon, & Nicolaides, 2015) or an increased maternal BMI (Wang et al, 2013). 
Furthermore, as a result of the ease with which NIPT is offered via a simple blood draw and the 
absence of any risk may also incur potential additional drawbacks. Building on pre-existing 
ethical debates as to women’s difficulty to choose to reject technologies approved by their 
obstetricians (Wertz & Fletcher, 1993) women have already expressed concerns of feeling 
more pressured into accepting the test and less justified in declining it (Lewis, Silcock, & Chitty, 
2013). In addition to this, and in light of recent evidence supporting its effectiveness not only in 
high risk but also in low risk pregnancies (Nicolaides et al, 2012), it is likely that NIPT will be 
offered routinely as part of standard antenatal care. This is likely to jeopardise informed 
consent, as it is likely that women will be offered the option of NIPT without appropriate genetic 
counselling beforehand; up until the introduction of NIPT women undergoing their 1
st
 trimester 
combined screening test were offered minimal information about the genetic abnormalities 
detected and the subsequent steps they would have to take to confirm a high-risk indication and 
were only provided with further information should they be classified as being at high risk (Benn 
& Chapman, 2010). While this served to protect low risk women from unnecessary emotional 
disturbance and also catered to the limited availability of genetic counsellors, in the event of a 
NIPT it may pose greater danger as women may be proceeding without realising the potential 
outcomes and the gravity of the decisions they may then be faced with. However, in the 
absence of risk they are more likely to undergo such a blood test and thus potentially may be 
setting themselves up for a more distressing experience having not given the appropriate 
consideration to all factors in advance (Schmitz, Henn, & Netzer,2009). Nonetheless, despite 
the apparent simplicity of NIPT, at the end of it women are likely to be faced with life-changing 
decisions such as terminating or continuing with their pregnancies (following confirmation via an 
invasive test) and therefore it is of utmost importance for the informed decision process to 
remain a priority during implementation of any structural changes in prenatal testing. 
Following the volume of evidence in support of the effectiveness of NIPT it is now available in 
the private sector in numerous countries and discussions are centered on ways of implementing 
it in the public sector (Everett & Chitty, 2014). Considering the current prenatal testing policies 
within the NHS there have been several propositions so far: NIPT could either replace the 
standard combined screening test at 11-13 weeks of gestation and be routinely offered to all 
pregnant women, or alternatively it could replace invasive testing although there are 
reservations in this area due to its small but significant false-positive rates (Lewis et al, 2014). 
The final and most likely and cost-effective suggestion so far is for NIPT to be used as a 
contingent screening for women who are identified as moderate-high risk through the 11-13 
week test (Gil et al, 2014). This would lead to very high detection rates, whilst also maintaining 
the advantages of the combined screening through ultrasound and biochemistry, consequently 
minimising the number of confirmatory invasive tests required and the associated procedure 
related miscarriages (Nicolaides, Syngelaki, Poon, Gil, & Wright, 2014). 
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Preliminary findings suggest that the introduction of NIPT has already had a significant impact 
on foetal medicine practice so far as indicated through a marked reduction in invasive tests 
(Ferres, Lichten, Sachs, Lau, & Bianchi, 2014). More specifically a UK study reported a 26% 
decrease in the rate of invasive tests requested by high-risk women and a 94% decrease in 
women who would have previously rejected invasive tests but who now opted for the NIPT (Gil 
et al, 2015).  
With the imminent wider implementation of NIPT through its incorporation in the public health 
system, it is important to consider the factors that affect women’s decision to have an invasive 
test, non-invasive or no test at all. While some such studies have been carried out in relation to 
invasive testing and even more so in relation to screening, due to the fairly recent introduction 
of NIPT in prenatal testing, studies are only now starting to explore the decision making process 
addressing this new addition. Overall, preliminary evidence suggests an overwhelmingly 
positive response of women to non-invasive testing as it would offer safe, early, and accurate 
results (Hill, Fisher, Chitty,& Morris, 2012). This finding was also supported by a more recent 
clinical trial where NIPT was introduced as a contingent to the routine antenatal screening in an 
NHS hospital and found that within the high risk population most women chose NIPT instead of 
invasive tests and within the intermediate risk population NIPT was chosen by more than 90% 
of the patients (Gil et al, 2015). Nonetheless, considering the disparity in women’s choices 
including a small yet significant portion of women who continue to refuse any kind of testing 
(Allyse, Sayres, Goodspeed, & Cho, 2014) it is important to look into the factors that influence 
this decision and identify any different patterns between the groups so as to be able to provide 
relevant support during this challenging process. 
3.1.1. Aim of this study 
Using the questionnaire that was developed and pilot-tested for the purposes of this study 
(Appendix 10), the aim was to identify the factors that mostly influence uptake of prenatal 
diagnostic testing, including NIPT. As described in more detail in Chapter 2, the following 
factors were included in the questionnaire: Perceived Behavioural Control; Attitudes towards 
prenatal testing; Attitudes towards chromosomal abnormalities; Attitudes towards doctors and 
medicine; Health Locus of Control; and Anxiety. In addition, the role of socio-demographical 
factors, family and medical history, were also explored in terms of their role in the decision 
making process.   
3.1.2. Study Hypotheses 
The hypotheses are as follows: 
 Women with an increased sense of behavioural control will be more likely to opt in for 
further testing whether invasive or non-invasive. 
 Women with a positive attitude towards prenatal testing will be more likely to opt in for 
further testing whether invasive or non-invasive. 
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 Women with a positive attitude towards chromosomal abnormalities will be more likely 
to opt in for further testing whether invasive or non-invasive. 
 The more positive the attitude towards doctors and medicine the more likely that these 
women will opt in for further testing whether invasive or non-invasive. 
 Women with a greater internal or powerful others locus of control will be more likely to 
have further testing whereas women with a greater chance locus of control will be more 
inclined towards no further testing. 
 The role of anxiety and other socio-demographical and family/medical history factors 
was also explored in relation to the decision-making process.   
3.2. Methods 
3.2.1. Sample 
Women attending for their first trimester combined screening test were approached to 
participate in this study prior to finding out their risk status for carrying a baby with a 
chromosomal abnormality such as Down’s syndrome. As with the pilot study, the inclusion 
criteria included women aged 18 or over, the ability to comprehend English language, and 
absence of any mental health conditions which were assessed through a screening tool 
incorporated in the questionnaire. 
3.2.2. Materials 
The questionnaire (PDMQ) that was used in this study comprised of the following sub-scales: 
a) Anxiety (HADS; Zigmond & Snaith, 1983). 
This consists of seven items scored on a Likert-type scale (0-3) and total scores range from 0 to 
21. The higher the score the greater the level of anxiety. It has been used extensively in clinical 
and non-clinical populations and has good psychometric properties, with a reported specificity 
of 0.78 and sensitivity of 0.9 (Bjelland, Dahlb, Haug,&Neckelmann, 2002). 
b) Multidimensional Health Locus of Control Scale – Form A (MHLC; Wallston & Wallston, 
1978).  
This consists of 18 items scored on a 6-point Likert type scale (1=Strongly Disagree, 6=Strongly 
Agree). It comprises of three further sub-scales, namely Internality (IHLC) which measures the 
extent to which one believes they have control over their own health; Powerful Others 
externality (PHLC) which measures how much one believes that powerful others such as 
physicians or other health professionals control their health; and, Chance externality (CHLC), 
which measures how much one assigns their health to luck, fate, or chance. Each participant is 
scored on each of the three sub-scales that are interpreted as follows: a score of 23-30 
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indicates a strong inclination towards that particular subscale; a score of 15-22 indicates a 
moderate inclination and a score of 6-14 indicates a low inclination towards that subscale. 
c) Attitudes to doctors and medicine (ADMS; Marteau, 1990). 
This measure which was developed and tested on an antenatal population consists of the 
following four subscales that were found to be of good internal reliability: Positive Attitudes 
towards Doctors (cronbachα=0.76); Negative Attitudes towards Doctors (cronbachα=0.67); 
Positive Attitudes towards Medicine (cronbachα=0.67); and, Negative Attitudes towards 
Medicine (cronbachα=0.61). Items are scored on a 5-point Likert type scale (1=strongly 
disagree, 5=strongly agree) 
 
d) Perceived Behavioural Control.  
This scale was developed for the purposes of this study and consists of three items scored on a 
5-point Likert type scale (1=Strongly Disagree, 5=Strongly Agree). It was pilot tested on our 
target population of women attending for their first trimester screening test and had a good 
internal reliability (Cronbach α=.804). 
e) Attitudes towards prenatal testing.  
This scale which consists of 3 items scored on a 5-point Likert type scale was also developed 
for the purposes of this study and was found to have good internal reliability through the pilot 
test conducted on our target population (Cronbach α=.738). 
f) Attitudes towards chromosomal abnormalities. 
This scale consisting of two items and scored on a 5-point Likert type scale was developed for 
the purposes of this study and contrary to the previous two was found to have a low internal 
reliability (Cronbach α=.466). Nonetheless, this is probably due to the limited number of items 
and it was therefore decided to include it in the current study.  
g) Screening Tool.  
A brief screening measure for mental health issues was developed for the purposes of this 
study. This included a mixture of ten health-related issues covering both, mental health, such as 
depression and schizophrenia, and common health problems, such as migraine and allergies. 
The aim of the common health problems was to slightly mask the emphasis on asking 
questions just about mental health. Participants were also asked to state any medication they 
were taking at the time. The purpose of this screening tool was to allow for exclusion of those 
who were suffering from any sort of mental health issue, which may have impacted on their 
responses to the other scales of the questionnaire. 
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3.2.3. Procedure 
All women attending for their first trimester combined screening test at King’s College Hospital 
(KCH) between the months of September 2014 and January 2015 were approached to 
participate in this study. At the end of their screening procedure their sonographer briefly 
informed them of the purposes of this study and handed them a pack that included the 
questionnaire (Appendix 10), a participant information sheet (Appendix 15), a consent form 
(Appendix 16), and a debrief sheet (Appendix 17). Incentives were also used as a means to 
encourage participation, and included a free packet of Pregnacare supplement tablets with 
each questionnaire and a prize draw that would be taking place at the end of the study and 
which would automatically include all women who had participated in the study, with a prize of a 
£200 voucher to be spent in a big retailer chain-store that specialises in products for expectant 
mothers and general merchandise for new-borns and children up to 8 years old.  Women who 
were interested to participate were given the option to either return the questionnaire via post 
using the enclosed pre-paid envelope or by handing it back to their medical team.  
3.2.4. Statistical Analysis 
The statistical programme SPSS version 21 was used to compute the descriptives of our 
sample, cross-tabulations of variables and mean comparisons. R version 3.0.3 was used to 
perform the logistic regressions. 
The normality of the data was explored using the excess skewness and excess kurtosis 
statistics. Several researchers have suggested an acceptable limit of +2 for the excess 
(Trochim & Donnelly, 2006; Field, 2000; Gravitater & Wallnau, 2014). We used the parametric t-
test to compare the mean levels of the predictors (PAD, NAD, and Chance locus of control) and 
the non-parametric equivalent Mann-Whitney U test for the rest of the predictor variables 
(anxiety, PAM, NAM, Internal locus of Control, etc.) for the low vs. intermediate/high risk 
groups. Equality of variance (homogeneity) between the groups was assessed using Levene’s 
test and where the homogeneity was rejected, the Welch t-test statistic will be reported (Ruxton, 
2006). The non-parametric Kruskal Wallis test (equivalent of ANOVA) was used for the 
comparison of mean level of predictors across the low vs. intermediate vs. high risk group due 
to the highly unequal sample sizes. We furthermore assessed the effect size differences in the 
mean scores of Amnio/CVS vs. no test and NIPT vs. no test, using Cohen’s D effect size.  
 
The penalised maximum likelihood estimations were used for the regression model as 
proposed by Firth (1993) as well as the methodology proposed by King (2001) since the 
likelihood of selecting an Amnio/CVS test was rare (4 women out of 414 - 0.97%). The two 
methods correct the bias in the coefficient estimations, a problem usually seen in the study of 
rare events. Therefore they will essentially produce more accurate estimates of the effect of 
different factors in the event under consideration (uptake of an invasive test). The Akaike AIC 
was used to compare the goodness of fit of the two regressions (Venables, 2002). The R 
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packages used were logistf
1
 for the Firth logistic and relogit
2
 for the Kings methodology.  The 
logistf and relogit were also used for the logistic regression of the Harmony vs. No test model 
since the problem of separation (Harmony 36.8% vs No test 63.2%) also existed (Heinze, 
2006). 
3.3. Results 
3.3.1. Overall description 
Overall, 421 questionnaires were collected but with four participants providing incomplete data 
the total sample comprised of 417 participants (N=417). Table 3.1 provides a summary of the 
decision outcome in relation to whether participants decided to have an invasive test (CVS), 
NIPT or no further test, which also represents the output measure for this study. 
 
Table 3.1 
Summary of decision outcome for the overall sample (N=417) 
DECISION OUTCOME NUMBER OF 
PARICIPANTS 
(%) 
Invasive test (CVS) 4 (1%) 
Non-invasive prenatal test (NIPT) 151 (36.2%) 
No further test 262 (62.8%) 
TOTAL SAMPLE (N) 417 (100%) 
 
 
In order to gain further insight to factors that affected the decision outcome this was examined 
in relation to risk status for T21 (Down’s syndrome) and separately in relation to risk status for 
T13 (Patau’s syndrome) / T18 (Edward’s syndrome). This was based on the fact that following 
their combined screening test women are provided with two separate results representing a risk 
status for T21, and a risk status for T13/T18 which are grouped together. It is likely that 
depending on the identified genetic condition women’s decisions may differ and therefore such 
an exploration may provide useful information (Verweij, de Boer, & Oepkes, 2014). However, 
due to a further three missing cases where the decision outcome was not reported the final 
sample comprised of 414 participants (N=414). Table 3.2 and Table 3.3 illustrate women’s 
decision outcomes in relation to risk status for T21 and T13/T18 respectively.  
 
 
                                                          
1
http://cran.r-project.org/web/packages/logistf/index.html 
2
http://zeligproject.org/ 
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Table 3.2 
Decision outcome depending on risk status for T21 (Down’s syndrome) 
RISK STATUS 
(n) 
CVS NIPT No Test Number of participants 
(n) per group (%) 
Low 0 9 254 263 (63.5%) 
Intermediate 0 134 5 139 (33.6%) 
High 4 8 0 12 (2.9%) 
Total 4 151 259 N=414 (100%) 
 
 
 
Table 3.3 
Decision outcome depending on risk status for T13 (Patau’s syndrome) / T18 (Edward’s 
syndrome) 
RISK STATUS 
(n) 
CVS NIPT No Test Number of participants 
(n) per group (%) 
Low 0 99 258 357 (86.2%) 
Intermediate 4 49 1 54 (13%) 
High 0 3 0 3 (0.7%) 
Total 4 151 259 N=414 (100%) 
 
Further tests were then conducted to identify women who are either low risk on both T21 and 
T13/T18 or have some element of risk (intermediate or high) on either one or both of the 
conditions (Table 3.4). 
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Table 3.4 
Women’s risk status across conditions (T21 vs. T13/T18) 
 
As seen in Table 3.4, overall there were 253 participants that were low risk on all chromosomal 
abnormalities tested for and all of them chose to have no further test. 
The remaining 161 participants had some level of risk (moderate or high) on one or both the 
conditions tested for. Out of these, four chose to have an invasive test (CVS), 151 chose to 
have NIPT, and six decided to have no further testing at all. This is in line with recent evidence 
whereby, when women were offered the additional option of NIPT over invasive tests, the 
majority of high risk and 90% of intermediate risk women chose to have a NIPT (Gil et al, 2014). 
With studies including NIPT in women’s options only recently emerging there are no official 
national statistics to draw upon, but a 26% drop in uptake of invasive tests and a 95% decrease 
in women who would have chosen no further testing prior to the introduction of NIPT, have 
been reported (Gil et al, 2014).     
3.3.2. Sample description 
The vast majority of the sample (n=290, 69%) was white and of a European, Middle Eastern, 
North African or Hispanic ethnic origin. A further 77 participants (18%) were black African, 
Caribbean, or African American. The remaining sample comprised of East Asian (n=20, 2%), 
South Asian (n=25, 6%), and mixed (n=15, 4%) ethnic origins. The mean age was 35.4, with 
ages ranging from 19 to 45. The majority of women (n=258, 61.3%) had a university 
postgraduate degree, while a further 84 (19.9%) reported having either a university or a college 
degree, and 69 (16.4%) had graduated from secondary school.  
In terms of religion, almost half the sample (n=201, 48%) was Christian, and nearly as many 
participants (n=174, 42%) reported having no religion. Out of the remaining participants, 32 
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reported being Muslims, Hindus or Buddhists whereas a further 5 stated ‘other’ religion and 4 
refused to disclose such information. 
The vast majority of women (n=358, 85.6%) were living with a partner whether married or not 
and 41 (9.8%) were in a relationship but not living together. Sixteen women (3.8%) reported not 
being in a relationship at the time of the survey and a further 3 (0.7%) declined to disclose their 
marital status. 
A 98% of the sample reported no family history of chromosomal abnormality as opposed to 
seven participants who stated they had a family member with such a condition. Likewise, the 
majority of the sample (n=390, 93.1%) conceived naturally, while 20 women (4.8%) had IVF 
treatment and seven (1.75%) took fertility drugs.  
In terms of having other children the sample was fairly equally split, with 238 women (56.8%) 
being pregnant to their first child and the remaining 179 (42.7%) reporting having one or more 
other children. Furthermore, 113 women (27%) reported having had a previous miscarriage as 
opposed to 301 (73%) who did not.  
Out of the total sample only six women (1%) reported having had an invasive diagnostic test in 
the past. Finally, the vast majority (253 women; 61%) stated that they got pregnant ‘very easily’ 
and a further 76 (18%) found it ‘quite easy’. 33 women replied ‘neutral’, with 27 (6%) and 26 
(6%) women stating it was ‘quite difficult’ or ‘very difficult’ respectively.  
3.3.3. Mental Health and decision making regarding prenatal testing 
Cross-tabulation was performed in order to account for any differences in the decision making 
patterns of women with mental health issues. Mental health was originally measured in terms of 
depression (n=8), anxiety disorder (n=6), both depression and anxiety disorder (n=3), and 
bipolar disorder (n=1). However, due to the small numbers they were all grouped together into a 
mental health group category (n=18) that was compared to the remaining non-mental health 
group (n=396). 
The two above groups were then compared in terms of their risk status and were therefore 
divided into two further categories: 1) low risk on both T21 and T13/T18 (mental health vs. non-
mental health) and 2) moderate/high risk on T21 and/or T13/T18 (mental health vs. non-mental 
health). The outcome measure was women’s decision outcome (invasive test, NIPT, or no test).  
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Table 3.5 
Comparison of low risk (on both T21 and T13/T18) mental health vs. non-mental health groups 
As seen in Table 3.5, all women who were low risk, regardless of mental health status, chose to 
have no further test. Therefore, no further analysis was warranted for this group since no 
differences are observed in the decision outcome. 
Table 3.6 
Comparison of intermediate / high risk (on T21 and/or T13/T18) mental health vs. non-mental 
health groups  
 
Within the intermediate / high risk group all women with a mental health issue opted for NIPT, 
whereas the non-Mental Health group was more varied (Table 3.6). However, there were no 
significant differences between the two groups x
2
(2, N=161) = 0.558, p= .757 and therefore no 
further analysis was required in relation to women’s decision making patterns. 
To sum up, the comparison between women with mental health issues and women without 
showed that we don’t have sufficient evidence to prove that having a mental health disorder 
influences women’s decision in relation to prenatal testing. Nevertheless, due to the very small 
number of women with mental health problems in our sample, further studies are needed to 
address this issue. 
3.3.4. Descriptive statistics for variables examined 
 
Table 3.7 shows the descriptive statistics of the predictor variables. It also depicts the z-
transformed statistics for predictor to predictor comparison. Normality of the distribution is 
explored with the use of the excess skewness and kurtosis. It is observed that the predictors 
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anxiety, Positive Attitudes to Doctors (PAD), Positive Attitudes to Medicine (PAM), Negative 
Attitudes to Doctors (NAD), Negative Attitudes to Medicine (NAM), internal, chance, powerful 
others locus of control, attitudes to prenatal testing, attitudes to genetic abnormality, and 
perceived behavioural control (PBC), have a highly-skewed distribution (|excess|>2). Attempted 
transformations to normalise the distribution failed hence non-parametric tests will be deployed 
for comparisons across groups.  
It is important to note that whilst we would normally adjust the level of significance so as to 
account for the multiple comparisons, it was decided that a significance level of p=.05 would be 
retained. The reason for this is that due to the low sample size in the high-risk group and the 
group that underwent invasive tests (because of the nature of the topic) this, in itself, makes it 
difficult to detect any statistical significance and even though adjusting the level of significance 
would reduce the chance of a Type I error (reporting something as significant when it really is 
not) it would, on the other hand, increase the chance of a Type II error (significant findings going 
undetected) which is not less important (Perneger, 1998; Rothman, 1990; Cole, 1979). The 
main purpose of this study was to add to the literature referring to prenatal testing but with the 
recent addition of NIPT and thus potentially prove useful for future studies (i.e. meta-analyses) 
that would emphasise the effect sizes reported. Therefore, a p value of .05 was considered 
appropriate for these purposes.  
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Table 3.7 
Descriptive statistics for 11 variables examined prior to comparing between groups 
  
Anxiety 
Score 
(HADS) 
Positive 
attitudes to 
doctors 
Positive 
attitudes to 
medicine 
Negative 
attitudes to 
doctors 
Negative 
attitudes 
to 
medicine 
Internal 
locus of 
control 
Chance 
locus of 
control 
Powerful 
Others 
locus of 
control 
Attitudes to 
prenatal 
diagnostic 
tests 
Attitudes to 
genetic 
abnormalities 
Perceived 
behavioural 
control 
N 419 414 414 414 414 409 408 409 410 410 410 
Mean 5,365 12,604 13,464 12,580 12,324 24,538 16,934 17,929 12,471 5,693 12,032 
SD 3,282 2,720 2,295 2,749 2,803 4,200 4,814 5,378 2,452 1,605 2,010 
Minimum 0 5 5 6 5 9 6 6 3 2 4 
Maximum 15 20 19 21 24 34 32 34 15 10 15 
Range 15 15 14 15 19 25 26 28 12 8 11 
Z values            
Minimum -1,63 -2,8 -3,69 -2,39 -2,61 -3,7 -2,27 -2,22 -3,86 -2,3 -4 
Maximum 2,94 2,72 2,41 3,06 4,17 2,25 3,13 2,99 1,03 2,68 1,48 
Range 4,57 5,52 6,1 5,46 6,78 5,95 5,4 5,21 4,89 4,99 5,47 
Reliability statistics            
Cronbach's alpha 0,757 0,723 0,466 0,573 0,615 0,638 0,621 0,717 0,7 0,436 0,768 
Number of items 7 4 4 6 5 6 6 6 3 2 3 
Distribution statistics            
Kurtosis -0,072 -0,242 0,207 0,037 0,429 0,289 0,071 -0,091 0,342 -0,111 0,939 
SE Kurtosis 0,238 0,239 0,239 0,239 0,239 0,241 0,241 0,241 0,24 0,24 0,24 
Skewness 0,664 0,034 -0,252 0,156 0,245 -0,437 0,133 0,357 -0,865 -0,468 -0,626 
SE Skewness 0,119 0,12 0,12 0,12 0,12 0,121 0,121 0,121 0,121 0,121 0,121 
Excess Kurtosis -0,30 -1,01 0,87 0,15 1,79 1,20 0,29 -0,38 1,43 -0,46 3,91 
Excess Skewness 5,58 0,28 -2,10 1,30 2,04 -3,61 1,10 2,95 -7,15 -3,87 -5,17 
 
Note: SE = Standard Error, Excess Kurtosis = Kurtosis/ SE of Kurtosis, Excess Skewness = Skewness/ SE of Skewness 
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a) Low risk versus Intermediate / High Risk groups. 
Prior to any statistical analysis a description of the data is presented so as to get a first 
impression of the tendencies in women’s decision making process. To begin with, the mean 
scores and standard deviations are considered for the low risk group in comparison to the 
intermediate / high risk group providing an overview of any different patterns between women of 
low risk and women who were diagnosed with some level of risk, whether moderate or high. 
In general, the two groups (low risk vs. intermediate / high risk) presented with somewhat 
similar scores on all tested variables. Firstly, there was no significant difference in anxiety levels 
between women in the low risk group (M=5.333, SD=3.2) and women in the intermediate / high 
risk group (M=5.429, SD=3.5), U=20131, p=0.89. This is not surprising considering that 
questionnaires were completed before women were informed of their risk status and therefore 
they were all starting from a relatively same baseline. 
One interesting observation was that women in the low risk group reported a more positive 
attitude towards doctors (M=12.702, SD= 2.7) compared to women of an intermediate / high risk 
(M=12.419, SD=2.8) but women with some level of risk reported a more positive attitude 
towards medicine (M=13.644, SD=2.2) compared to women of low risk (M=13.319, SD=2.4). 
However, these differences between the two groups did not reach statistical significance 
(t(406)=1.03, p=0.30 and U=18561, p=0.30 respectively) and are therefore likely to be attributed 
to coincidence.  
In addition, both groups reported a greater internal locus of control than ‘chance’ or ‘powerful 
others’, although women in the intermediate / high risk group scored relatively higher on all 
sources of locus of control. In accordance with the scoring instructions of the MHLOC scale 
(Walston, 2005) both groups had a strong inclination towards ‘internal’ locus of control as they 
scored above 23, and a moderate inclination towards ‘chance’ and ‘powerful others’ locus of 
control where they scored between 15 and 22 which are the cut-off points. In comparing the two 
groups, there was a significant difference in the ‘internal locus of control’ scale with women in 
the intermediate / high risk group (M=25.127, SD=4.2) scoring higher than women in the low 
risk group (M=24.176, SD=4.2), U=216972, p=0.04. In terms of the other two scales there was 
no significant difference, with t(401)=-0.70, p=0.49 for ‘chance’ locus of control, and U=19232, 
p=0.91 for ‘powerful others’ locus of control.  
Women with some level of risk reported a statistically significant more positive attitude towards 
prenatal diagnostic tests (M=12.791, SD=2.4) compared to women of low risk (M=12.252, 
SD=2.5), U=17018, p=0.03. This is interesting considering that data was collected before 
women found out their risk level and therefore this could not have been influenced by their 
awareness of being at risk. Upon further exploration of the data, one potential explanation for 
this is that women in the intermediate / high risk group were significantly older (M=35.54, 
SD=4.8) than women in the low risk group (M=30.55, SD=5.3), t(412)=-9,61, p<0,001. It is 
possible that older women are aware of their age-related risk and thus may have developed a 
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more positive attitude as a protective mechanism in the event that their increased risk is 
confirmed and they are faced with a decision to have further testing. They may also have had 
more interaction with other women’s positive experiences of prenatal diagnostic tests although 
this is difficult to assume without having specific data to back it up. On the contrary, women of 
low risk reported a more positive attitude towards genetic abnormalities (M=5.764, SD=1.6) 
than women of intermediate / high risk (M=5.589, SD=1.6) although the difference did not reach 
statistical significance, U=18190, p=0.27. This again may be explained by the significant 
difference in age between the two groups: younger women may believe they are at a lower risk 
because of their age and therefore the concept of a child with a genetic abnormality may be far 
from them so as not to cause negative feelings and preconceptions.   
Finally, women in the intermediate / high risk group reported a slightly higher level of perceived 
behavioural control (M=12.139, SD=2.0) than women in the low risk group (M=11.935, SD=2.0). 
This is quite important as these women were subsequently faced with the decision to take up 
further diagnostic testing or not and thus having a sense of control is something that is likely to 
have aided this process. However, it is important to note that the difference between the two 
groups was not statistically significant, U=18328, p=0.33.  
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Table 3.8 
Means (M) and Standard Deviations (SD) for questionnaire variables, for low and moderate/high risk groups respectively 
  Anxiety 
Score 
(HADS) 
Positive 
attitudes to 
doctors 
Positive 
attitudes to 
medicine 
Negative 
attitudes 
to doctors 
Negative 
attitudes to 
medicine 
Internal 
locus of 
control 
Chance 
locus of 
control 
Powerful 
Others locus 
of control 
Attitudes to 
prenatal 
diagnostic tests 
Attitudes to 
genetic 
abnormalities 
Perceived 
behavioural 
control 
Low Risk N 252 248 248 248 248 245 244 245 246 246 246 
Raw scores Mean 5.333 12.702 13.319 12.520 12.557 24.176 16.770 17.886 12.252 5.764 11.935 
 SD 3.2 2.7 2.4 2.7 2.8 4.2 4.7 5.4 2.5 1.6 2.0 
Z value scores Mean -0,0087 0,0359 -0,0633 -0,0217 0,083 -0,0863 -0,0339 -0,0081 -0,0892 0,0446 -0,0481 
 Min -1,63 -2,8 -3,69 -2,39 -2,61 -3,7 -2,27 -2,22 -3,86 -2,3 -4 
 Max 2,94 2,72 2,41 3,06 4,17 2,25 2,71 2,99 1,03 2,06 1,48 
 Range 4,57 5,52 6,1 5,46 6,78 5,95 4,99 5,21 4,89 4,36 5,47 
Moderate / 
High Risk 
N 161 160 160 160 160 158 158 158 158 158 158 
Raw scores Mean 5.429 12.419 13.644 12.675 12.019 25.127 17.114 18.006 12.791 5.589 12.139 
 SD 3.5 2.8 2.2 2.8 2.8 4.2 5.0 5.4 2.4 1.6 2.0 
Z value scores Mean 0,0026 -0,0049 -0,0077 0,0004 0,0078 0,0025 -0,0059 0,0007 -0,0032 0,0018 -0,0084 
 Min -1,63 -2,8 -3,69 -2,39 -2,61 -3,7 -2,27 -2,22 -3,86 -2,3 -4 
 Max 2,94 2,72 2,41 3,06 4,17 2,25 3,13 2,99 1,03 2,68 1,48 
 Range 4,57 5,52 6,1 5,46 6,78 5,95 5,4 5,21 4,89 4,99 5,47 
T tests/ Mann 
Whitney U 
T/ U 20131 1.03 18561 -0.55 17174 216972 -0.70 19232 17018 18190 18328 
Level of 
significance 
P 
0.89 0.30 0.30 0.58 0.02* 0.04* 0.49 0.91 0.03* 0.27 0.33 
Note. * indicates statistical significance at the 0.05 level, t-test for Positive attitudes to doctors, Negative attitudes to doctors, Chance locus of control. Mann-Whitney 
U test for the rest of the variables 
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b) Intermediate / High risk group: comparison within groups based on decision outcome 
Further insight to the intermediate / high risk group in terms of their decision outcome (invasive 
test vs. NIPT vs. no testing) was considered plausible in order to identify any indications of 
potential different patterns in the decision-making process.  
As observed in Table 3.8, there was no significant difference amongst the three groups on any 
of the factors under examination. However, extremely unequal sample sizes may affect the 
homogeneity of variances assumption and bias the statistical significance (Field, 2013; p175). 
Therefore effect sizes were also calculated to provide further insight to any differences between 
the no-test group and each of the other two groups (CVS and NIPT groups respectively)
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Table 3.9 
Means (M) and Standard Deviations (SD) for questionnaire variables in relation to decision outcome within the moderate / high risk group  
  Anxiety 
Score 
(HADS) 
Positive 
attitudes 
to doctors 
Positive 
attitudes to 
medicine 
Negative 
attitudes 
to doctors 
Negative 
attitudes to 
medicine 
Internal 
locus of 
control 
Chance 
locus of 
control 
Powerful 
Others locus 
of control 
Attitudes to 
prenatal 
diagnostic tests 
Attitudes to 
genetic 
abnormalities 
Perceived 
behaviour
al control 
CVS N 4 4 4 4 4 4 4 4 4 4 4 
Raw Scores Mean 3.75 14.75 15.75 12.75 13.25 27.25 14.25 17.25 14.75 4.5 12.25 
 SD 1.5 1.3 1.5 1.0 4.3 1.7 3.4 4.1 0.5 1.3 0.5 
Z value scores Mean -0,491 0,789 0,996 0,062 0,331 0,6458 -0,558 -0,126 0,930 -0,743 0,109 
 Minimum -0,72 0,15 0,23 -0,21 -1,19 0,11 -1,23 -1,1 0,62 -1,68 -0,02 
 Maximum 0,19 1,25 1,54 0,52 2,38 1,06 0,43 0,76 1,03 0,19 0,48 
 Range 0,91 1,1 1,31 0,73 3,57 0,95 1,66 1,86 0,41 1,87 0,5 
Harmony N 151 150 150 150 150 148 148 148 148 148 148 
Raw scores Mean 5.4437 12.387 13.633 12.653 11.947 25.142 17.068 17.919 12.764 5.635 12.169 
 SD 3.6 2.7 2.2 2.9 2.7 4.2 5.0 5.4 2.4 1.6 2.0 
Z value scores 
 
 
 
Mean 0,0249 -0,0799 0,0739 0,0268 -0,1345 0,1438 0,0278 -0,0019 0,1194 -0,0359 0,0683 
Minimum -1,63 -2,43 -1,95 -2,39 -2,61 -2,75 -2,27 -1,85 -3,86 -2,3 -4 
Maximum 2,94 2,35 2,41 3,06 2,38 2,01 3,13 2,62 1,03 2,68 1,48 
Range 4,57 4,78 4,36 5,46 4,99 4,76 5,4 4,46 4,89 4,99 5,47 
No test N 6 6 6 6 6 6 6 6 6 6 6 
Raw score Mean 6.1667 11.667 12.5 13.167 13 23.333 20.167 20.667 12.167 5.167 11.333 
 SD 3.9 3.6 2.2 2.6 3.2 4.9 4.7 5.4 2.7 1.0 2.2 
Z value scores Mean 0,2452 -0,3446 -0,42 0,2135 0,2413 -0,2868 0,6716 0,5091 -0,124 -0,3278 -0,3474 
 Minimum -1,02 -2,06 -1,51 -0,57 -0,83 -2,27 -0,61 -0,54 -2,23 -1,05 -2,01 
 Maximum 2,33 1,25 0,67 1,97 1,67 1,06 1,68 2,06 0,62 0,19 0,98 
 Range 3,35 3,31 2,18 2,55 2,5 3,33 2,29 2,6 2,86 1,25 2,98 
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  Anxiety 
Score 
(HADS) 
Positive 
attitudes 
to doctors 
Positive 
attitudes to 
medicine 
Negative 
attitudes 
to doctors 
Negative 
attitudes to 
medicine 
Internal 
locus of 
control 
Chance 
locus of 
control 
Powerful 
Others locus 
of control 
Attitudes to 
prenatal 
diagnostic 
tests 
Attitudes to 
genetic 
abnormalities 
Perceived 
behaviour
al control 
Level of 
significance 
p
1
 0,752 0,238 0,174 0,885 0,366 0,239 0,184 0,459 0,194 0,383 0,599 
No test vs. 
CVS 
Cohen’s d
2 
0,76 1,04 1,67 0,19 0,07 0,97 1,39 0,69 1,19 0,60 0,76 
No test vs. 
Harmony 
Cohen’s d 0,20 0,26 0,52 0,18 0,39 0,43 0,63 0,51 0,25 0,30 0,20 
Note. 
1 
Kruskal-Wallis  
2 
Cohen’s d effect sizes: 0.20=small effect size, 0.50=medium effect size, and 0.80=large effect size.
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c) Effect sizes for no test group vs. Amniocentesis / CVS group 
Interestingly the effect sizes were mostly large on the majority of variables between women who 
chose to have no further testing and women who chose to have a CVS (Table 3.9). This 
suggests that with a larger sample size it is most likely that there would be a significant 
difference between these two groups on these factors (anxiety levels; positive attitudes to 
doctors; positive attitudes to medicine; internal locus of control; chance locus of control; 
powerful others locus of control; attitudes to prenatal diagnostic testing; and, perceived 
behavioural control).  
Based on the ‘large’ effect sizes it appears that women who chose to have a CVS, have more 
positive attitudes to doctors (M=14.75, SD=1.3) and medicine (M=15.75, SD=1.75) compared to 
women who chose to have no further test (M=11.667, SD=3.6 and M=12.5, SD=2.2 
respectively). In addition, women in the CVS group reported a greater internal locus of control 
(M=27.25, SD=1.7) than women in the ‘no test’ group (M=23.333, SD=4.9), whereas women 
who chose to have no further testing reported a greater ‘chance’ locus of control (M=20.167, 
SD=4.7) than women who opted for a CVS (M=14.25, SD=3.4). In addition, women in the CVS 
group reported a more positive attitude towards prenatal diagnostic tests (M=14.75, SD=0.5) 
than women in the ‘no test’ group (M=12.167, SD=2.7), and a greater perceived behavioural 
control (M=12.25, SD=0.5 vs. M=11.333, SD=2.2). One interesting finding is that women who 
chose to have no test reported greater levels of anxiety (M=6.1667, SD=3.9) than women who 
chose to have a CVS (M=3.75, SD=1.5).  
d) Effect sizes for no test group vs. NIPT group. 
In terms of comparing women who chose to have no further testing to women who opted for 
NIPT, no large effect sizes were identified. However, there were several ‘medium’ effect sizes, 
indicating that the relative magnitude of differences between the two groups “would be large 
enough to be visible to the naked eye” (Cohen, 1988, p.26) should the comparable samples be 
of a more equal size. More specifically, these results suggest that women in the NIPT group 
have more positive attitudes to medicine (M=13.633, SD=2.2) than women in the ‘no test’ group 
(M=12.5, SD=2.2). Likewise, women who chose to have a Harmony test reported a greater 
‘internal’ locus of control (M=25.142, SD=4.2) than women who chose no further testing 
(M=23.333, SD=4.9). On the contrary, women in the ‘no test’ group had a greater ‘chance’ locus 
of control (M=20.167, SD=4.7) than women in the NIPT group (M=17.068, SD=5.0) as well as a 
greater ‘powerful others’ locus of control (M=20.667, SD=5.4 vs. M=17.25, SD=4.1).  
 
3.3.5. Logistic Regression 
Logistic regression Analyses were subsequently carried out in order to assess the cumulative 
effect of the variables under investigation to the decision to have an invasive, a non-invasive or 
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no further test at all. Logistic regression, as a multivariate analysis, will adjust the effect of all 
the factors under consideration and surface the statistically significant factors towards decision 
making.  
a) The role of the psychological factors under investigation in women’s decision to have an 
invasive test (CVS) 
Initially, logistic regression was carried out on the overall sample (N=414) to explore the role of 
the 11 variables under investigation on the decision to have an invasive test (CVS). 
As illustrated in Table 3.10, none of the 11 variables under investigation were shown to have a 
significant impact, with a 0.05 level, on women’s decision to have an invasive test. However, a 
tendency is observed in three of the variables and their impact on women’s decision to have a 
CVS test. More specifically, anxiety levels were negatively associated with the decision 
outcome (odds ratio=0.60, p=0.08) suggesting that a woman with increased levels of anxiety is 
less likely to choose to have an invasive test. In addition, negative attitude to medicine (NAM) 
and attitudes to prenatal testing (Apretest) were both positively associated with the decision 
outcome leading to a somewhat controversial finding: women with a negative attitude towards 
medicine are suggested to be more likely to have an invasive test (odds ratio=1.47, p=0.07) 
whilst on the other hand, women with a positive attitude to prenatal testing are also more likely 
to have an invasive test (odds ration=2.43, p=0.07). 
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Table 3.10 
Firth Logistic Regression on the role of psychological factors in decision to have a CVS (N=414) 
 
b) The role of the psychological factors under investigation in women’s decision to have NIPT 
A regression analysis was also carried out on the overall sample (N=414) to explore the role of 
the 11 variables under investigation on the decision to have NIPT. 
As illustrated in Table 3.11 three factors reached statistical significance. More specifically, 
women with a negative attitude to doctors (NAD) are more likely to have a non-invasive test 
(odds ratio=1.10, p=0.05) as are women with an internal locus of control (odds ratio=1.06, 
p=0.02). On the other hand, women with a negative attitude to medicine (NAM) are less likely to 
have a non-invasive test (odds ratio=0.88, p=0.01) as this variable was negatively associated 
with the decision outcome. 
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Table 3.11 
Firth Logistic Regression on the role of psychological factors in decision to have NIPT (N=414) 
 
c)  The inclusion of risk status as a predictive variable in the decision to have an invasive test 
(CVS) 
Logistic regression of CVS as the chosen test (0=otherwise) on the risk status for T21 and 
T13/T18, and the psychological factors (Anxiety, PAD, PAM, etc.) has shown the statistically 
significant effect of the T21 risk status (p=0.04) on the final decision of pregnant women 
towards CVS. The results indicate that in the presence of risk for T21, the results regarding risk 
for T13/T18 do not contribute to the decision of the pregnant woman towards CVS (p=0.37). 
Likewise, no psychological factors statistically contribute to the decision towards CVS (Table 
3.12).  
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Table 3.12  
Firth Logistic regression on CVS (N=414), including risk for T21 and T13/T18 
 
Nonetheless, even though there is no statistically significant effect of any of the psychological 
factors on the decision to have an invasive test, a closer look at the odds ratio values (Table 
3.12) indicates some tendencies that may be of interest to take into consideration. An odds ratio 
indicates the odds of an outcome occurring in the presence of a particular event happening as 
opposed to the odds of it happening in the absence of that event and therefore, even if not 
statistically significant it provides important information in that it reveals a tendency that may 
become significant, i.e. in the presence of a bigger sample size and even if not, the size of the 
OR (>1) may be indicative of factors that may still influence the outcome to some extent.  For 
example, a more positive attitude to doctors (PAD) indicates that the likelihood of a woman 
having a CVS is increased (odds ratio=1.36). Likewise, but to a slightly lesser degree, a positive 
attitude to medicine (PAM) seems to also increase the odds of a woman choosing an invasive 
test (odds ratio=1.17). Interestingly, negative attitudes to medicine (NAM) seem to have a 
greater effect on the decision to have a CVS by increasing the likelihood of a woman making 
this choice (odds ratio=1.32).  
d) The inclusion of risk status as a predictive variable in the decision to have a non-invasive 
test (Harmony) 
We proceeded with excluding the cases (N=4) where CVS was chosen, and investigated the 
association of T21 and T13/T18 risk status as well as the psychological factors to the decision 
towards NIPT (NIPT N=151-36.8% vs. No Test N=259-63.2%). Results of the firth logistic 
 81 
regression indicate the significance of both T21 results (p<0.0001) and the T13/T18 results 
(p<0.0001) in the decision to have NIPT (Likelihood=444.16 p<0.0001). The psychological 
factors remain insignificant to the model 
Table 3.13 
Firth Logistic regression on NIPT (N=410) including risk for T21 and T13/T18 
 
Nonetheless, despite not reaching statistical significance a closer look at the odds ratio values 
(Table 3.13) indicates that a more positive attitude towards medicine (PAM) increases a 
woman’s likelihood to have NIPT (odds ratio=1.21), as does an increased perceived 
behavioural control (PBD) (odds ratio=1.25).  
e) The impact of the psychological factors under investigation on the decision to have NIPT in 
women who were low risk in T13/T18 but intermediate risk for T21 
Further analysis was carried out in order to cross-tabulate patients’ test decision by the T13/T18 
and T21 risk status results (Table 3.14). At a LOW risk for T13/T18, we observe that 99 out of 
357 (27.7%) patients chose to do NIPT over ‘No test at all’, while only 9 out of 263 (3.4%) 
patients at LOW risk for T21 chose to do NIPT (Table 3.14). This is probably due to the fact that 
95 out of the 99 LOW T13/T18 patients also had an intermediate risk for T21. This indicates the 
significance of an identified risk for T21 (over the T13/T18 risk) towards the decision to have 
NIPT.  
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Table 3.14 
Patients’ decision outcome depending on risk for T13/T18 
 
Due to the above finding (Table 3.14) that the vast majority of women who were considered low 
risk for T13/T18 but moderate risk for T21 (N=100) chose to have NIPT (N=95) a logistic 
regression was also carried out in order to account for the contribution of the factors under 
investigation in this decision and identify any different patterns with the previous groups.  
Table 3.15 
Patients’ decision outcome depending on risk for T21 
 
None of the variables under investigation reached statistical significance for this group of 
women. However, a closer look at the odds ratio values indicates some tendencies that may be 
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of interest for future research. Firstly, it is suggested that a positive attitude to doctors (PAD) as 
well as a positive attitude to medicine (PAM) increase the likelihood of a woman in this category 
(low risk for T13/T18 and moderate risk for T21) to have NIPT (odds ratio=1.27 and 1.29 
respectively). Likewise, a positive attitude to prenatal testing and a positive attitude to genetic 
abnormalities also increase the likelihood of a Harmony test in this group (odds ratio=1.21 and 
1.29 respectively). Finally, to an even greater extent than the aforementioned, an increased 
perceived behavioural control (PBC) also increases the likelihood of a woman in this group to 
have NIPT (odds ratio=1.37).  
Table 3.16 
Logistic regression of NIPT test decision for LowT13/T18 and Moderate T21 risk (N=100) 
 
 
f) The role of socio-demographic factors in women’s decision making process 
Due to the limited number of participants choosing to have an invasive test (CVS; N=4), the role 
of socio-demographic factors was only explored in relation to women’s decision to have a non-
invasive test (NIPT; N=151). As illustrated in Table 3.17, in the presence of risk for T21 and/or 
T13/T18 there is no significant effect of any of the socio-demographic factors on women’s 
decision to have NIPT. In other words, when a woman has some element of risk identified 
neither the psychological factors under investigation nor the socio-demographic characteristics 
affect her decision making process but rather, it is only her risk status that significantly affects 
her decision to have NIPT.  
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Table 3.17 
The role of psychological factors, risk status and socio-demographics in women’s decision 
making process 
 
3.4. Discussion 
The aim of this study was to explore women’s decision making process in relation to uptake of 
prenatal diagnostic tests including NIPT. Using a questionnaire that was previously validated 
through a pilot study, the following factors were explored: anxiety levels; attitudes to doctors 
and medicine; attitudes to prenatal testing; attitudes to genetic abnormalities; locus of control; 
and, perceived behavioural control.  
Initially, the role of the aforementioned factors was explored in relation to the decision to have 
an invasive or non-invasive test separately. Firstly, women with a more negative attitude 
towards medicine were found to be more likely to have an invasive test (CVS) (although results 
did not reach statistical significance, a clear tendency was observed) and less likely to have a 
non-invasive test (NIPT). While at a first glance, this finding appears controversial it is 
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interesting to explore potential explanations for this. For instance, unsurprisingly a woman who 
is not particularly invested in medicine is more likely to be critical of new interventions and thus 
less trusting towards newly developed tests such as NIPT. However, despite a sceptical 
approach towards medicine in general she may still be positively inclined towards well 
established screening / diagnostic tests such as CVS and amniocentesis that have proven 
efficiency throughout several years.  
In addition, there may be a contextual effect that could shed light on this finding, as previously 
suggested in the literature. Conroy et al (2002), reported a striking difference in women’s 
attitudes depending on context, with participants reporting a more negative view of the medical 
profession in general than their family medical practice and even more so their antenatal care 
service, suggesting that a more intense interaction with a medical service is associated with a 
more positive attitude. Within this context, an alternative explanation for the seemingly 
controversial results could be that the questionnaire used in this study measured attitudes to 
medicine in general thus potentially masking the real attitudes that are relevant within a more 
specific antenatal care service context. This could also account for another finding of this study 
whereby, a negative attitude to doctors significantly predicted uptake of NIPT. In their study, 
Conroy et al (2002) reported 40% of participants viewing all doctors as good doctors, compared 
to 85% viewing their family doctors as good doctors and almost 100% expressing a belief that 
the doctor looking after their pregnancy was a good doctor. Therefore, it is possible that the 
results of this study could be different if a measure tailored to explore more specifically 
women’s attitudes towards their antenatal care doctors rather than doctors in general had been 
used.  
As expected, and even though this was not statistically significant, a more positive attitude to 
prenatal testing would appear to predict uptake of invasive diagnostic tests such as CVS. This 
contradicts the findings of a qualitative study by Garcia et al (2002) where both acceptors and 
decliners of prenatal testing expressed positive attitudes towards the offering of prenatal testing 
and therefore could not be accounted for as a predictor of their decision outcome. However, 
within that study women who declined invasive testing called upon ethical principles and 
parents’ obligation not to take risks on their baby’s health therefore drawing upon invasive tests’ 
negative attributes and thus indirectly expressing a negative view that may have affected their 
decision to one degree or another.  
Shedding some light on these discrepant findings an earlier study that used a combination of 
questionnaire and interview methods found that even though in the close-ended questionnaire 
most women expressed positive attitudes towards prenatal testing when given the opportunity 
to elaborate through an interview they also showed awareness of and some concern over the 
negative aspects of such procedures (Moyer et al, 1999). Therefore, it is possible that the 
methodology (questionnaire-based) of our study only captured part of women’s attitudes and a 
less structured approach may have revealed a more balanced view leading to potentially 
different results.  
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Alternatively, it could be argued that attitudes could be categorized into those focusing on a 
specific target (i.e. CVS) and those focusing on behaviours that are directed towards specific 
targets (i.e. having a CVS) (Bryant et al, 2010). Whilst one may generally value the offering of a 
diagnostic test, she may call upon other, such as ethical and moral, values in shaping her 
attitude towards taking up the test herself. The scale used in our study measured attitudes 
towards prenatal tests and therefore it would be interesting to explore this in relation to more 
explicitly measuring attitudes towards one having a diagnostic test. 
In terms of invasive diagnostic test (CVS) uptake, no significant findings were reported, yet a 
tendency was observed in the role of anxiety and the decision outcome, which is of interest to 
consider. Interestingly, it was revealed that the higher the anxiety levels the less likely the 
woman was to choose to have a CVS.  While there is evidence in the literature describing 
fluctuations in women’s emotional state throughout pregnancy and particularly during the 
decision making process for prenatal diagnosis (Kaiser et al, 2004) most studies have focused 
on measuring anxiety levels in women who have already been identified as being at a greater 
risk either due to increased maternal age or first trimester screening procedures (Heyman et al, 
2006). Within this group of women, elevated levels of anxiety –triggered by doubts and fear 
regarding foetal integrity (Hertling-Schaal, Perrotin, De Poncheville, Lansac, & Body -Schaal, 
2001) -  have been reported, and these are followed by a drop in most cases after receiving 
reassuring results (Kaiser et al, 2004). In addition, and contrary to our findings, other research 
has shown that for women with an identified higher risk profile, anxiety is reportedly a major 
reason for which they choose to have an invasive diagnostic procedure with some even 
reporting it to be the only reason for this decision as a means to seek reassurance (Cederholm 
& Sjoden, 1999). Nonetheless, due to our study being prospective and therefore data being 
collected prior to women finding out their risk status it is difficult to make any direct comparisons 
with such previous studies. It is still important, however, to consider wider evidence as well as 
potential explanations for our findings. 
Taking a closer look at other evidence, a study by Marteau et al (1989) found no difference in 
anxiety levels between women who chose to have an invasive test and women who declined it 
during the first trimester suggesting that they all start from similar levels and anxiety is not a 
decisive factor during this process. This again contradicts our findings according to which there 
is a tendency in women who decline invasive testing to have markedly higher levels of anxiety.  
In terms of the present findings, the observed difference in anxiety levels between those who 
chose and those who declined further testing may be reflecting a difference in coping styles 
with the importance of this previously having been stressed in the literature in relation to 
women’s experience of threat of giving birth to a child with a chromosomal abnormality or other 
congenital defect (Bodegird, Fyro, & Larsson, 1988). A possible explanation is that our 
participants, having just had their first trimester scan but not received their results yet may have 
become more aware of the potential adverse outcome ahead therefore becoming more anxious 
but dealing with any such concerns over their baby’s health by avoiding them and thus 
choosing not to have any further testing. Based on the study by Marteau et al (1989), however, 
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it appears that untested women’s anxiety tends to increase throughout pregnancy as compared 
to women who do proceed with invasive diagnosis. Therefore, it would have been interesting to 
have had a follow-up measure and explore whether this indeed is the case for our sample as 
well. In that case this would highlight a potentially vulnerable group of women and would call for 
the development of appropriate support tools and resources that would enable a smoother 
journey for both the mother and the unborn baby. Alternatively, another explanation may be that 
the increased anxiety in women who chose to forego invasive diagnostic testing was due to 
other secondary factors that coincided with the timing of the testing but was not caused by this. 
Use of a more specific measure, tailored to pregnancy factors, may be able to shed more light 
on this suggestion. Nonetheless, while the above considerations may be of research and 
clinical research it is important to bear in mind that only a tendency was observed rather than a 
statistically significant finding and therefore further research would be required before drawing 
firm conclusions. 
A final factor that was found to significantly predict uptake of non-invasive prenatal testing 
(NIPT) whilst risk status was controlled for, was internal health locus of control. This is not 
surprising, as it has been suggested that an internal locus of control is associated with positive 
health behaviours (Turriff-Jonasson, 2004) as well as health-related information seeking 
(Wallston, Maides, & Wallston, 1976), whereas a ‘chance’ or ‘powerful others’ locus of control 
has been associated with a sense of powerlessness and the adoption of more unhealthy 
lifestyles (Steptoe & Wardle, 2001). Therefore, pregnant women in our sample with an internal 
locus of control may have viewed prenatal testing as part of prenatal care and therefore a 
health promoting behaviour that they were willing to engage in in their attempt to exert positive 
control over their foetus’s health. This is in line with previous studies that have also found that 
an internal health locus of control predicted women’s inclination to undergo screening and 
invasive testing (Lumley et al, 2006) and in comparison to couples who did not undergo 
screening, those who did were found to perceive a greater responsibility for their own actions 
and how these would impact on their unborn baby’s health (Henneman et al, 2001). However, 
whilst previous studies have confirmed the predictive value of locus of control in relation to 
prenatal genetic testing attitudes, others have led to some counter-intuitive findings whereby a 
chance locus of control instead of an internal locus of control was positively correlated with 
willingness to undergo prenatal testing (Furr and Seger, 1998).  
Such mixed results together with the fact that in our study internal locus of control was only 
found to have a predictive value in relation to non-invasive testing (NIPT) but not invasive 
procedures (CVS), lend themselves to further exploration in future studies. This is especially 
due to inconsistencies with other studies where it has been reported that internal locus of 
control – defined as one’s belief in their own ability to control their health – is associated with 
the decision making process regarding genetic testing (Chen & Goodson, 2007). It may be that 
a more specific measure to pregnancy behaviours would be more appropriate when exploring 
locus of control in relation to prenatal testing. While the Multi-dimensional Health Locus of 
Control that was used in our study explores one’s expectancies over their own health, when it 
comes to pregnancy the expectations tested involve women’s expectations regarding the 
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foetus’s health. Therefore, future studies could use a more tailored measure that has been 
developed for these purposes, namely Fetal Health Locus of Control Scale (FHLC; Labs & 
Wurtele, 1986). Similar to the more general scales, the FHLC also measures internal (FHLC-I), 
external-chance (FHLC-C), and external-powerful others (FHLC-P) dimensions with items 
adapted to capture subtleties related to pregnancy behaviours. Generally, FHLC-I has been 
found to be positively associated with positive health behaviours, such as breastfeeding 
(Haslam, Lawrence, & Haefeli, 2003) and information seeking on pregnancy (Sheih, Broome, & 
Stump, 2010), and negatively associated with negative health behaviours, such as smoking 
(Haslam & Lawrence, 2004), and drinking (Rao, 1997). However, only one study has used the 
FHLC scale in relation to prenatal testing and contrary to their original hypotheses found no 
significant relationships between FHLC and prenatal testing (Turriff-Jonasson, 2004). More 
specifically, there were no significant differences between women who underwent maternal 
serum screening or amniocentesis and women who did not, on any of the three scales (internal; 
chance; powerful others).  Therefore, whilst this measure may be valuable in determining 
women’s health behaviours depending on their perceived control over their baby’s health more 
research needs to be done before drawing conclusions about the reliability of the FHLC and 
indeed the role of locus of control in the decision-making process related to prenatal testing. 
At a second stage, we added women’s risk status for T21 and T13/T18 separately in the 
analysis so as to see whether this affects the results in any way. For both, invasive (CVS) and 
non-invasive (NIPT) tests, all psychological factors became insignificant and only risk was 
found to be significantly associated with women’s decision outcome. More specifically, a 
greater risk for T21 was significantly associated with women’s decision to have an invasive test 
(CVS) whereas a greater risk for either T21 or T13/T18 significantly predicted women’s decision 
to have a non-invasive test (NIPT). Overall, these findings are in line with a previous 
prospective interview study where half the women participating expressed a positive attitude to 
undergoing invasive testing after, however, receiving their screening results, highlighting the 
importance of individualised risk status in this decision (Brajenovic-Milic et al, 2008). In addition, 
an audit report that retrospectively looked at the records of 110.180 women across four 
hospitals, explored the relationship between risk status following maternal serum screening 
(MSS) results and uptake of invasive diagnostic tests (Alberman, 2003). This audit found that 
risk status based on MSS results significantly predicted uptake of diagnostic tests, a finding that 
was also confirmed by Mueller (2005) who reported that MSS results significantly influenced 
women’s choice of amniocentesis. Likewise, Lumley et al (2006) found that traditional risk 
status as determined by maternal age and family history of genetic disorders also predicted 
uptake of invasive testing regardless of maternal serum screening results. However, it has also 
been suggested that it is more the perceived risk of a woman rather than her actual risk that 
predicts uptake (Marteau et al, 1991) and therefore it may be of use to separate between the 
two before considering the impact of risk on women’s participation in prenatal testing.  
In terms of our findings, however, it is interesting that only an increased risk for T21 was 
predictive of invasive testing whereas both a greater risk for T21 and for T13/T18 were 
predictive of women’s decision to have a non-invasive test. This means that after being 
 89 
informed of their higher risk status for carrying a baby with Down’s syndrome women were 
equally likely to either have an invasive or a non-invasive test. This in itself is not surprising as it 
has been previously reported that some women may want to have a definitive diagnosis and 
thus opt for an invasive test, whereas others –who may have previously declined any further 
testing due to fear of risk of miscarriage- may opt for the alternative non-invasive procedure that 
offers valuable information without any risks and a 99% detection rate for T21 (Chetty, 2013). In 
both cases, it seems that women are highly invested in getting as close to a definitive diagnosis 
as they can that will then aid them in subsequent decisions such as whether to terminate the 
pregnancy if a positive diagnosis is made or prepare for the birth and the upbringing of a baby 
with Down’s syndrome (Fransen, 2009).  
However, when women were informed of their greater risk for carrying a baby with T13 or T18 
this significantly affected their decision to undergo a non-invasive test whereas it didn’t seem to 
lead to invasive test uptake. Considering that T21 (Down’s syndrome), even though non-
curable, is not a lethal condition and is associated with a life expectancy of 50 years whereas 
most cases of T13 and T18 either die before birth or barely survive further than a few months 
after being born (Verweij et al, 2014), it could be assumed that women would be more inclined 
to find out for sure whether their baby has a life limiting condition (T13/T18) and at the same 
time more reluctant to take the risk of procedure related miscarriage for a foetus that may still 
live a relatively fulfilling life (T21). However, these results may be suggesting that regardless of 
the prognosis and life expectancy, women are very protective of their unborn babies and try to 
minimize any risks by avoiding invasive testing. In addition, the fact that only a higher risk for 
Down’s syndrome significantly affected women’s choice of invasive testing may be due to the 
anticipated implications of raising a child that will have some level of mental retardation, as well 
as an increased risk for morbidity, including leukaemia, cardiac problems and early-onset 
dementia (Norwitz & Levy, 2013), therefore having a potentially greater impact on them and 
their family unit. Nonetheless, with the non-invasive test only recently being introduced further 
studies of a qualitative nature would be of interest in order to explore women’s choices even 
further. 
To sum up, it appears that when risk is controlled for there are some psychological factors that 
affect women’s decision making process regarding uptake of prenatal testing. A low level of 
anxiety, a negative attitude to medicine and a positive attitude to prenatal testing were all 
predictors of invasive diagnostic testing. On the other hand, a negative attitude towards doctors 
as well as medicine and an internal health locus of control were found to significantly affect 
women’s decision to undergo a non-invasive prenatal test (NIPT). Interestingly, however, when 
risk was included in the analysis all psychological factors became insignificant. Within this 
context uptake of invasive testing (CVS) was only significantly predicted by an increased risk 
for T21, whereas uptake of non-invasive testing (NIPT) was predicted by both an increased risk 
for T21 and T13/T18. These findings suggest that whilst the decision-making process regarding 
prenatal testing is complex and several factors may come into play, it is women’s individualized 
risk following the combined screening test that mostly determines decision outcome. With non-
invasive testing only recently being introduced into medical practice, further research would be 
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required before drawing any firm conclusions. In addition, it would be interesting for future 
studies to further explore why women with a greater risk for T13/T18 would opt for a Harmony 
but not for an invasive diagnostic test. Meanwhile, based on our findings and the significant 
impact of identified risk, more effort should be directed towards the communication of risk to 
patients so as to facilitate understanding of the results and an informed decision whilst also 
catering to the emotional impact that such information may have on patients.   
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4. Chapter Four: Implications for research and practice 
This study originally set out to explore the factors that influence women’s decision to have an 
invasive prenatal diagnostic test or not. This was guided by the rationale that invasive 
procedures entail a risk of miscarriage and also, whilst they provide an accurate diagnosis 
which is considered their greatest attribute, a positive result (confirming a chromosomal 
abnormality) leads to subsequent critical decisions such as deciding whether to terminate the 
pregnancy or not (Zlotogora, 2002). However, even for women who are fully committed to 
seeing the whole pregnancy through, the news that they are carrying a baby with a congenital 
abnormality still requires a period of adjustment as well as more practical preparations for the 
birth of an affected foetus as well as its upbringing, i.e. through getting in touch with relevant 
support groups or simply seeking further information about the needs and requirements of 
raising a child with disabilities. Therefore, the whole prenatal diagnosis process is a 
multifaceted area that can have a significant impact on women’s lives and thus, it is important 
that appropriate attention is given to ensure an informed decision and generally facilitate a 
smooth process for everyone involved.  
Midway the study, however, the research focus had to be slightly adapted so as to incorporate a 
new – non-invasive – test, NIPT, that became available within our research site and which 
offered a highly accurate result, although not definitive, without the risk of miscarriage (ACOG, 
2012). This had an immediate impact on the prenatal diagnosis scene with the vast majority of 
women opting for this choice and initial figures showing a 26% drop in the uptake of invasive 
tests as well as a 95% decrease in women who would have previously opted for no further 
testing (Gil, Giunta, Macalli, Poon, & Nicolaides, 2015). However, despite the encouraging 
progress in medical technology and the reduced risk for procedure-related losses of unaffected 
foetuses, those who are identified as high risk are still required to have an invasive test to 
confirm the result before proceeding to further decisions, thus still maintaining these types of 
tests an important part of the diagnostic process (Farrell, Agatisa, Mercer, Smith, & Phillipson, 
2015).  
From many aspects, the addition of a new non-invasive test in the prenatal diagnostic process, 
is a positive development with women having more options and more importantly these 
including highly accurate tests that eliminate the risk of miscarriage.. However, from a Health 
Psychology perspective the expansion of what was already a complex process also draws 
attention to many other elements that may easily be overlooked therefore posing different kinds 
of risk to women and their emotional well-being. Therefore, this section will aim to draw on key 
findings from this study and adopting a critical stance will attempt to consider implications for 
future research and practice. Research limitations of this study will also be addressed.  
4.1. What do women choose – invasive or non-invasive tests? 
From this study, it appears that the vast majority of women whether intermediate or high risk will 
opt for NIPT as opposed to an invasive test. From an open-ended question that was included in 
the questionnaire it appears that the elimination of risk is what makes NIPT so appealing to 
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women. This is something that has been reported in the literature (Farrell et al, 2015), with 
safety representing the key reason for women choosing NIPT especially amongst those at high 
risk (Lewis, Hill, & Chitty, 2016), and indicates a massive change in the prenatal diagnosis field 
as it leads to a significant reduction in the uptake of invasive diagnostic tests.  
On the other hand, there were still women from the high-risk group that opted for the invasive 
test. Again, through the open-ended question that was included in the questionnaire it was 
apparent that the main reason for this was that an invasive test would provide them with a 
definitive diagnosis. This resembles findings reported elsewhere in the literature, with women 
preferring invasive tests over NIPT primarily because they did not feel sufficiently reassured by 
the results of the latter (Lewis et al, 2016). This highlights the fact that invasive diagnostic tests 
cannot – for the time being at least – be replaced by NIPT despite the risk of miscarriage. 
Should the accuracy of NIPT be further improved to resemble that of invasive tests then 
considerations of removing invasive tests from clinical practice will only be plausible. 
An interesting finding from this study was that women who were at high risk for T13/T18 were 
more likely to choose a non-invasive test whereas women at a high risk of T21 would choose an 
invasive test. This seems counter-intuitive on two counts: firstly, the accuracy of non-invasive 
tests for T13/T18 is not as good as it is for T21; and secondly, the prognosis for a foetus with 
T13/T18 is very bleak with life expectancy being less than one year and that if they make it 
through the whole pregnancy (Lakovschek, Streubel, & Ulm, 2011), contrary to the life 
expectancy and quality of life of people with T21 which are constantly on the rise. The current 
questionnaire data suggests, however, that women are naturally protective of their unborn baby 
regardless of any potential threats, and thus factors such as severity of the condition being 
diagnosed do not necessarily affect their decision in relation to prenatal testing.  
What this suggests is, that women from both moderate and high-risk groups show a preference 
for NIPT as it lifts off the concern of procedure-related miscarriage that accompanies invasive 
tests. This is in line with findings from the general literature whereby not only most women 
(Lewis et al, 2014) but also most men (van Schendelet al, 2015) report a positive attitude 
towards NIPT. Georgsson et al (2016) further supported this by reporting that even though most 
their participants were not aware of NIPT prior to taking part in their study, two thirds of them 
would actually consider having the test if they or their partner were pregnant. This sheds light 
on the importance of extended counselling being provided alongside the introduction of NIPT to 
clinical practice so as to facilitate an informed decision (Vanstone, King, de Vrijer, & Nisker, 
2014).  
However, as seen through this study women also greatly value the accuracy of invasive tests 
and therefore this would offer great support for the efforts being made in the medical field to 
further develop NIPT and improve its efficacy on all levels. From a psychological perspective 
however, it still remains a priority that best ethical standards are maintained and practical efforts 
should be put in place for this purpose. Thoughts on this are addressed in the following section. 
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4.2. What are the non-medical risks of the wider application of non-invasive tests? 
One area that has already received much research attention is related to ethical considerations 
regarding NIPT becoming more widely available. For example, the ease with which this test is 
delivered – through a blood draw – should not in any way compromise the level of genetic 
counselling and support that is provided to these women (Murdoch et al, 2016). There is 
concern that with already limited resources in genetic counselling and the absence of any 
medical risk associated with NIPT, protocols around communicating all the relevant information 
and potential outcomes to women prior to them accepting the test may be compromised due to 
the absence of any immediate threat (Menezes et al, 2013). It is, however, of utmost 
importance that medical staff remain aware of the importance of this and continue to thrive to 
elicit an informed decision from women whilst communicating key information and preparing 
them for the indirect risks that they may be exposed to (i.e. if NIPT indicates high risk for any of 
the three main chromosomal abnormalities it is currently used for, an invasive test – and thus a 
risk of miscarriage – would be required before a definitive diagnosis can be made).  
One important factor to consider is that according to current clinical practices, even though 
women may be provided with some written information on screening and its purpose prior to 
having their first trimester combined test, they only receive genetic counselling after their 
individualised risk shows that they are at moderate or high risk. This means that when faced 
with an adverse result, women may already be in a heightened psychological state to be able to 
process new information rationally and arrive to an informed decision. Thus, they may become 
even more stressed and rely on others, such as their doctors or other external sources, to make 
their decision. Whilst NICE guidelines recommend that women be informed of the purpose of 
any screening procedure before it is carried out, it is unclear how much time is invested in the 
communication of potential outcomes and subsequent decisions that may lay ahead prior to 
women receiving their combined screening results (NICE, 2008). It would be interesting for 
future studies to explore the impact of informing all women prior to them receiving their results 
and how this may be beneficial or not for them. Might this expose women to a potential increase 
in anxiety levels because of the potential risks coming to the forefront of their minds? And if so, 
is this transient and balances out for those who then receive a “screen negative” result? Does 
having more information beforehand indeed allow women to assess their options more 
rationally without the added stress of a “screen positive” result already at hand? A longitudinal 
study where women’s knowledge of potential future options against their anxiety levels are 
assessed before and after receiving their combined screening results could potentially lead to 
changes in the current practice that may be in women’s best psychological interest. This would 
shed light on the current controversy within the literature whereby some have reported a 
lingering anxiety throughout pregnancy as a result of screening procedures highlighting the 
possibility of something being wrong with the foetus (Green et al, 2004), whilst others reporting 
a continuous decrease in anxiety during pregnancy in women who participated in screening 
(Lou, Mikkelsen, Hvidman, Petersen, & Nielsen, 2015). In addition, and in light of the 
introduction of NIPT into clinical practice, the 7-10 day turnaround period required for the results 
has also been associated with prolonged anxiety in women that usually, however, decreases 
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upon receipt of a negative result, yet in some cases remains elevated (Lewis et al, 2016). This 
may reflect a lack of faith in NIPT’s reliability, an increased concern due to conflicting results 
between the combined screening test and NIPT, or simply a personality trait of heightened 
anxiety that may characterise some of the women; further research exploring this aspect would 
be of clinical importance as it could help guide health professionals as to how they can more 
efficiently council and support such women. 
Another important element is ensuring the best communication methods are used that 
correspond to women’s needs and preferences. When it comes to prenatal testing women are 
usually given a probabilistic number (i.e. 1/280) that is, however, not always easy to 
comprehend (Pighin, Bonnefon, & Savadori, 2011). Risk communication is undoubtedly a 
complex matter, but it might be that women are more able to understand a verbal explanation of 
the results (i.e. “not likely”) especially in this context where emotions are highly involved 
(Timmermans, 2005). Future research should focus on identifying women’s preferred method of 
risk communication and develop appropriate resources that will help health professionals on 
this sensitive subject.  
Further to this, it is of utmost importance that health professionals involved in the prenatal 
diagnosis process are aware of how to accurately interpret NIPT test results. Considering the 
importance of informed decision making when it comes to medical issues (Brauer, 2015), and 
the extent to which women rely on their doctors for understanding the results (Hedrick, 2005) 
this is an area that requires the attention of policy makers and potentially hospital directors that 
are in charge of their staff training. While there are guidelines on how to use this test, there are 
no published guidelines on quality control and assurance, thus leaving a window for potential 
misuse and misinterpretation unless further measures are taken to prevent this from happening 
(Lutgendorf, Stoll, Knutzen, & Foglia, 2014). In addition, it has been highlighted by parents of 
children with Down’s syndrome that in order for one to make an informed decision when it 
comes to prenatal testing it is important not only to be counselled about the test options and 
their implications but also about the condition they are being tested for and how it is, for 
example, to live with a child with Down’s syndrome (van Schendel et al, 2016). Nonetheless, 
with NIPT being trialled for use with several different disorders it will become increasingly 
difficult for health professionals to provide such counselling to all parents, thus unveiling a 
potential disadvantage of the wider use of this test.  
 
4.3. How will the wider use of NIPT affect the prenatal diagnostic practice? 
Undoubtedly the development of NIPT was revolutionary for prenatal diagnosis practice and it is 
commonly acknowledged that it will continue to have a significant impact on current practice (Gil 
et al, 2014). As it continues to be improved in terms of accuracy and also in terms of the range 
of conditions it is able to detect, it is thought that it will also continue to rise in women’s 
preference (Chetty, Garabedian, & Norton, 2013). There is, however, a continuing debate on 
which cases it will be more suitable for.  
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With a general understanding being that the cost of this will be unsustainable for the NHS to roll 
it out as a routine practice offered to all pregnant women, NIPT may be most appropriate for 
women falling in the intermediate risk category (1:2500). Therefore, it may be best suited as a 
half-way step that is offered to women in the moderate/high risk group between their combined 
screening and an invasive test. This would allow for a more accurate personalised estimated 
risk to be offered to women thus discriminating between those who are at a very high risk and 
those for whom even though present, the level of risk does not warrant the additional risk of 
miscarriage that would be associated with an invasive procedure. As a result, many women 
who would otherwise not have proceeded with any further test due to the associated risk now 
have a greater insight and can potentially gain further reassurance. On the other hand, those 
who would have instantly sought reassurance through an invasive test now also have the 
opportunity to minimise the risks by weighing up the pros and cons of getting a 100% result 
versus a 99%. In line with shared decision making that has been the advocated approach in 
medical decision making since the mid-1990s (Moumjid, Gafni, Bremond, & Carrere, 2007) it is 
important that health professionals and patients share both the process and the ownership of 
the decision outcome (Coulter, 1999). In other words, through genetic counselling women 
should get a clear understanding of the risk or severity of the condition being screened for, as 
well as the risks, benefits, and alternatives of the screening and diagnostic tests being offered; 
in addition, they should be given the time and space to weigh their personal values against the 
potential costs and benefits of the tests under offer and engage in decision-making to the extent 
that they feel comfortable with (Sheridan, Harris, & Wolf, 2004). 
Nonetheless, even though the uptake of invasive tests has already significantly decreased 
following the introduction of NIPT (Gil et al, 2014), these are by no means to be removed from 
current prenatal diagnosis as they are the only means of getting a definitive diagnosis about the 
health of the foetus. One potential concern however, may have to do with the skill of doctors 
performing invasive tests being compromised due to lack of practice. This leads to the question: 
what effect will the introduction of NIPT have on the procedure-related risk of miscarriage? At 
the moment this is reported to be approximately 1% (Hill et al, 2012) depending on the skill of 
the clinician, and an undesirable outcome of the infrequency of their performance would be an 
increase in this risk. This may see invasive diagnostic tests becoming the object of more highly 
specialized professionals who have the level of skill required to perform such a high-risk 
procedure, but it is important for all health professionals in this field to be mindful of such 
potential downfalls and thus incorporate measures within their practice to prevent this from 
happening. This could involve all new doctors being required to assist and perform a certain 
amount of invasive diagnostic procedures under the supervision of an experienced consultant 
as part of their training and that this also be regularly sustained through internal clinical skills 
workshops. It is important to minimize the risks posed to any pregnancy and the development of 
non-invasive tests is definitely a step in the right direction. However, with invasive tests still 
being an integral part of the process involving high-risk cases, it is important not to let it fade in 
the back with more serious consequences for those who still have to go through it.  
 
 96 
4.4. How do women choose? 
In terms of the primary research question there are some important findings to draw on. Firstly, 
as far as invasive tests are concerned none of the psychological factors under investigation 
played a significant role in women’s decision making process. It seems that a negative attitude 
to medicine and a positive attitude to prenatal tests increase the likelihood of a woman having 
an invasive test whereas a greater level of anxiety has the contrary effect with such women 
being less likely to choose this type of test. Possible explanations for these findings have been 
discussed earlier in Chapter 3 but it is important to note that while these factors may have 
played some role and could potentially be further explored in future research, they did not reach 
statistical significance.  
On the contrary, as far as NIPT is concerned, some psychological factors were found to 
significantly contribute to a woman’s decision: a negative attitude to doctors and an internal 
locus of control increase the likelihood of a woman choosing to have a non-invasive test 
whereas a negative attitude to medicine decreases her chances.  
In considering all the above findings together, a consistent finding seems to revolve around 
negative attitudes towards medicine that seem to shape women’s decision at least to some 
extent one way or the other: while it drives them in the direction of invasive tests, it averts them 
from non-invasive tests. The most obvious explanation for this would be that despite being 
negatively biased towards medicine in general, when it comes to the serious matter of their 
unborn baby’s well-being women are still willing to put their faith into long-standing and well-
established procedures, whilst being more critical towards newly developed tests. This is 
important in that it means these women may be posing themselves at a greater risk that is 
associated with invasive procedures without really making the best of medical technology’s 
rapid advances. It may be that this particular population, predisposed by their own conceptions 
about medicine or technology advancements, do not seek information on new methods of 
prenatal testing and diagnosis and thus, are more ignorant of the real costs and benefits of such 
procedures. Whilst it was originally intended to include knowledge of prenatal tests as a variable 
in the questionnaire developed for this study, items relating to it were dropped during the factor 
analysis process and thus ‘knowledge’ was not assessed in relation to women’s decision 
making processes.  Therefore it is difficult to draw safe conclusions and further research is 
required to explore this further. Nonetheless, it could still be argued that while it may be easier 
to trust a medical procedure that has been around for years, it may be useful for particular 
attention to be paid to these women – especially if future studies identify a more limited 
knowledge-base - in educating them about the new non-invasive test and thus enabling them to 
come to a truly balanced and informed decision. This is in line with ongoing research regarding 
technology acceptance which has been defined as ‘the approval, favourable reception and 
ongoing use of newly introduced devices and systems’ (Ziefle & Schaar, 2011). Evidence 
suggests a general distrust towards medical technology, and women in particular perceiving the 
value of medical technology as lower than men as they tend to focus more on the ‘costs’ versus 
the ‘benefits’ of using such methods (Ziefle & Schaar, 2011). Therefore, it may be that women 
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attending their appointment for their first trimester combined screening test will have to be 
approached in a more sensitive manner so as not to further alienate them and the information 
will have to be communicated to them in a simple manner that is sharp enough to engage their 
attention and ensure they have a clear understanding of both the benefits and the costs of any 
test that is being offered to them. A focus group interview with such women would help in 
identifying what the best means of communicating this information might be as well as exploring 
what key cognitions may play in their mind affecting their attitudes and beliefs. This would 
enable health professionals to initially assess their acceptability towards new medical 
information and subsequently develop an appropriate intervention so as to tailor information to 
the needs of these women. 
Another important finding that significantly contributed to women’s choice of NIPT but which 
was also found to have a large effect size on women’s decision to have an invasive test 
(although not statistically significant) was internal locus of control. It appears that women who 
believe they have greater control over their health are more likely to have some sort of test 
whereas those with a chance locus of control were found to be more likely to choose no further 
testing. This again, shifts our attention to the beliefs women hold about the controllability of a 
condition and what it is that actually shapes this belief. While this is consistent with some 
previous studies (Lumley et al, 2006) and may be explained by women viewing screening and 
testing as a proactive health behaviour, there are still conflicting findings within the wider 
literature (Furr & Seger, 1998) indicating that further research is required before drawing firm 
conclusions. As discussed in Chapter 3, a more pregnancy-related measure of locus of control 
such as the Fetal Health Locus of Control Scale (FHLC; Labs & Wurtele, 1986) that has long 
been developed but has only been used in one study relating to prenatal testing (Turriff-
Jonnason, 2004) would be of interest to be further explored along these lines as it could provide 
useful insight to women’s feelings of controllability over the health of their baby. Should further 
support for the contribution of internal locus of control be established, this would provide 
grounds for appropriate interventions to be developed that will aim to empower women so as to 
facilitate a greater sense of control and thus potentially a more proactive role in their antenatal 
care decisions.  
In relation to the above, the role of others in women’s decision making process regarding 
uptake of prenatal tests, seems to also warrant further exploration. The general indication in the 
wider literature so far, is that partners are the most influential on women’s decision-making 
process, followed by family and friends (Georgsson et al, 2016). However, prior research has 
also shown that women tend to go along with their partner’s opinion in the case of a 
disagreement (Garcia et al, 2008) and therefore this might mean that they do not necessarily 
make a decision that is in line with their own values and attitudes. The impact on this on their 
psychological well-being is unknown, especially if the pregnancy outcome is not optimal, and 
therefore efforts should be put into ensuring that all women are making informed decisions 
when it comes to prenatal testing. This may mean involving the partners more in the whole 
process so as to ensure that both parties have all the necessary information required prior to 
making such a decision and also opening the lines of communication between them so as to 
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facilitate a mutual deliberation and decision making process. More research involving partners 
is required in order to shed light on this front. 
Finally, probably the most important finding of this study was that when personalised risk based 
on the first trimester combined screening test was included in the model, all psychological and 
socio-demographic factors became insignificant and this was the single factor that influenced 
women’s decision making process. As far as invasive tests are concerned a high risk for T21 
was the only significant predictor whereas for non-invasive tests a high risk for both, T13/T18 
and T21, were significantly related to decision outcome. This was a prospective study, with data 
being collected prior to women finding out their risk status, thus indicating that further research 
on women after being informed of their risk status would be warranted. What happens to them, 
emotionally and cognitively, when they are actually informed of a threatening outcome? Is their 
locus of control, for example, completely wiped out rendering them more vulnerable to what 
now may seem out of their control? How are their attitudes towards doctors and medicine 
affected? Do they find themselves becoming more open to tests in hope of a reassuring result? 
Future studies aiming to answer these questions would be of clinical importance as they would 
allow relevant tools to be developed so as to compliment the communication of risk results and 
facilitate adjustment to the news and a comprehensive processing of the information thus 
enabling an informed decision regarding further action. A recent study that was published after 
the analysis of our data (Beulen et al, 2016), reported that a web-based decision aid facilitates 
autonomous informed decision when it comes to prenatal testing and therefore further 
exploration along these lines or other effective resources may be appropriate.   
4.5. What about “low-risk” women? 
So far it has been clear that most of the attention has been focused on women identified as 
being at intermediate or high risk of having a baby with a chromosomal abnormality and how to 
best support them in their decisions. But in adopting a more holistic view of our findings another 
striking outcome could be that all women who were low risk on both T21 and T13/T18 opted for 
no further testing at all. While this may have been a result of them not being directly offered the 
choice by their medical team, it also suggests that having a reassuring outcome from the 
combined screening test is enough confirmation for women to not want to seek further 
reassurance. While this is important in that it does not expose these women to any risk of 
iatrogenic miscarriage it does not necessarily mean that women in this category do not 
experience any anxiety or feel completely reassured by their screening results. It would be 
interesting to explore these women’s feelings following a “screen-negative” result and how they 
understand this finding. Notably, the combined test detects approximately 85-90% of Down 
Syndrome pregnancies with a 4.2% false positive rate (Alfirevic & Neilson, 2004) and therefore 
it is possible that even in the event of a normal result a woman may still be carrying a baby with 
Down’s Syndrome. Women are informed of this likelihood and evidence suggests that they 
have the ability to use personalized screening information in making a scientifically and ethically 
rational decision about invasive testing (Nicolaides, Chervenak, McCullogh, Avgidou, & 
Papageorghiou, 2005). However, little research has been done to explore how much this 
 99 
screening affects their emotional state. This is not to suggest that invasive tests should be 
offered or carried out on all women but certainly highlights the contribution of NIPT that offers 
close-to-diagnostic results without any risks.  
However, at this point in time at least, it is not within screening policy to offer NIPT to all women 
as this would incur significant costs on the NHS without being considered absolutely necessary, 
and therefore some could argue it casts this group of women at a slightly disadvantageous 
position. It is encouraging, however, that evidence supports the effectiveness of non-invasive 
prenatal testing on a routinely screened first trimester population (Nicolaides et al, 2012) 
suggesting that even if not routinely offered it may still be a better option than directly having an 
invasive test for women who still wish to have further reassurance despite receiving a “screen-
negative” result from their combined screening. 
From a Health Psychology perspective, it is important to ensure that equal psychological 
support is in place for all pregnant women regardless of their combined screening results. With 
pregnancy itself, regardless of prenatal screening tests, being associated with psychological 
stress and anxiety in many women (Statham, Green, & Katesios, 1997), it is likely that 
undergoing tests for the identification of any abnormality may increase women’s anxiety and 
concerns by bringing to the forefront of their mind the potential adverse outcomes. But how truly 
reassured are women after receiving a “low-risk” result? Whilst there is some evidence to 
suggest that early screening for Down’s syndrome by means of ultrasound does not increase 
women’s anxiety in the second trimester and two months post-delivery (Ohman, Saldvedt, 
Grunewald, & Waldenstrom, 2004), it is observed that most studies focus on women receiving 
an adverse result and therefore more longitudinal studies in the UK targeting women with a 
normal outcome, would be warranted in order to explore the impact of the combined test and 
therefore determine the level of support that is required for this population.  
It is important to note that in the present study anxiety levels at baseline measurement (prior to 
combined screening test results) were relatively stable across all women indicating that there 
may not be much variation in women’s anxiety response prior to being informed about their 
results. The mean levels were 5.33 and 5.43 in low and moderate/high risk groups respectively 
which according to the recommended cut-off point of 8 for the anxiety scale (HADS 
questionnaire) does not indicate clinical anxiety. While positive in terms of women’s emotional 
well-being, it would have been interesting to also measure their anxiety levels post-results in 
order to assess the impact of the screening and how being ascribed a personalized risk may 
have affected them.   
4.6. Strengths & Limitations 
Despite the important findings, this study is not without limitations. First of all, the methodology 
– which was questionnaire-based- may have been restrictive in terms of identifying potential 
factors that influence women’s decision-making process. An attempt to prevent this restrictive 
nature of data collection was made by including an open-ended question where women were 
asked to disclose the key factors affecting their choice. However, even though this provided 
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some further insight, it would have been even more insightful to include some interviews, either 
individual or in the form of focus groups, in our data collection process where women would 
have the opportunity to expand on their thoughts and potentially reveal more aspects that could 
not be captured in the limited space of one open-ended question. 
In addition, there were several factors that we originally set out to explore, yet these were 
rejected during the factor analysis in the pilot study. Such factors include knowledge and the 
influence of important others (subjective norms), that have been reported in the literature with 
conflicting findings (Michie et al, 2002) and therefore require further investigation especially 
since the addition of NIPT into clinical practice. However, a strength to counter-balance this, 
was that a holistic approach was adopted where a combination of different models was used to 
guide the development of our questionnaire, thus not limiting the scope of the factors explored 
to one set of variables. 
Another potential limitation is that the original scope of the study was to explore women’s 
decision making process regarding the uptake of invasive diagnostic tests and therefore the 
pilot study was mainly focused on amniocentesis and CVS. With the introduction of NIPT in the 
clinical practice of our research site, however, it was considered plausible to expand the scope 
of our study so as to additionally include NIPT. It was thought that this would provide more 
interesting and useful clinical/research information considering the changes that will inevitably 
occur in the field of prenatal diagnosis with the increasing use of NIPT, especially since there 
are talks about rolling it out in the NHS (Morris, Karlsen, Chung, Hill, & Chitty, 2014).. It is 
important to note, that following our decision to expand the original scope of the study 
appropriate amendments were made to the questionnaire so as to include NIPT as well and 
these were approved by the Stamford National Research Ethics Committee prior to conducting 
our main study. Nonetheless, some of the questions had to be somewhat more generalised 
following these changes, i.e., looking at attitudes towards prenatal testing rather than attitudes 
towards invasive vs. non-invasive procedures. A more targeted approach may have clarity to 
the differences between the two different testing methods and would be of use to be explored 
by future studies. 
Having said this, a strength of our study is that it was prospective and therefore explored 
women’s intentions to take up a particular test which was then confirmed or disconfirmed by 
following up with her final decision. This could have been further improved by follow-up 
interviews where women would have the opportunity to reflect on their original intentions and 
actual behaviour as well as on what else may have ended up affecting their decision if this was 
changed after the receipt of a screen-positive result. This would provide insight to the 
everlasting debate in the literature as to how much intentions predict actual behaviours. 
Moreover, another limitation is the small sample size in high-risk women and women choosing 
to have an invasive test. This is justified, however, by the nature of our study and a strength of 
the study to offset this drawback is that a special statistical method was used that is applicable 
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to such cases (rare events such as being at high risk) and thus allowing for the detection of 
significant results even in the event of unequal sample sizes. 
Finally, the fact that our study was based only on one research site limits the generalisability of 
the findings. Further research on multiple sites would allow for more firm conclusions to be 
drawn and also allow for greater variability in the population being tested. This may also lead to 
different findings in terms of religious and socio-cultural influences on women’s decision making 
process that has been suggested before but was not evident in this study, or indeed confirm 
that these factors do not ultimately determine women’s choices.  
Whilst all the above points are to be considered in the context of our current findings, this study 
offers important information for future clinical and research use on a topic that is now 
expanding, in light of the changes that are currently under way in the prenatal diagnosis scene. 
4.7. Concluding remarks  
This study was one of the first to address women’s decision making processes in relation to 
prenatal diagnosis including the new non-invasive NIPT test. Unsurprisingly low-risk women 
opted for no further testing but moderate and high risk women predominantly opted for NIPT 
with some exceptions of high risk cases seeking the definitive diagnosis of the invasive tests. 
This is thought to be representative of the general population as seen through initial evidence 
(Gil et al, 2015) and indicates a major shift in prenatal diagnosis as it was practiced until now. 
With NIPT becoming more widely available and the uptake of invasive tests reducing, it is 
important for Health Professionals to keep in mind the potential ethical and practical drawbacks 
whilst maintaining as their priority that an informed decision is made on behalf of women.  
Whilst attitudes towards medicine, internal locus of control, and the role of partners are all areas 
that would warrant further research, if there was one key finding that overrules the rest is that 
when personalized risk estimate based on the first trimester combined screening is included in 
the model then this forms the single predictor of women’s decision. Therefore, it may be more 
appropriate that greater attention is focused on risk communication and doctor-patient 
relationship. If finding out their risk level is going to play such a significant role in women’s 
decision, it is of utmost importance that this is communicated to them in a sensitive and easily-
comprehensible manner whilst also encouraging an open communication whereby women feel 
comfortable raising their concerns with their healthcare professionals. This is something that 
should be encouraged in all practices as a means of empowering women to gather the 
information they need from reliable sources that can also be complimented by other means 
such as the recommendation of particular websites by their healthcare team. Through this 
continuous growth in the doctor-patient communication it is hoped that a smooth process will be 
facilitated in an otherwise inevitably complex and emotionally-laden situation.    
 102 
5. References 
 
Aalfs, C. M., Oort, F., J., Haes, H., Leschot, N.J., & Smets, M.A. (2006). Counselor-counselee 
interaction in reproductive genetic counseling: does a pregnancy in the counselee make a 
difference? Patient Education and Counseling, 60, 80-90. 
Abdi, H., & Williams, L.J. (2010). Principal component analysis. Wiley Interdisciplinary Reviews: 
Computational Statistics, 2, 433-459. 
Abu-Musa, A.A., Nassar, A.H., & Usta I.M. (2008). Attitude of women with IVF and spontaneous 
pregnancies towards prenatal screening. Human Reproduction, 23(11), 2438-2443. 
ACOG (2012). Noninvasive prenatal testing for fetal aneuploidy: Committee opinion No 545. 
Ahman, A., Runestam, K., & Sarkadi, A. (1991). Did I really want to know this? Pregnant 
women’s reaction to detection of a soft marker during ultrasound screening.Patient Education 
and Counseling, 81, 87-93. 
Ahmed, S., Ahmed, M., Sharif, S.M., Sheridan.E.,& Taylor (2012). Attitudes towards prenatal 
testing and termination of pregnancy in British Pakistani parents and relatives of children with 
recessive conditions in the UK.Prenatal Diagnosis, 32, 954-959. 
Ahmed, S., Bryant, L.D., Tizro, Z., & Schickle, D. (2012). Interpretations of informed choice in 
antenatal screening: A cross-cultural, Q-methodology study. Social Science & Medicine, 74, 
997-1004. 
Ajzen I. (1991). The Theory of Planned Behavior. Organizational Behavior and human decision 
processes. 50,  179-211. 
Ajzen, I. (1991). The theory of planned behavior.OrganBehavHumDecis Process, 50, 179–211. 
Alberman, E., Huttly, W., Hennessy, E., & McIntosh, A. (2003). The use of record linkage for 
auditing the uptake and outcome of prenatal serum screening and prenatal diagnostic tests for 
Down Syndrome. Prenatal Diagnosis, 23, 801-806. 
Alfirevic Z. & Walkinshaw S.A. (2010). Amniocentesis and Chorionic Villous sampling, RCOG 
Green Top Guideline. & Guideline No 8.  
Alfirevic, Z. & Neilson, J.P. (2004). Antenatal screening for Down’s syndrome: Nuchal 
translucency plus biochemical tests has the lowest false positive rate. BMJ, 329, 811-812. 
 103 
Alfirevic, Z., Gosden, C.M.,& Neilson, J.P. (2000).Chorion villus sampling versus amniocentesis 
for prenatal diagnosis. Cochrane Database Syst Rev, 2:CD000055. 
Alkazaleh, F., Thomas, M., Grebenyuk, L., Glaude, L., Savage, D., Johannesen, J., Caetano, 
M., & Windrim, R. (2004). What women want: women’s preferences of caregiver behavior when 
prenatal sonography findings are abnormal.UltrasoundObstetGynecol, 23, 56-62. 
Allyse, M., Sayres, L.C., Goodspeed, T.A., & Cho, M.K. (2014).Attitudes towards non-invasive 
prenatal testing for aneuploidy among US adults of reproductive age.Journal of Perinatology, 
34, 429-434. 
Allyse, M., Sayres, L.C., King, J.S., Norton, M.E. and Cho, M.K. (2012). Cell-free fetal DNA 
testing for fetal aneuploidy and beyond: clinical integration challenges in the US context. Human 
Reproduction, 27(11), 3123-3131. 
American College of Obstetricians and Gynecologists (ACOG) (2007). Screening for fetal 
chromosomal abnormalities. Washington (DC): American College of Obstetricians and 
Gynecologists (ACOG); ACOG practice bulletin, no.77. 
American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics (2012). 
Committee opinion no. 545. Noninvasive prenatal testing for fetal aneuploidy. Obstetrics and 
Gynecology 120(6): 1532–4. 
American College of Obstetricians and Gynecologists (ACOG), 2012. Non-invasive prenatal 
testing for fetal aneuploidy. Committee opinion No.545.Obstetrics & Gynecology,120(6), 1532–
1534. 
Anderson, G. (1999). Nondirectiveness in prenatal genetics:Patients read between the lines. 
Nursing Ethics, 6, 126–136. 
Anderson, G. & Brown, C. (2009). Fetal chromosomal abnormalities: antenatal screening and 
diagnosis. American Family Physician, 79(2), 117-123. 
Anderson, J., Rainey, M., & Eysenbach, G. (2003).The impact of cyberhealthcare on the 
physician-patient relationship.Journal of Medical Systems, 27(1), 67-84. 
Anderson, L.A., DeVellis, R.F., Boyles, B., & Feussner, J.R. (1989). Patients’ perceptions of 
their clinical interactions: development of the multidimensional desire for control scales. Health 
Education Research: Theory & Practice, 4(3), 383-397. 
Antenatal care: routine care for the healthy pregnant woman, NICE Clinical Guideline (March 
2008). 
 104 
Asch, A. (1999). Prenatal diagnosis and selective abortion: a challenge topractice and policy. 
Am J PublicHealth, 89, 1649–1657. 
Ashoor, G., Syngelaki, A., Wagner, M., Birdir, C. and Nicolaides, K.H. (2012). “Chromosome-
selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 
and trisomy 18,” American Journal of Obstetrics & Gynecology, vol. 206, no. 4, pp. 322.e1–
322.e5. 
Ashoor, G., Syngelaki, A., Wang, E., Struble, C., Oliphant, A., Song, K., & Nicolaides, K. 
(2013).Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective 
cell-free DNA analysis method.UltrasoundObstetGynecol, 41, 21-25. 
Baig S., Ho S.S.Y., Ng B.L., Chiu L., Koay E.S.C., Leow G.H., Gole L., Kothandaraman N., 
Chan J., Sun X., Chan Y.H., Rauff M., Su L.L, Biswas A., & Choolani M. (2010). Development 
of quantitative-fluorescence polymerase chain reaction for the rapid prenatal diagnosis of 
common chromosomal aneuploids in 1,000 samples in Singapore. Singapore Med J 51(4), 343-
348. 
Bandura A. (1977). Social Learning Theory. Englewood Cliffs, New Jersey: Prentice-Hall. 
Barrett, A., Advani, H.V., Chitty, L.S., & Choolani, M. (2016). Evaluation of preferences of 
women and healthcare professionals in Singapore for implementation of noninvasive prenatal 
testing for Down Syndrome. Singapore Medical Journal, doi:10.11622/smedj.20/6/14. 
Bartels, D.M., Leroy, B.S., McCarthy, P., & Caplan, A.L. (1997). Nondirectivenessin genetic 
counseling: a survey of practitioners. Am J MedGenet, 72, 172–179. 
Bauer, A. (2011). Factors influencing decision-making in prenatal screening for Down 
Syndrome. A paper presented to the faculty of The University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for thedegree of Master of Public Healthin the Department 
of Maternal and Child Health. 
Beaumont, 2012. An introduction to Principal Component Analysis & Factor Analysis Using 
SPSS 19 and R. 
Beck, U. (1992). From Industrial Society to the Risk Society: Questions of Survival, Social 
Structure and Ecological Enlightenment. Theory, Culture and Society, 9 (1), 97-123. 
Becker, M.H., Kaback, M.M., Rosenstock, I.M., & Ruth, M.V. (1975). Some influences on public 
participation in a genetic screening program. Journal of Community Health, 1(1), 3-14. 
Bekker, H.L., Hewison, J., &Thornton, J.G. (2003). Understanding whydecision aids work: 
linking process and outcome. Patient EducCouns, 50, 323–329. 
 105 
Benn, P., Borell, A., Chiu, R., Cuckle, H., Dugoff, L., Faas, B., Gross, S., Johnson, J., Maymon, 
R., Norton, M., Odibo, A., Schielen, P., Spencer, K., Huang, T., Wright, D., & Yaron, Y. 
(2013).Position statement from the aneuploidy screening committee on behalf of the board of 
the International Society for Prenatal Diagnosis.Prenatal Diagnosis, 33(7), 622-629. 
Benn, P., Cuckle, H., & Pergament, E. (2013). Non-invasive prenatal testing for aneuploidy: 
current status and future prospects. Ultrasound Obstet Gynecol, 42, 15-33. 
Benn, P.A. & Chapman, A.R. (2010).Ethical challenges in providing non-invasive prenatal 
diagnosis.CurrOpinObstetGynecol, 22, 128–134. 
Bennett, R. (2001) Antenatal genetic testing and the right to remain in ignorance,Theory in 
Medical Bioethics, 22, 461–71. 
Berkenstadt, M., Shiloh, S., Barkai, G., Katznelson, M., & Goldman, B. (1999). Perceived 
Personal Control (PPC): A new concept in measuring outcome of genetic counseling. American 
Journal of Medical Genetics, 82, 53-59. 
Berland, G.K., Elliott, M.N., Morales, L.S., Algazy, J.L., Kravitz, R.L., Broder, M.S., Kanouse, 
D.E., Munoz, J.A., Puyol, J.A., Lara, M., Watkins, K.E., Yang, H., & McGlynn, E.A. (2001). 
Health information on the internet: Accessibility, quality, and readability in English and Spanish. 
JAMA, 285(20), 2512-2621. 
Bertaux, D. (1981). From the life-history approach to the transformation of sociological practice. 
In Daniel Bertaux (Ed.), Biography and society: The life history approach in the social 
sciences (pp.29-45). London: Sage. 
Beulen, L., van den Berg, M., Faas, B.H.W., Feenstra, I., Hageman, M., van Vugt, J.M.G., & 
Bekker, M.N. (2016). The effect of a decision aid on informed decision-making in the era of non-
invasive prenatal testing: a randomised controlled trial. European Journal OF Human Genetics, 
24, 1409-1416. 
Bianchi, D.W., Oepkes, D., & Ghidini, A. (2013).Current controversies in prenatal diagnosis 1: 
should noninvasive DNA testing be the standard screening test for Down syndrome in all 
pregnant women? Prenatal Diagnosis, 33, 1-6. 
Bijma, H.H., Van der Heide, A., Wildschut, H.I.J., Van der Maas, P.J., & Wladimiroff, J.W. 
(2007). Impact of decision-making in a multidisciplinary perinatal team. Prenatal Diagnosis, 27, 
97-103. 
Bjelland, I., Dahlb, A.A., Haug, T.T., &Neckelmann, D. (2002).The validity of the Hospital 
Anxiety and Depression Scale. An updated literature review.Journal of Psychosomatic 
Research, 52(2), 69–77. 
 106 
Bodegird, G., Fyro, K., & Larsson, A. (1988). Psychological reactions in 102 families with a new-
born who has a falsely positive screening test for congenital hypothyroidism, Acta Prediatr. 
Scand., suppl304, 3-21. 
Bountziouka, V. & Panagiotakos, D.B. (2012). The Role of Rotation Type used to Extract 
Dietary Patterns through Principal Component Analysis, on their Short-Term Repeatability. 
Journal of data science, 10, 19-36. 
Brajenović-Milić, B., Babić, I., Ristić, S., Vraneković, J., Brumini, G., & Kapović, M. (2008). 
Pregnant women's attitudes toward amniocentesis before receiving Down’s syndrome 
screening results. Women’s Health Issues, 18(2), 79-84. 
Brauer, S. (2015). Moral implications of obstetric technologies for pregnancy and motherhood. 
Med Health Care and Philosophy, 1-10. 
Bricker, L., Garcia, J., & Henderson, J. (2000). Ultrasound screening in pregnancy: a systematic 
review of the clinical effectiveness, cost-effectiveness and women´s views. Health Technology 
Assessment, 4(16), 1-193. 
Broom, A. (2005). Virtually healthy: the impact of internet use on disease experience and the 
doctor-patient relationship. Qualitative Health Research, 15(3), 325-345. 
Browner, C.H. & Preloran, H.M. (1999).Male partners’ role in Latinas’ amniocentesis 
decisions.Journal of Genetic Counseling, 8(2), 85-108. 
Bryant, L.D., Green, J.M., & Hewison, J. (2010). The role of attitudes towards the targets of 
behaviour in predicting and informing prenatal testing choices. Psychology and Health, 25(10), 
1175-1194. 
Bushby K., Finkel R., Birnkrant D.J., Case L.E., Clemens P.R., Cripe L., Kaul A., Kinnett K., 
McDonald C., Pandya J., Poysky J., Shapiro F., Tornezsko J., & Constantin C. (2010). 
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and 
pharmacological and psychosocial management. The Lancet, 9, 77-90. 
Campbell, J.D., Stanford, J.B., & Ewigman, B. (1996). The social pregnancy interaction model: 
conceptualizing cognitive, social and cultural barriers to prenatal care. Applied Behavioral 
Science Review, 4(1), 81-87. 
Carroll, J.C., Brown, J.B., Reid, A.J., & Pugh, P. (2000).Women’s experience of maternal serum 
screening.Canadian Family Physician, 46, 614-620. 
Cattell, R. B. (1966). The scree test for the number of factors. Multivariate Behavioral Research, 
1, 245-276. 
 107 
Cattell, R. B. (1978). The scientific use of factor analysis in behavioral and life sciences. New 
York: Plenum. Cattell, R. B., & Dreger, R. M. (Eds.) 
Cederholm, M., Axelsson, O., & Sjoden, P.O. (1999). Women’s knowledge, concerns and 
psychological reactions before undergoing an invasive procedure for prenatal karyotyping. 
Ultrasound Obstetrics and Gynecology, 14, 267-272. 
 
Cederholm, O.A. & Sjoden, P.O. (1999). Women’s knowledge, concerns and psychological 
reactions before undergoing an invasive procedure for prenatal karyotyping. Ultrasound Obstet 
Gynecol, 14, 267-272. 
Chen, L.S. & Goodson, P. (2007). Factors affecting decisions to accept or decline cystic fibrosis 
carrier testing/screening: a theory-guided systematic review. Genetics in Medicine, 9(7), 442-
450. 
Chetty, S., Garabedian, M. J., & Norton, M. E. (2013).Uptake of noninvasive prenatal testing 
(NIPT) in women following positive aneuploidy screening.Prenatal diagnosis, 33(6), 542-546. 
Chitty, L.S., Hill, M., White, H., Wright, D., & Morris, S. (2012). Noninvasive prenatal testing for 
aneuploidy – ready for prime time?American Journal of Obstetrics and Gynecology, 269-275. 
Christianson A.L., Howson C.P., & Modell B. (2006). March of Dimes Global Report on birth 
defects: the hidden toll of dying and disabled children. March of Dimes Birth Defects 
Foundation, White Plains, New York, USA (Available online at: www.marchofdimes.com). 
Clare Williams, C., Alderson, P., & Farsides, B. (2002). Too many choices? Hospital and 
community staff reflect on the future of prenatal screening. Social Science & Medicine, 55, 743-
753. 
Clarke, A. (1997). The process of genetic counselling.InHarper, P. &Clarke, A. (Eds.), Genetics, 
society andclinical practice (pp. 179–200). Oxford: BIOS ScientificPublishers. 
Cohen, J. (1962). The statistical power of abnormal-social psychological research: A review. 
Journal of Abnormal and Social Psychology, 65, 145-153. 
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: 
Erlbaum. 
Cole, P. (1979). The evolving case-control study. J Chronic Dis, 32, 15-27. 
 108 
Conner, M. & Norman, P. (1994). Comparing the health belief model and the theory of planned 
behaviour in health screening. In D. R. Rutter and L. Quine (Eds), Social Psychology and 
Health: European Perspectives, pp. 1-24. Aldershot: Avebury. 
Conroy, R.M., Teehan, M., Siriwardena, R., Smyth, O., McGee, H.M., & Fernandes, P. (2002). 
Attitudes to doctors and medicine: the effect of setting and doctor-patient relationship. Journal 
of Health Psychology, 7, 117-125. 
Coulter A. (1999). Shared decision-making: a summary and future issues. In: Maslin, A.M., 
Powles, T.J., eds. Breast Cancer: Sharing the decision. Oxford, UK: Oxford University Press. 
Creswell, J. (1998). Qualitative inquiry and research design: Choosing among five traditions. 
Thousand Oaks, CA: Sage. 
Dahl, K., Hvidman, L., Jorgensen, F.S., & Kesmodel, U.S. (2011).Knowledge of prenatal 
screening and psychological management of test decisions.UltrasoundObstetGynecol, 38, 152-
157. 
Daniilidis, A., Karydas, J., Zournatzi, V., Tantanasis, T., Giannoulis, C., & Tzafettas, J. (2008). A 
four-year retrospective study of amniocentesis: one centre experience. Hippokratia, 12(2), 113-
115. 
Davies, B.L. & Doran, T.A. (1982). Factors in a woman’s decision to undergo genetic 
amniocentesis for advanced maternal age. Nursing Research, 31(1), 56-59. 
Davis-Floyd, R.E. (1994). The Technocratic Body: American Childbirth as Cultural Expression. 
Social Science & Medicine. 38(8), 1125-1140. 
Davis-Floyd, R.E. (2001). The Technocratic, Humanistic, and Holistic Paradigms of Childbirth. 
International Journal of Gynecology & Obstetrics, 75, S5-S23. 
Davison, A., Barns, I., & Schibeci, R. (1997). Problematic publics : A critical review of surveysof 
public attitudes towards biotechnology. Science, Technology and Human Values, 22,317 348. 
De Jong, A., Dondorp, W.J., Die-Smulders, C., Frints, S., & de Wert, G. (2010). Non-invasive 
prenatal testing: ethical issues explained. European Journal of Human Genetics, 18, 272-277. 
Devellis, B. M., Blalock, S. J. and Sandler, R. S. (1990), Predicting Participation in Cancer 
Screening: The Role of Perceived Behavioral Control. Journal of Applied Social Psychology, 20, 
639–660. 
Diaz, J., Griffith, R., Reinert, S., Friedmann, P., & Moulton, A. (2002).Patients’ use of the 
internet for medical information.Journal of General Internal Medicine, 17, 180-185. 
 109 
Dixon, A.M. (1994).The need for greater patient awareness inroutine antenatal 
ultrasound.Radiography Today, 60(684), 9–11. 
Dormandy, E., Michie, S., Hooper, R., & Marteau, T.M. (2005). Low uptake of prenatal 
screening for Down Syndrome in minority ethnic groups and socially deprived groups: a 
reflection of women’s attitudes or a failure to facilitate informed choices? International Journal of 
Epidemiology, 34, 346-352. 
Dormandy, E., Michie, S., Hooper, R., & Marteau, T.M. (2006). Informedchoice in antenatal 
Down syndrome screening: a cluster-randomisedtrial of combined versus separate visit testing. 
Patient EducCouns, 61, 56–64. 
Dumit, J., & Davis-Floyd, R. (2000). Children of the third millenium. In R. Davis-Floyd, & J. 
Dumit (Eds.), Cyborg babies (pp. 1–20). New York: Routledge. 
Ehrenreich, B., & English, D. (1978). For her own good: 150 years of experts’ advice to women. 
New York: Anchor Books. 
Elwyn G., Gray J., & Clarke A. (2000). Shared decision-making and non-directiveness in 
genetic counselling. Journal of Medical Genetics, 37, 135-138. 
Elwyn, G., Edwards, A., & Kinnersley, P. (1999).Shared decision-making in primary care: the 
neglected second half of the consultation.British Journal of General Practice, 49, 477-482. 
Elwyn, G., Gray, J., & Clarke, A. (2000).Shared decision-making andnon-directiveness in 
genetic counselling.J Med Genet, 37, 135–138. 
Erdfelder, E., Faul, F., & Buchner, A. (1996). GPOWER: A general power analysis program. 
Behavior research methods, instruments, & computers, 28(1), 1-11. 
Everett, T. R., & Chitty, L. S. (2015). Cell‐free fetal DNA: the new tool in fetal medicine. 
Ultrasound in Obstetrics & Gynecology, 45(5), 499-507. 
Everett, T.R. & Chitty, L.S. (2014).Cell-free fetal DNA: The new tool in 
FetalMedicine.Ultrasound in Obstetrics &Gynecology, in press. 
Eysenbach, G. & Diepgen, T.L. (1998). Towards quality management of medical information on 
the internet: evaluation, labeling, and filtering of information. BMJ, 317 (7171), 1496-1500. 
Eysenbach, G., Powell, J., Kuss, O., & Sa E.U. (2002). Empirical studies assessing the quality 
of health information for consumers on the world wide web. JAMA, 287(20), 2691-2700. 
Fajnzylber, E., Hotz, V.J., & Sanders, S.G. (2010). An economic model of amniocentesis 
choice. Advances in Life Course Research, 15, 11-26. 
 110 
Fang, C.Y., Dunkel-Schetter, C., Tatsugawa, Z.H., Fox, M.A., Bass, H.N., Grody, W.W. (1997). 
Attitudes toward genetic carrier screening for cystic fibrosis among pregnant women: the role of 
Health Beliefs and avoidant coping style. Women’s Health: Research on gender, behavior and 
policy, 3(1), 31-51. 
Farrell, R.M., Agatisa, P.K., Mercer, M.B., Smith, M.B., & Phillipson, E. (2015). Balancing risks: 
the core of women’s decisions about noninvasive prenatal testing. AJOB Empirical Bioethics, 
6(1), 42-53. 
Farrell, R.M., Hawkins, A., Barragan, D., Hudgin s, L., & Taylor, J. (2015). Knowledge, 
understanding, and uptake of non-invasive prenatal testing among Latina women. Prenatal 
Diagnosis, 35(8), 748-753. 
Fasouliotis, S.J., & Schenker, J.G. (2000). Maternal-fetal conflict. European Journal of 
Obstetrics & Gynecology and Reproductive Biology, 89, 101-107. 
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009). Statistical power analyses using 
G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods, 41, 
1149-1160. 
Feise, R. (2002). Do multiple outcome measures require p-value adjustment? BMC Med Res 
Methodol, 2(1).  http://dx.doi.org/10.1186/1471-2288-2-8  
Ferres, M.A., Lichten, L., Sachs, A., Lau, K., &Bianchi, D. (2014).Rate of diagnostic procedures 
foraneuploidy in the post non-invasive DNA testing (NIDT) era.PrenatDiagn, 34(Suppl 1), 53. 
Field, A. (2000). Discovering Statistics using SPSS for Windows. London – Thousand Oaks – 
New Delhi: Sage publications. 
Field, A. (2013). Discovering statistics using IBM SPSS Statistics. London: Sage Publications. 
Firth, D. (1993). Bias reduction of maximum likelihood estimates. Biometrika, 80, 27–38. 
Fisher, W. A. (1984). Predicting contraceptive behaviour among university men: The role of 
emotions and behavioural intentions. Journal of Applied Social Psychology, 14, 104-123. 
Fiske, S.T. & Taylor, S.E. (1984). Social Cognition. Random House: NewYork. 
Fletcher, J., Hicks, N.R., & Boyd, P.A. (1995). Using decision analysis to compare policies for 
antenatal screening for Down’s syndrome. British Medical Journal, 311, 351-356. 
Fox, S. & Duggan, M. (2013). Pew Internet & American Life Project, January 15, 2013. URL 
http://pewinternet.org/Reports/2013/Health-online.aspx  accessed on 21February 25, 2015 
 111 
France, E.F., Wyke, S., Ziebland, S., Entwistle, V.A., & Hunt, K. (2011). How personal 
experiences feature in women’s accounts of use of information for decisions about antenatal 
diagnostic testing for foetal abnormality. Social Science & Medicine, 72, 755-762. 
Fransen, M.P., Wildschut, H.I.J., Vogel, I., Mackenbach, J.P., Steegers, E.A.P., & Essink-Bot, 
M.L. (2009). Ethnic differences in considerations whether or not to participate in prenatal 
screening for Down Syndrome. Prenatal Diagnosis, 29, 1262-1269. 
French, B.N., Kurczynski, T.W., Weaver, M.T., & Pituch, M.J. (1992). Evaluation of the Health 
Belief Model and decision making regarding amniocentesis in women of advanced maternal 
age. Health Education Quarterly, 19(2), 177-186. 
Fuchs KM, Peipert JF. First trimester Down syndrome screening: public health implications. 
Semin Perinatol. 2005;29(4):267-71. 
Fuller, C.A. & Gallagher, R. (1999). Perceived benefits and barriers of prenatal care in low 
income women. Journal of the American Academy of Nurse Practitioners, 11(12), 527-532. 
Furr, L.A. & Seger, R.E. (1998). Psychosocial predictors of interest in prenatal genetic 
screening. Psychological Reports, 82, 235-244. 
Furr, L.A. & Seger, R.E. (1998). Psychosocial predictors of interest in prenatal genetic 
screening. Psychological Reports, 82, 235-244. 
Futch, T., Spinosa, J., Bhatt, S., de Feo, E., Rava, R.P., & Sehnert, A.J. (2013). Initial clinical 
laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma 
DNA samples. Prenatal Diagnosis, 33(6), 569-74. 
Garber K.B., Visootsak J., & Warren S.T. (2008). Fragile X Syndrome. European Journal of 
Human Genetics, 16, 666-672. 
Garcia, E., Timmermans, D.R.M., & van Leeuwen, E. (2008). The impact of ethical beliefs on 
decisions about prenatal screening tests: searching for justification. Social Science & Medicine, 
66, 753-764. 
Garcia, J., Bicker, L., Henderson, J., Martin, M., Mugford, M., Nielson, J., & Roberts, T. (2002). 
Women’s views of pregnancy ultrasound: A systematic review. Birth, 29(4), 225-250. 
Geipel, A., Berg, C., Katalinic. A., Ludwig, M., Germer, U., Diedrich, K., & Gembruch, U. (2003). 
Different preferences for prenatal diagnosis in pregnancies following assisted reproduction 
versus spontaneous conception. Reproductive BioMedicine Online, 8(1), 119-124. 
 112 
General Medical Council (2009). Good Medical Practice. London: General Medical Council. 
Available at: www.gmc-uk.org/Static/documents/content/ GMP_0910.pdf (accessed on 10 July 
2011). 
Georgsson, S., Sahlin, E., Iwarsson, M., Nordenkjold, M., Gustavsson, P., & Iwarsson, E. 
(2016). Knowledge and attitudes regarding non-invasive prenatal testing (NIPT) and 
preferences for risk information among high school students in Sweden. Journal of Genetic 
Counseling, doi: 10.1007/s10897-016-9997-y. 
Gerber, B.S. & Eiser, A.R. (2001).The patient-physician relationship in the internet age: future 
prospects and the research agenda. J Med Internet Res, 3(2), e15. 
Gil, M. M., Akolekar, R., Quezada, M. S., Bregant, B., & Nicolaides, K. H. (2014). Analysis of 
cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. Fetal diagnosis 
and therapy, 35(3), 156-173. 
Gil, M. M., Giunta, G., Macalli, E. A., Poon, L. C., & Nicolaides, K. H. (2015). UK NHS pilot 
study on cell‐free DNA testing in screening for fetal trisomies: factors affecting uptake. 
Ultrasound in Obstetrics & Gynecology, 45(1), 67-73. 
Gil, M.M,, Quezada, M.S., Revello, R., Akolekar, R., & Nicolaides, K. (2015). Analysis of cell-
free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. 
Ultrasound ObstetGynecol, 45, 249-266. 
Gil, M.M., Giunta, G., Macalli, E.A., Poon, L.C., & Nicolaides, K.H. (2015). UK NHS pilot study 
on cell-free DNA testing in screening for fetal trisomies: factors affecting uptake. Ultrasound 
ObstetGynecol, 45, 67-73. 
Gill, V., Lavin, J., & Sim, M. (2010). Managing sickle cell disease. Nursing made incredibly 
easy, 8(6), 24-32. 
Gillick, M.R. (2007). The technological imperative and the battle for the hearts of America. 
Perspectives in Biology and Medicine, 50, 276–294. 
Gottfreðsdóttir, H., Björnsdóttir, K., &Sandall, J. (2009). How do prospective parents who 
decline prenatal screening account for their decision? A qualitative study.Soc.Sci.Med., 69(2), 
274-277. 
Gravetter, F., & Wallnau, L. (2014). Essentials of statistics for the behavioral sciences (8th 
ed.). Belmont, CA: Wadsworth. 
 113 
Green J &Statham, H. (1996).Psychosocial aspects of prenatal screening and diagnosis. In: 
Marteau,T.,Richards, M. (eds). The Troubled Helix: Social and Psychological Implications of the 
New HumanGenetics. New York: Cambridge University Press, 140–163. 
Green, J. & Thorogood, N. (2009). Qualitative methods for health research (2nd ed.). Thousand 
Oaks, CA: Sage. 
Green, J.M., Hewison, J., Bekker, H.L., Bryant, L.D., & Cuckle, H.S. (2004). Psychosocial 
aspects of genetic screening of pregnant women and newborns: a systematic review. Health 
Technol Assess, 8, 1-109. 
Green, J.M., Snowdon, C., & Statham, H. (1993). Pregnant women’s attitudes to abortion and 
prenatal screening. Journal of reproductive and infant psychology, 11(1), 31-39. 
Habing, B. (2003). Exploratory Factor Analysis. Website: 
http://www.stat.sc.edu/~habing/courses/530EFA.pdf   (downloaded 20 November 2013). 
Haga, S.B., Barry, W.T., Mills, R., Ginsburg, G.S., Svetkey, L., Sullivan, J., & Willard, H.F. 
(2013).Public knowledge of and attitudes toward genetics and genetic testing.Genetic testing 
and molecular biomarkers, 17(4), 327-335. 
Hair, J.F. Jr., Anderson, R.E., Tatham, R.L., & Black, W.C. (1998). Multivariate Data Analysis, 
(5
th
 Edition). Upper Saddle River, NJ: Prentice Hall. 
Hallowell, N., Statham, H., Murton, F., Green, J., & Richards, M. (1997). ‘Talking about chance': 
the presentation of risk informationduring genetic counseling for breast and ovarian cancer. J 
Gen Counseling,6, 269-285. 
Harris, R.A., Nease, R.F., & Kuppermann, M. (2004). Cost utility of prenatal diagnosis and the 
risk-based threshold. The Lancet, 363, 276-282.  
Hart, A., Henwood, F., & Wyatt, S. (2004). The role of the internet in patient-practitioner 
relationships: findings from a qualitative research study. J Med Internet Res, 6(3), e36. 
Haslam, C. & Lawrence, W. (2004). Health-related behavior and beliefs of pregnant smokers. 
Health Psychology, 23, 486-491.  
Haslam, C., Lawrence, W. & Haefeli, K. (2003). Intention to breastfeed and other important 
health-related behaviour and beliefs during pregnancy. Family Practice, 20, 1-15. 
Hedrick, J. (2005). The Lived Experience of Pregnancy While Carrying a Child With a Known, 
Nonlethal Congenital Abnormality. Journal of Obstetric, Gynecologic, & Neonatal Nursing, 
34, 732–740. 
 114 
Heinze, G. (2006). A comparative investigation of methods for logistic regression with separated 
or nearly separated data. Statistics in Medicine, 25, 4216-4226. 
Henneman, L., Bramsen, I., van der Ploeg, H.M., Ader, H.J., van der Horst, H.E., Gille, J.J.P., & 
ten Kate, L.P. (2001). Participation in preconceptional carrier couple screening: characteristics, 
attitudes, and knowledge of both partners. J Med Genet, 38, 695-703. 
Henneman, L., Timmermans, D.R.M., & Van derWal, G. (2004).Public experiences,knowledge 
and expectations about medical genetics and the use ofgenetic information. Community Genet, 
7, 33–43. 
Hertling-Schaal E., Perrotin F., De Poncheville L., Lansac J., & Body G. (2001). Maternal 
anxiety related to prenatal screening and invasive testing: detection and management. 
Gynecology Obstetrique & Fertilite, 29(6), 440-446. 
Heyman B., Lewando Hundt G., Sandall J., Spencer K., Williams C., Grellier R., & Pitson L. 
(2006). On being at higher risk: A qualitative study of prenatal screening for chromosomal 
anomalies. Social Science & Medicine, 62, 2360-72. 
Heyman, B., Hundt, G., Sandall, J, Spencer, K., Williams, C., Grellier, R., & Pitson, L. (2006). 
On being at higher risk: A qualitative study of prenatal screening for chromosomal anomalies. 
Social Science and Medicine, 62, 2360-2372. 
Hill, M., Fisher, J., Chitty, L.S., & Morris, S. (2012). Women’s and health professionals’ 
preferences for prenatal tests for Down Syndrome: a discrete choice experiment to contrast 
noinvasive prenatal diagnosis with current invasive tests. Genetics in Medicine, 14(11), 905-
913. 
Hosseini S.M. (2007). Maternal anxiety during pregnancy: its relations to birth outcomes and to 
offspring depression during late childhood and adolescence. Dissertation Abstracts 
International: Section B: The Sciences and Engineering, 68(1-B), 202.  
Howson C.P. & Modell B. (2008). Controlling birth defects: reducing the hidden toll of dying and 
disabled children in low-income countries (Disease Control Priorities Project). Retrieved on 
June 1
st
 2012 from www.dcp2.org  
Huizink, A.C., Mulder, E.J.H., Robles de Medina, P.G.R., & Visser, G.H.A., 2004. Is pregnancy 
anxiety a distinctive syndrome? Early Human Development, 79(2), 81-91. 
Hunt L.M., De Voogd K.B., & Castaneda H. (2005). The routine and the traumatic in prenatal 
genetic diagnosis: does clinical information inform patient decision-making? Patient education 
and counselling, 56, 302-312. 
 115 
Ilgin-Ruhi, H., Yurur-Kutlay, N., Tukun, A., & Bokesoy, I. (2005). The role of genetic counseling 
on decisions of pregnant women aged 35 years or over regarding amniocentesis in Turkey. 
European Journal of Medical Genetics, 48(1), 13-19. 
Jallinoja, P. & Aro, A.R. (2000). Does knowledge make a difference? The association between 
knowledge about genes and attitudes towards gene tests.Journal of Health Communication, 5, 
29-39. 
Jha, P., Kumar, R., Vasa, P., Dhingra, N., Thiruchelvam, D., & Moineddin, R. (2006). Low male-
to-female sex ratio of children born in India: national survey of 1· 1 million households. The 
Lancet, 367(9506), 211-218. 
Johanson, R., Newburn, M., & MacFarlane, A. (2002). Has the Medicalisation of Childbirth 
Gone Too Far? BMJ: British Medical Journal. 324(7342), 892-895. 
Jonsdottir, O.V. (2012). Medicalisation of Childbirth in Western Society: Can Women Resist the 
Medicalisation of Childbirth?  
Kaiser, A.S., Ferris, L.E., Katz, R., Pastuszak, A., Llewellyn-Thomas, H., Johnson, J.A., & 
Shaw, B.F. (2004). Psychological responses to prenatal NTS counseling and the uptake of 
invasive testing in women of advanced maternal age. Patient Education and Counseling, 54, 
45-53. 
Kaiser, H. F. (1960). The application of electronic computers to factor analysis. Educational 
andPsychological Measurement, 20, 141-151. 
Kaposy, C. (2013). A disability critique of the new prenatal test for Down Syndrome. Kennedy 
Institute of Ethics Journal, 23, 299-324. 
Karasahin, E., Gezginc, K., & Alanbay, I. (2008). Expectation versus reality: A device to 
illustrate anticipated and perceived pain from amniocentesis. International Journal of 
Gynecology and Obstetrics, 101, 295-303. 
Karasahin, E., Gungor, S., Goktolga, U., Keskin, U., Gesginc, K., & Baser, I. (2008). Anticipated 
and perceived pain from mid-trimester amniocentesis. International Journal of Gynecology and 
Obstetrics, 101, 290-294. 
Kelly, S.E. &Farrimond, H.R. (2012) Non-invasive prenatal genetic testing: A study of public 
attitudes.Public Health Genomics, 15 (2), 73-81. 
Kenen, R., Smith, A.C.M., Watkins, C., & Zuber-Pittore, C. (2000). To use or not to use: male 
partners’ perspectives on decision making about prenatal diagnosis. Journal of Genetic 
Counseling, 9(1), 33-45. 
 116 
Kenen, R.H. & Smith, A.C.M. (1995). Genetic counseling for the next 25 years:models for the 
future, Journal of Genetic Counseling, 4(2), 115–124. 
Kennerknecht, I., Baur-Aubele, S., Grab, D., & Terinde, R. (1992). First trimester amniocentesis 
between the seventh and thirteenth weeks: evaluation of the earliest possible genetic diagnosis. 
Prenatal Diagnosis, 12(7), 595-601. 
Kessler, S. (1997). Psychological aspects of genetic counseling: nondirectivenessrevisited. Am 
J Med Genet, 72, 164–171. 
King, G., & Zeng, L. (2001). Logistic regression in rare events data. Political analysis, 9(2), 137-
163. 
King, J.S. (2012). And genetic testing for all…The coming revolution in non-invasive prenatal 
genetic testing.Rutgers Law Journal, 42, 599-658. 
Kirkham, C., Harris, S., & Grzybowski, S. (2005). Evidence-based prenatal care: Part I. General 
prenatal care and counselling issues. American Family Physician, 71(7), 1307-1316. 
Knight, G.J., Palomaki, G.E., Neveux, L.M., Smith, D.E., Kloza, E.M., Pulkkinen, A.J., Williams, 
J., & Haddow, J.E. (2005). Integrated serum screening for Down Syndrome in primary obstetric 
practice. Prenatal Diagnosis, 25(12), 1162-1167. 
Kowalcek, I., Muhlhoff, A., Bachmann, S., Gembruch, U. (2002). Depressivereactions and 
stress related to prenatal medicine procedures.UltrasoundObstetGynecol, 19, 18–23. 
Kupperman, M., Feeny, D., Gates, E., Posner, S.F., Blumberg, B., & Washington, A.E. (1999). 
Preferences of women facing a prenatal diagnostic choice: long-term outcomes matter most. 
Prenatal Diagnosis, 19, 711-716. 
Labs, S.M., & Wurtele, S. K. (1986). Fetal Health Locus of Control Scale: Development and 
validation. Journal of Consulting and Clinical Psychology, 54, 814-819. 
Labs, S.M., & Wurtele, S. K. (1986). Fetal Health Locus of Control Scale: Development and 
validation. Journal of Consulting and Clinical Psychology, 54, 814-819. 
Lagan, B.M., Sinclair, M., & Kernohan, W.G. (2010). Internet use in pregnancy informs women’s 
decision making: a web-based survey. Birth, 37(2), 106-115. 
Lakovschek, I. C., Streubel, B., & Ulm, B. (2011), Natural outcome of trisomy 13, trisomy 18, 
and triploidy after prenatal diagnosis. Am. J. Med. Genet., 155, 2626–2633. 
 117 
Lalor, J.G. &Devane, D. (2007). Information, knowledge and expectations of the 
routineultrasound scan. Midwifery, 23, 13-22. 
Larion, S., Warsof, S.L., Romary, L., Mlynarczyk, M., Peleg, D., & Abuhamad, A.Z. 
(2014).Uptake of noninvasive prenatal testing at a large academic referral center.Am J 
ObstetGynecol, 211(6), 651-658. 
Lee, A.M., Lam, S.K., Lau, S.M.S.M., Chong, C.S.Y., & Fong, D.Y.T. (2007). Prevalence, 
course, and risk factors for antenatal anxiety and depression. Obstet Gynecol, 110, 1102-1112. 
Legare, F., St-Jacques, S., Gagnon, S., Njoya, M., Brisson, M., Fremont, P., Rousseau, F. 
(2011). Prenatal screening for Down Syndrome: a survey of willingness in women and family 
physicians to engage in shared decision-making. Prenatal Diagnosis, 31, 319-326. 
Lesser, Y. & Rabinowitz, J. (2001). Elective amniocentesis in low-risk pregnancies: Decision 
making in the era of information and uncertainty. American Journal of Public Health, 91 (4), 
639-641. 
Lewis, C., Choudhury, M., & Chitty, L.S. (2014). ‘Hope for safe prenatal gene tests’. A content 
analysis of how UK press media are reporting advances in non-invasive prenatal testing. 
Prenatal Diagnosis, 34, 1-8. 
Lewis, C., Cullinane, F.N., Bishop, A.J., Chitty, L.S., Marteau, T.M.,& Halliday, J.L. (2006).A 
comparison of Australian and UKobstetricians’ and midwives’ preferences for screening tests 
for Down syndrome. Prenat Diagn, 26, 60–66. 
Lewis, C., Hill, M., & Chitty, L.S. (2016). A qualitative study looking at informed choice in the 
context of non-invasive prenatal testing for aneuploidy. Prenatal Diagnosis, 36(9), 875-881. 
Lewis, C., Hill, M., & Chitty, L.S. (2016). Women’s experiences and preferences for service 
delivery of NIPT for aneuploidy in a public health setting: A mixed methods study. PLOS One, 
11(4), http://doi.org/10.1371/journal.pone.0153147  
Lewis, C., Hill, M., Silcock, C., Daley, R., & Chitty, L.S. (2014). Non-invasive prenatal testing for 
trisomy 21: a cross-sectional survey of service users’ views and likely uptake. BJOG: An 
International Journal of Obstetrics and Gynaecology, 121, 582-594. 
Lewis, C., Silcock, C., & Chitty, L.S. (2013).  Non-Invasive Prenatal Testing for Down's 
Syndrome: Pregnant Women's Views and Likely Uptake. Public Health Genomics, 16, 223-232. 
Lippman, A. (1999). Embodied knowledge and making sense of prenatal diagnosis. Journal of 
Genetic Counseling, 8(5), 255-274. 
 118 
Lo, Y.M., Corbetta, N., Chamberlain, P.F., Rai, V.,Sargent, I.L., Redman, C.W.,& Wainscoat, 
J.S. (1997). Presence of fetal DNA in maternal plasma and serum. Lancet, 350, 485–487. 
Locock, L. & Alexander, J. (2006).’Just a bystander’?Men’s place in the process offetal 
screening and diagnosis.SocSci Med, 62, 1349–59. 
Locock, L., Field, K., McPherson, A., & Boyd, P. (2008). Women’s accounts of the physical 
sensation of chorionic villus sampling and amniocentesis: expectations and experience. 
Midwifery, doi: 10.1016/j.midw.2008.02.002 
Lou, S., Mikkelsen, L., Hvidman, L., Petersen, O.B., & Nielsen, C.P. (2015). Does screening for 
Down’s syndrome cause anxiety in pregnant women? A systematic review. Acta Obstet 
Gynecol Scand, 94, 15–27. 
Lowe, P., Powell, J., Griffiths, F., Thorogood, M., &Locock, L. (in press).“Making it all normal”: 
The role of the internet in problematic pregnancy. UNPUBLISHED 
Lumley, M.A., Zamerowski, S.T., Jackson, L., Dukes, K., & Sullivan, L. (2006). Psychosocial 
correlates of pregnant women’s attitudes toward prenatal maternal serum screening and 
invasive diagnostic testing; beyond traditional risk status. Genetic Testing, 10(2), 131-138. 
Lutgendorf, M.A., Stoll, K.A., Kmutzen, D.M., & Foglia, L.M. (2014). Non-invasive prenatal 
testing limitations and unanswered questions. Genetics in Medicine, 16(4), 281-285. 
Markens, S., Browner, C.H., & Mabel, P. (2010). Interrogating the dynamics between power, 
knowledge, and pregnant bodies in amniocentesis decision making. Sociology of Health & 
Illness, 32(1), 37-56. 
Markens, S., Browner, C.H., & Preloran, H.M. (2003). “I’m not the one they’re sticking the 
needle into”: Latino couples, fetal diagnosis, and the discourse reproductive rights. Gender & 
Society, 17, 462-481. 
Markens, S., Browner, C.H., & Press, N. (1999). ‘Because of the risks’: how US pregnant 
women account for refusing prenatal screening. Social Science and Medicine, 49, 359-369. 
Marteau, T.M. (1990). Attitudes to doctors and medicine: the preliminary development of a new 
scale. Psychology and Health, 4, 351-356. 
Marteau, T.M., Dormandy, E., & Michie, S. (2001). A measure of informed choice. Health 
Expectations, 4, 99-108. 
Marteau, T.M., Johnston, M., Kidd, J., Michie S., & Cook, R. (1992). Psychological models in 
predicting uptake of prenatal screening. Psychology and Health, 6, 13-22. 
 119 
 
Marteau, T.M., Johnston, M., Plenicar, M., Shaw, R.W., & Slack, J. (1988). Development of a 
self-administered questionnaire to measure women’s knowledge of prenatal screening and 
diagnostic tests. Journal of Psychosomatic Research, 32 (4/5), 403-408. 
Marteau, T.M., Johnston, M., Shaw, R.W., Michie, S., Kidd, J., & New, M. (1989). The impact of 
prenatal screening and diagnostic testing upon the cognitions, emotions and behaviour of 
pregnant women. Journal of Psychosomatic Research, 33(1), 7-16. 
Marteau, T.M., Kidd, J., Cook, R., Michie, S., Johnston, M., & Slack, J. (1991). Perceived risk 
not actual risk predicts uptake of amniocentesis. British Journal of Obstetrics and Gynecology, 
98, 282-286. 
Marteau, T.M., Kidd, J., Cook, R., Michie, S., Johnston, M., Slack, J., & Shaw, W. (1992). 
Psychological effects of having amniocentesis: are these due to the procedure, the risk or the 
behavior? Journal of psychosomatic research, 36 (4), 395-402. 
Marteau, T.M., Kidd, J., Cook, R., Michie, S., Johnston, M., Slack, J. & Shaw, R. W. (1991), 
Perceived risk not actual risk predicts uptake of amniocentesis. BJOG: An International Journal 
of Obstetrics & Gynaecology, 98, 282–286.  
Marteau, T.M., Saidi, G., Goodburn, S., Lawton, J., Michie, S., & Bobrow, M. (2000). Numbers 
or words?A randomised control trial of presenting screen negative results to pregnant 
women.Prenatal Diagnosis, 20, 714-718. 
McCoyd, J.L.M. (2010). Authoritative knowledge, the technological imperative and women’s 
resposes to prenatal diagnostic technologies. Cult Med Psychiatry, 34, 590-614. 
McMullan, M. (2006). Patients using the internet to obtain health information: How this affects 
the patient-health professional relationship. Patient Education and Counseling, 63, 24-28. 
Menezes, M., Meagher, S., & Da Silva Costa, F. (2013). Ethical considerations when offering 
non-invasive prenatal testing. Rev Bras Gynecol Obstet. 35(5),195-198. 
Mercer, C.H., Tanton, C., Prah, P., Erens, B., Sonnenberg, P., Clifton, S., Macdowall, W., 
Lewis, R., Field, N., Datta, J., Copas, A.J., Phelps, A., Wellings, K., & Johnson, A.M. (2013). 
Changes in sexual attitudes and lifestyles in Britain through the life course and over time: 
findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet, 382, 
1781-1794. 
 120 
Mercer, M.B., Agatisa, P.K., & Farrell, R.M. (2014). What patients are reading about 
noninvasive prenatal testing: an evaluation of internet content and implications for patient-
centered care.Prenatal Diagnosis, 34, 986-993. 
Michie, S., Bron, F., Bobrow, M., & Marteau, T.M. (1997).Nondirectivenessin genetic 
counseling: an empiricalstudy. Am J Hum Genet, 60,40–47. 
Michie, S., Dormandy, E., French, D.P.,& Marteau, T.M. (2004). Using thetheory of planned 
behaviour to predict screening uptake in twocontexts.Psychol Health, 19, 705–718. 
Michie, S., Dormandy, E., Marteau, T. M. (2002). The multi-dimensional measure of informed 
choice: a validation study. Patient Education and Counseling, 48, 87-91. 
Michie, S., Drake, H., Bobrow, M., & Marteau, T. (1995).A comparison of public and 
professionals’ attitudes towards genetic developments.Public Understanding of Science, 4,243 
253. 
Milic., B., Babic, I., Ristic, S., Vranekovic, J., Brumini, G., & Kapovic, M. (2008). Pregnant 
women’s attitudes toward amniocentesis before receiving Down Syndrome screening results. 
Women’s Health Issues, 18, 79-84. 
Mischler E. (1984). The discourse of medicine: dialectics of medical interviews. Norwood, NJ: 
Ablex Publishing Corporation. 
Mishler, E. (1984).The discourse of medicine: dialectics of medical interviews.Norwood, NJ: 
Ablex Publishing Corporation. 
Morahan-Martin, J.M. (2004). How internet users find, evaluate and use online health 
information: a cross-cultural review. Cyberpsychology& Behavior, 7(5), 497-510. 
Morren, M., Rijken, M., Baanders, A.N., & Bensing, J. (2007). Perceived genetic knowledge, 
attitudes towards genetic testing, and the relationship between these among patients with a 
chronic disease.Patient Education and Counselling, 65, 197-204. 
Morris, S., Karlsen, S., Chung, N., Hill, M., & Chitty, L.S. (2014). Model-based analysis of costs 
and outcomes of non-invasive prenatal testing for Down’s syndrome using cell free fetal DNA in 
the UK National Health Service. PloSone, 9(4), e93559. 
Moumjid, N., Gafni, A., Bremond, A., & Carrere, M.O. (2007). Decision making in the medical 
encounter: Are we all talking about the same thing? Medical Decision Making, 27, 539-548. 
 121 
Moyer, A., Brown, B., Gates, E., Daniels, M., Brown, H.D., & Kuppermann, M. (1999). Decisions 
about prenatal testing for chromosomal disorders: perceptions of a diverse group of pregnant 
women. Journal of Women’s Health & Gender-based Medicine, 8(4), 521-531. 
Mueller, V.M., Huang, T., Summers, A.M., & Winsor, H.M. (2005). The influence of risk 
estimates obtained from maternal serum screening on amniocentesis rates. Prenatal Diagnosis, 
25, 1253-1257. 
Murdoch, B., Ravitsky, V., Ogbogu, U., Ali-Khan, S., Bertier, G., Birko, S., Bubela, T., De Beer, 
J., Dupras, C., Ellis, M., Moreno, P.G., Joly, Y., Kamenova, K., Master, Z., Marcon, A., Paulden, 
M., Rousseau, F., & Caulfield, T. (2016). Non-invasive prenatal testing and the unveiling of an 
impaired translation process. JOCG, http://dx.doi.org/10.1016/j.jogc.2016.09.004  
Murray, E., Lo, B., Pollack, L., Donelan, K., Catania, J., Zapert, L.K., & Turner, R. (2003). The 
impact of health information on the internet on health care and the physician-patient 
relationship: National US Survey among 1.050 US Physicians. J Med Internet Res, 5(3), e17. 
National Institute for Health and Clinical Excellence [NICE] (2008).NICE clinical guideline 62. 
Antenatal care: Routine care for the healthy pregnant woman. 
National Screening Committee (NSC, 2015). Screening tests for you and your baby. Available 
at http://www.screening.nhs.uk/annbpublications  
NCHPEG (2012). Non-invasive prenatal testing (NIPT) factsheet. Retrieved December 1, 2016 
from http://www.nchpeg.org/index.php?option=com_content&view=article&id=384&Itemid=255.  
Ng, C.C.M., Lai, F.M., Yeo, G.S.H. (2004).Assessment of maternal anxiety levels beforeand 
after amniocentesis. Singapore Med J, 45(8), 370–4. 
NHS FASP (2010). Fetal Anomaly Screening Programme. 
NICE (2008). Antenatal Care: Routine care for the healthy pregnant woman. NICE Clinical 
Guidelines, No.62. National Collaborating Centre for Women’s and Children’s Health (UK). 
London: RCOG Press. 
Nicolaides, K.H. (2004).  Nuchal translucency and other first-trimester sonographic markers of 
chromosomal abnormalities. Am J Obstet Gynecol, 191, 45-67. 
Nicolaides, K.H. (2011). Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn, 31, 
7–15. 
Nicolaides, K.H., Chervenak, F.A., McCullough, L.B., Avgidou, K., & Papageorghiou, A. (2005). 
Evidence-based obstetric ethics and informed decision-making by pregnant women about 
 122 
invasive diagnosis after first-trimester assessment of risk for trisomy 21. American Journal of 
Obstetrics and Gynecology, 193, 322-326. 
Nicolaides, K.H., Syngelaki, A., Ashoor, G., Birdir, C., & Touzet, G. (2012). Non-invasive 
prenatal testing for feta ltrisomies in a routinely screened first-trimester population. Am J Obstet 
Gynecol, 207, 374-380. 
Nicolaides, K.H., Syngelaki, A., Gil, M., Atanasova, V.,& Markova D. (2013).Validation of 
targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of 
aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn, 33, 575–579. 
Nicolaides, K.H., Syngelaki, A., Poon, L.C., Gil, M.M.,& Wright, D. (2014).First-trimester 
contingent screening for trisomies 21, 18 and 13by biomarkers and maternal blood cell-free 
DNA testing.FetalDiagnTher, 35, 185–192. 
Norton, M.E., Brar, H., & Weiss, J. (2012). “Non-Invasive Chromosomal Evaluation (NICE) 
study: results of a multicentre prospective cohort study for detection of fetal trisomy 21 and 
trisomy 18,” American Journal of Obstetrics & Gynecology, vol. 207, no. 2, pp. 137.e1–137.e8. 
Norton, M.E., Brar, H.,& Weiss, J. (2012).Noninvasivechromosomal evaluation (NIE) 
study:results of a multicenter prospective cohortstudy for detection of fetal trisomy 21 and 
trisomy18. Am J ObstetGynecol, 207, 137-145. 
Norwitz, E.R. & Levy, B. (2013). Non-invasive prenatal testing: the future is now. Reviews in 
Obstetrics & Gynecology, 6(2), 48-62. 
NSC – National Screening Committee (2015). Screening tests for you and your baby. Available 
at www.screening.nhs.uk  
O’Connor, A. M., Bennett, C. L., Stacey, D., Barry, M., Col, N. F., &Eden, K. B.,(2009). Decision 
aids for people facing health treatment or screening decisions.Cochrane Database Systematic 
Reviews, (3), CD001431. 
O’Connor, A.M. & O’Brien-Pallas, L.L. (1989). Decisional conflict. In: McFarlane, G.K. & 
McFarlane, E.A. (eds), Nursing Diagnosis and Intervention. Toronto: Mosby, pp.486-496. 
O’Connor, A.M., Bennett, C.L., Stacey, D., Barry, M., Col, N.F., Eden, K.B., Entwistle, V.A., 
Fiset, V., Holmes-Rovner, M., Khangura, S., Llewellyn-Thomas, H., & Rovner, D. (2009). 
Decision aids for people facing health treatment or screening decisions (Review). Cochrane 
Database of Systematic Reviews, Issue 3. Art, No: CD001431. DOI: 
10.1002/14651858.cd001431.pub2. 
Oakley, A. (1984). The captured womb. Oxford: Blackwell. 
 123 
Office for National Statistics (2013). Detailed characteristics for England and Wales, 2011. 
Available at: http://www.ons.gov.uk/ons/dcp171778_310514.pdf  
Office for National Statistics (2013). Live births in England and Wales by characteristics of 
Mother 1, 2013. Available at: http://www.ons.gov.uk/ons/rel/vsob1/characteristics-of-Mother-1--
england-and-wales/2013/stb-characteristics-of-mother-1--2013.html  
Ohman, S.G., Saltvedt, S., Grunewald, C., & Waldenstrom, U. (2004). Does fetal screening 
affect women’s worries about the health of their baby? Acta Obstet Gynecol Scand, 83, 634-
640. 
Ohman, S.G., Saltvedt, S., Waldenstrom, U., Grunewald, C., & Olin-Lauritzen, S. (2006). 
Pregnant women’s responses to information about an increased risk of carrying a baby with 
Down Syndrome. 
Palomaki, G.E., Deciu, C., Kloza, E.M., Lambert-Messerlian, G.M., Haddow, J.E., Neveux, L.M., 
Ehrich, M., van den Boom D., Bombard, A.T., Grody, W.W., Nelson, S.F., & Canick, J.A.(2012). 
DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as 
Down syndrome: an international collaborative study. Genet Med, 14, 296–305. 
Palomaki, G.E. (2011). Prenatal identification of trisomy 18 (Edwards syndrome). Retrieved 
09/01/2012 from http://qmro.qmul.ac.uk/jspui/handle/123456789/1317 
Panomai, N., Sanchaisuriya, K., Yamsri, S., Sanchaisuriya, P., Fucharoen, G., Fucharoen, S., & 
Schelp, F.P. (2010). Thalassemia and iron deficiency in a group of northeast Thai school 
children: relationship to the occurrence of anemia. European Journal of Pediatrics, 169(11), 
1317-1322. 
Pearson, K. (1901). On lines and planes of closest fit to systems of points in space. 
Philosophical Magazine 2, 559-572. 
People Science & Policy. Choosing the Future: Genetics and Reproductive Decision-Making 
Analysis of responses to the consultation Final report prepared for The Human Genetics 
Commission, May, 2005. 
Perneger, T.V. (1998). What’s wrong with Bonferroni adjustments. BMJ, 316, 1236-1238. 
Pesso R., Berkenstadt M., Cuckle H., Gak E., Peleg L., Frydman M., & Barkai G. (2000). 
Screening for fragile X syndrome in women of reproductive age. Prenatal Diagnosis, 20, 611-
614. 
Phipps, S. & Zinn, A.B. (1986). Psychological response to amniocentesis: II. Moodstate and 
adaptation to pregnancy [abstract]. Am J Med Genet, 25(1),131–42. 
 124 
Pighin, S., Bonnefon, J.F., & Savadori, L. (2011). Overcoming number numbness in prenatal 
risk communication. Prenatal Diagnosis, 31, 809-813. 
Pitukkijronnakorn, S., Promsonti, P., Panburana, P., Rangsiprakarn, R., & Chittacharoen, A. 
(2008). Prenatal Ultrasonographic Findings in “Trisomy 13”. Journal of the Medical Association 
of Thailand, 91(11), 1651-1655. 
Posner, S.F., Learman, L.A., Gates, E.A, Washington, A.E., & Kuppermann, M. (2004). 
Development of an attitudes measure for prenatal screening in diverse populations. Social 
Indicators Research, 65, 187-206. 
Powell, J.A., Lowe, P., Griffiths, F.E., & Thorogood, M. (2005).A critical analysis of the literature 
on the internet and consumer health information.Journal of telemedicine and telecare, 11(suppl 
1), 41-43. 
Prajapati, B., Dunne, M., & Armstrong, R. (2010). Sample size estimation and statistical power 
analyses. Optometry Today, 16(07), 10-18. 
Preece, M.A. & Green, A. (2002). Pregnancy and inherited metabolic disorders: maternal and 
fetal complications. Annals of Clinical Biochemistry, 39(5), 444-455. 
Press, N. & Browner, C.H. (1997). Why women say yes to prenatal diagnosis. Social Science & 
Medicine, 45(7), 979-989. 
Quine, L. & Rubin, R. (1997). Attitude, subjective norm and perceived behavioural control as 
predictors of women’s intentions to take hormone replacement therapy. British Journal of Health 
Psychology, 2, 199-216. 
Rado, S.N., Kosec, V., & Gall, V. (2013).The psychological effects of prenatal diagnostic 
procedures: maternal anxiety before and after invasive andnon-invasive procedures. Prenatal 
Diagnosis, 33, 1194-1200. 
Rao, M. (1997). An exploration of the predictability of drinking behavior of pregnant women 
using selected dimensions of the health belief model and the fetal health Locus of Control scale. 
Dissertation Abstracts International: Section B: The Sciences and Engineering, 57, 7218.  
Rapp, R. (1999). Testing women, testing the fetus. New York: Routledge. 
Ravitsky V. Non-invasive prenatal diagnosis: an ethical imperative. Nat Rev Genet 2009; 
10:733–733. 
Raymond F.L., Whittaker J., Jenkins L., Lench N., & Chitty L.S. (2010). Molecular prenatal 
diagnosis: the impact of modern technologies. Prenatal Diagnosis, 30, 674-681. 
 125 
RCOG (2014). Non-invasive prenatal testing for chromosomal abnormality using maternal 
plasma DNA. Scientific Impact Paper, No15. 
Rees, D.C., Williams, T.N., & Gladwin, M.T. (2010). Sickle-cell disease. Lancet, 376, 2018-
2031. 
Reis F.M., D’Antona D. & Petraglia F. (2002). Predictive Value of Hormone Measurements in 
Maternal and Fetal Complications of Pregnancy. Endocrine Reviews, 23(2), 230–257. 
Remennick, L. (2006). The quest for the perfect baby: why do Israeli women seek prenatal 
genetic testing? Sociology of Health & Illness, 28(1), 21-53. 
Rempel, G.R., Gender, L.M., Lynam, M.J., Sandor, G.G., &Farquharson, D. (2004).Parents’ 
perspectives on decision making after antenatal diagnosis of congenital heart disease.JOGNN, 
33(1), 64-70.  
Ressler, I.B., Bessett, D., Sroga, J.M., Rompola, S., Ferrari, R.M., Thomas, M.A., & Lindheim, 
S.R. (2014). The road to fatherhood using assisted reproduction technology: decision making 
processes and experiences among gay male intended parents and gestational surrogates. 
GynecolObstet Res Open J, 1(1), 12-17. 
Roelofsen, E.E.C., Kamerbeek, L.I., Tymstra, T., Beekhuis, J.R., & Mantingh, A. 
(1993).Women’s opinions on the offer and use of maternal serum screening, Prenatal 
Diagnosis, 13, 741–747. 
Rosen, T. & D’Alton, M.E. (2005). Down syndrome screening in the first and second trimester: 
what do the data show? Semin Perinatol, 29(6), 367-275. 
Rothman, K.J. (1990). No adjustments are needed for multiple comparisons. Epidemiology, 1, 
43-46. 
Rowley, P.T., Loader, S., Sutera, C.J., Walden, M., & Kozyra, A. (1991). Prenatal screening for 
hemoglobinopathies. III. Applicability of the Health Belief Model. American Journal of Human 
Genetics, 48, 452-459. 
Royal College of Obstetricians and Gynaecologists (2005). Amniocentesis and Chorionic Villus 
Sampling. London: RCOG. 
Royal College of Obstetricians and Gynaecologists (2010). Termination of pregnancy for fetal 
abnormality in England, Scotland, and Wales. Report of a working party. London: RCOG. 
 126 
Ruhi, H., Kutlay, N., Tukun, A., & Bokesoy, I. (2005). The role of genetic counseling on 
decisions of pregnant women aged 35 years or over regarding amniocentesis in Turkey. 
European Journal of Medical Genetics, 48, 13-19. 
Ruxton, G. (2006). The unequal variance t-test is an underused alternative to Student's t-test 
and the Mann-Whitney U test. Behavioral Ecology, 17(4), 688-690. 
http://dx.doi.org/10.1093/beheco/ark016 
 
Sagi, M., Shiloh, S., & Cohen, T. (1992). Application of the Health Belief Model in a study on 
parents’ intentions to utilize prenatal diagnosis of cleft lip and/or palate. American Journal of 
Medical Genetics, 44, 326-333. 
Sahlin, E., Nordenskjold, M., Gustavsson, P., Wincent, J., Georgsson, S., & Iwarsson, E. 
(2016). Positiv e attitiudes towards non-invasive prenatal testing (NIPT) in a Swedish cohort of 
1,003 pregnant women. PLoS One, 11(5). http://dx.doi.org/10.1371/journal.pone.0156088  
Saisto. T., Salmela-Aro, K., Nurmi, J.E., Kononen, T., & Halmesmaki, E. (2001). A randomized 
controlled trial of intervention in fear of childbirth. Obstetrics and Gynecology, 98(5), 820-826. 
Santalahti, P., Aro, A.R., Hemminki, E., Helenius, H., & Ryynanen, M. (1998). On what grounds 
do women participate in prenatal screening? Prenatal Diagnosis, 18, 153-165. 
Santalahti, P., Hemminki, E., Latikka, A.M., & Ryynanen, M. (1997). Women’s decision making 
in prenatal screening. Social Science and Medicine, 46 (8), 1067-1076. 
Sapp J.C., Hull S.C., Duffer S., Zornetzer S., Sutton E., Marteau T.M., & Biesecker B.B. (2010). 
Ambivalence toward undergoing invasive prenatal testing: an exploration of its origins. Prenatal 
Diagnosis, 30, 77-82. 
Saucier, J.B., Johnston, D., Wicklund, C.A., Robbins-Furman, P., Hecht, J.T., & Monga, M. 
(2005). Racial-ethnic differences in genetic amniocentesis uptake. Journal of Genetic 
Counseling, 14(3), 189-195. 
Sayres, L.C., & Cho, M.K. (2011).Cell-free fetal nucleic acid testing: a review of the 
technologyand its applications.Obstet Gynecol Surv, 66(7), 431-442. 
Schmitz, D., Henn, W.,&Netzer, C.(2009). No risk, no objections? Ethical pitfalls of cell-free fetal 
DNA and RNA testing.BMJ, 339 165. 
Schuchter K., Hafner E., Stangl G., Metzenbauer M., Hofinger D., & Philipp K. (2002). The first 
trimester ‘combined test’ for the detection of Down syndrome pregnancies in 4939 unselected 
pregnancies. Prenatal Diagnosis, 22(3), 211-215. 
 127 
Sedlmeier, P., & Gigerenzer, G. (1989). Do studies of statistical power have an effect on the 
power of studies?. Psychological bulletin, 105(2), 309. 
Sermon, K., Van Steirteghem, A., & Liebaers, I. (2004). Preimplantation genetic diagnosis. The 
Lancet, 363(9421), 1633-1641. 
Sewry C.A. (2010). Muscular dystrophies: an update on pathology and diagnosis. Acta 
Neuropathologica, 120, 343-358. 
Shavlev, D. (2003).The Gap between Positive and Negative Pregnancy Experiencesamong 
Young Israeli Mothers. An unpublished MA thesis.BarIlanUniversity,Department of Sociology 
and Anthropology. 
Sheih, C., Broome, M. E., & Stump, T. (2010). Factors associated with health information-
seeking in low-income pregnant women. Women & Health, 5,426-442.  
Sheridan, S.L., Harris, R.P., Woolf, S.H. (2004). Shared decision-making about screening and 
chemoprevention: a suggested approach from the U.S. Preventive Services Task Force. Am J 
Prev Med, 26, 56–66. 
Sherman S., Pletcher B.A., & Driscoll D.A. (2005). Fragile X syndrome: diagnostic and carrier 
testing. Genetics in Medicine, 7(8), 584-587. 
Sherod C., Sebire N.J., Soares W., Snijders R.J.M., Nicolaides K.H. (1997). Prenatal diagnosis 
of trisomy 18 at the 10-14 week ultrasound scan, Ultrasound in Obstetrics and Gynecology (10), 
387-390. 
Shiloh, S. (1996).Decision making in the context of genetic risk. InThe Troubled Helix: Social 
and Psychological Implications of theNew Human Genetics., Marteau, T.M., Richards, M. (eds). 
CambridgeUniversity Press: Cambridge; 82–103. 
Shiloh, S. (2006). Genetic Counseling: Psychological Models in research and practice. 
Encyclopedia of Life Sciences, doi: 10.1002/9780470015902.a0005624  
Siegrist, M., Cousin, M.E., & Keller, C. (2008). Risk communication, prenatal screening, and 
prenatal diagnosis: the illusion of informed decision-making. Journal of Risk Research, 11(1-2), 
87-97. 
Singer, E. (1991).Public attitudes toward genetic testing.Popul Res Policy Rev, 10(3), 235-255. 
Sjogren, B. &Uddenber, N. (1988). Attitudes towards disabled persons and the possible effects 
of prenatal diagnosis: An interview study among 53 women participating in prenatal diagnosis 
and 20 of their husbands. J PsychosomatObstetGynaecol, 6, 187–196. 
 128 
Skirton, H. & Jackson, L. (2015). Factors affecting the clinical use of Non-invasive prenatal 
testing. Journal of Clinical Diagnosis and Research, 3(1), 121-122. 
Smetana, J.G. (1979). Beliefs about the permissibility of abortion and their relationship to 
decisions regarding abortion. Journal of population, 2(4), 294-305. 
Sommerhalder, K., Abraham, A., Zufferey, M.C., Barth, J., & Abel, T. (2009). Internet 
information and medical consultations: experiences from patients’ and physicians’ perspectives. 
Patient Education and Counseling, 77, 266-271. 
Song, K., Musci, T.J., & Caughey, A.B. (2013). Clinical utility and cost of non-invasive prenatal 
testing with cfDNA analysis in high-risk women based on a US population. The Journal of 
Maternal-Fetal & Neonatal Medicine, 26(12), 1180-1185. 
Sparbel K.J.H. & Williams J.K. (2009). Pregnancy as foreground in Cystic Fibrosis carrier 
testing decisions in primary care. Genetic Testing and Molecular Biomarkers, 13(1), 133-142. 
Sparks, A.B., Struble, C.A., Wang, E.T., Song, K., and Oliphant, A. (2012).  “Noninvasive 
prenatal detection and selective analysis of cellfreeDNA obtained frommaternal blood: 
evaluation for trisomy 21 and trisomy 18,” American Journal ofObstetrics&Gynecology, vol. 206, 
no. 4, pp. 319.e1–319.e9. 
Spencer K., Charas O., Skentou H., Liao A.W., & Nicolaides K.H. (2000). Screening for trisomy 
13 by fetal nuchal translucency and maternal serum free b-cHG and PAPP-A at 10-14 weeks of 
gestation, Prenatal Diagnosis (20), 411-416. 
Spies S., Schipper K., Nollet F., & Abma T.A. (2010). A patient’s journey: Duchenne muscular 
dystrophy. British Medical Journal, 341, 1101-1103. 
Srinivasan, A., Bianchi, D.W., Huang, H., Sehnert, A.J., &Rava, R.P. (2013).Non-invasive 
detection of fetal sub-chromosome abnormalities via deep sequencing of maternal plasma.Am J 
Hum Genet, 92, 167–176. 
Statham, H., Green, J., & Katesios, K. (1997). Who worries that something might be wrong with 
the baby? A prospective study of 1072 women. Birth, 24.  
Steinberg, M.H. (2011). Sickle Cell Disease. Annals of Internal Medicine, 155(5), ITC3-1 (15 
pages). 
Steptoe, A., & Wardle, J. (2001). Health behaviour, risk awareness and emotional wellbeing in 
students from Eastern Europe and Western Europe. Social Science and Medicine, 53, 1621-
1630. 
 129 
Stevens, J. (1986). Applied multivariate statistics for the social sciences. Hillsdale, NJ: 
Lawrence Erlbaum Associates. 
Sun, J.C., Hsia, P.H., & Sheu, S.J. (2008). Women of advanced maternal age undergoing 
amniocentesis: a period of uncertainty. Maternal & Neonatal Health, 17, 2829-2837. 
Sundberg K., Bang J., Smidt-Jensen S., Brocks V., Lundsteen C., Parner J., Keiding N., 
and Philip J. (1997). Randomised study of risk of fetal loss related to early amniocentesis 
versus chorionic villus sampling. Lancet,  350  (9079) , pp. 697-703. 
Sutton, S. (1994). The past predicts the future: Interpreting behaviour-behaviour relationships in 
social psychological models of health behaviours. In D. R. Rutter & L. Quine (Eds), Social 
Psychology and Health: European Perspectives, pp. 71-88. Aldeahot: Avebury. 
Tabachnick, B.G.; Fidell, L.S. (2001). Using Multivariate Analysis. Boston: Allyn and Bacon.  
Tabor, A., &Alfirevic, Z. (2010). Update on procedure-related risks for prenatal diagnosis 
techniques. Fetal Diagn Ther, 27, 1–7. 
Tan, J.A., Lee, P.C., Wee, Y.C., Tan, K.L., Mahali, N.F., George, E., & Chua, K.H. (2010). High 
prevalence of Alpha- and Beta-Thalassemia in the Kadazandusuns in East Malaysia: 
challenges in providing effective health care for an indigenous group. Journal of Biomedicine 
and Biotechnology, 2010, 1-5. 
Taylor, H. & Leitman, R. (2002). Four-nation survey shows widespread but different levels of 
internet use for health purposes. Health Care News, 2(11). Available at 
http://harrisinteractive.com/news/newslettershealthcare.asp 
Taylor, I. (2000). Some patients are happy for doctors to make decisions. British Medical 
Journal, 320, 58. 
Tercanli, S., Vial, Y., & Merz, E. (2013). Non-invasive prenatal testing raises concern over 
screening strategies and the role of ultrasound. Ultraschall in Med, 34(5), 417-420. 
Tercyak, K.P., Johnson, S.B., Roberts, S.F., & Cruz, A.C. (2001). Psychological response to 
prenatal genetic counseling and amniocentesis. Patient Eduation and Counseling, 43, 73-84. 
Tiedje, L.B., Kingry, M.J., & Stommel, M. (1992). Patient attitudes concerning health behaviors 
during pregnancy: initial development of a questionnaire. Health Education Quarterly, 19(4), 
481-493. 
Tipping, M.E. & Bishop, C.M. (1999). Mixtures of probabilistic Principal Component Analysers. 
Neural Computation 11(2), 443-482. 
 130 
Trochim, W. M., & Donnelly, J. P. (2006). The research methods knowledge base (3rd ed.). 
Cincinnati, OH: Atomic Dog. 
 
Turriff-Jonasson, S. (2004). Use of prenatal testing, emotional attachment to the fetus and fetal 
health locus of control. Unpublished master’s thesis, University of Saskatchewan, Saskatoon. 
Tversky, A. & Kahneman, D. (1981). The framing of decisions and the psychology of choice. 
Science, 211, 453 - 458. 
Tymstra T. (2007). ‘At least we tried everything’: About binary thinking, anticipated decision 
regret, and the imperative character of medical technology. Journal of Psychosomatic 
Obstetrics & Gynecology, 28(3), 131. 
Tymstra, T. (1989). The imperative character of technology and the meaning of “anticipated 
decision regret”. International Journal of Technology Assessment in Health Care, 5, 207-213. 
Tymstra, T. (1991). Prenatal diagnosis, prenatal screening, and the rise of the tentative 
pregnancy. International Journal of Technology Assessment in Health Care, 7(4), 509-516. 
Ubel, P.A. (2010). Beyond costs and benefits: understanding how patients make health care 
decisions. The Oncologist, 15(suppl 1), 5-10. 
Vahanian, S. A., Baraa Allaf, M., Yeh, C., Chavez, M. R., Kinzler, W. L., & Vintzileos, A. M. 
(2014). Patient acceptance of non-invasive testing for fetal aneuploidy via cell-free fetal DNA. 
The Journal of Maternal-Fetal & Neonatal Medicine, 27(1), 106-109. 
Van den Berg, M., Timmermans, D.R.M., Kleinveld, J.H., Garcia, E., van Vugt, J.M.G., & van 
der Wal, G. (2005). Accepting or declining the offer of prenatal screening for congenital defects: 
test uptake and women’s reasons. Prenatal Diagnosis, 25, 84-90. 
Van den Berg, M., Timmermans, D.R.M., Kleinveld, J.H., van Eijk, J.T.M., Knol, D.L., van der 
Wal, G., & van Vugt, J.M.G. (2007). Are counsellors’ attitudes influencing pregnant women’s 
attitudes and decisions on prenatal screening? Prenatal Diagnosis, 27, 518-524. 
Van den Berg, M., Timmermans, D.R.M., Knol, D.L., Van Eijk, J.T.M., De Smit, D.J., Van Vugt, 
J.M.G., & Van der Wal, G. (2008). Understanding pregnant women’s decision making 
concerning prenatal screening. Health Psychology, 27(4), 430-437. 
Van den Berg, M., Timmermans, D.R.M., Ten Kate, L.P., Van Vugt, J.M.G., & Van der Wal, G. 
(2006). Informed decision making in the context of prenatal screening. Patient Education and 
Counseling, 63, 110-117. 
 131 
Van Schendel, r.v., Dondorp, w.j., Timmermans, D.R., van Hugle, e.j., DE boer, A., Pajkrt, E., 
Lachmeijer, A.M., & Henneman, L. (2015). NIPT-based screening for Down Syndrome and 
beyond: what do pregnant women think? Prenatal Diagnosis, 35(6), 598-604. 
Van Schendel, R.V., Kater-Kuipers, A. van Vliet-Lachotzki, E.H., Dondorp, W.J., Cornel, M.C., & 
Henneman, L. (2016). What do parents of children with Down Syndrome think about non-
invasive prenatal testing (NIPT)? J Genet Counsel, doi:10.1007/s10897-016-0012-4.  
Vanstone, M., King, C., de Vrijer, B., & Nisker, J. (2014). Non-invasive prenatal testing: ethics 
and policy considerations. Journal of Obstetrics and Gynaecology Canada, 36(6), 515-526. 
Venables, W. N. and Ripley, B. D. (2002) Modern Applied Statistics with S. New York: Springer 
(4th ed)  
Vergani, P., Locatelli, A., Biffi, A., Ciriello, E., Zagarella, A., Pezzullo, J, & Ghidini, A. (2002). 
Factors affecting the decision regarding amniocentesis in women at genetic risk because of age 
35 years or older. Prenatal Diagnosis, 22, 769-774. 
Verweij, J., de Boer, M.A., & Oepkes, D. (2014). Non-invasive prenatal testing for trisomy 13: 
more harm than good? Ultrasound Obstet Gynecol, 44, 112-114. 
Vigan, C., Vodovar, V., Goujard, J., Garel, M., Vayssiere, F., Goffinet, F. (2002). European 
Journal of Obstetrics & Gynecology and Reproductive Biology, 104, 14-20. 
Vogt, C.A. & Fesenmaier, D.R. (1998). Expanding the functional information search model. 
Annals of tourism research, 25(3), 551-578. 
Vora, N.L.,& O’Brien, B.M. (2014). Non-invasive prenatal testing for microdeletion syndromes 
and expanded trisomies: proceed with caution. Obstet Gynecol, 123, 1097–1099. 
Wallston, K. A., Maides, S. A., & Wallston, B. S. (1976). Health-related information seeking as a 
function of health-related locus of control and health value. Journal of Research in Personality, 
10, 215-222. 
Wallston, K. A., Wallston, B. S.,&DeVellis, R. (1978). Development of the multidimensional 
health locus of control (MHLC) scales. Health Education Monographs, 6, 160-170. 
Wallston, K.A. (2005). The validity of the Multidimensional Health Locus of Control Scales. 
Journal of Health Psychology, 10, 623-631. 
Wallston, K.A.& Wallston, B.S. (2005).The validity of the multidimensional Health Locus of 
Control Scales.Journal of Health Psychology, 10(4), 623-631. 
 132 
Wang, E., Batey, A., Struble, C., Musci, T., Song, K., & Oliphant, A. (2013). Gestational age and 
maternal weight effects on cell-free DNA in maternal plasma. Prenatal Diagnosis, 33, 662-666. 
Weatherall D.J. (2000). Single gene disorders of complex traits: lessons from the thalassaemias 
and other monogenic diseases. BMJ, 321(7269), 1117-1120. 
Weatherall D.J., Akinyanju O., Fucharoen S., Olivieri N. & Musgrove P. (2006). Inherited 
disorders of Haemoglobin. In: Disease control priorities in developing countries (ed. by Jamison 
D. et al), pp. 663-680. Oxford University and the World Bank, New York. 
Weil, J. (2003). Psychosocial genetic counseling in the post-nondirective era:a point of view. J 
Genet Couns12,199–211. 
Weinans, M.J.N., Huijssoon, A.M.G., Gerrits, M.C.F., Beekhuis, J.R., & Mantingh, A. (2000). 
How women deal with the results of serum screening for Down syndrome in the second 
trimester of pregnancy. Prenatal Diagnosis, 20, 705-708. 
Welkenhuysen, M., Evers-Kiebooms, G., & Ydewalle, G. (2001). The language of uncertainty in 
genetic risk communication: framing and verbal versus numerical information. Patient Education 
and Counseling, 43, 179-187. 
Wertz, D.C., &Fletcher, J.C. (1993).A critique of some feminist challenges to prenatal diagnosis. 
J Womens Health, 2, 173–188. 
WHO (2006). Joint WHO-March of Dimes meeting on the management of birth defects and 
haemoglobin disorders. Geneva: WHO. 
Widaman, K.F. (1993). Common factor analysis versus principal component analysis: 
differential bias in representing model parameters? Multivariate Behavioral Research, 28(3), 
263-311. 
Williams C., Anderson P., & Farsides B. (2002). Is nondirectiveness possible within the context 
of antenatal screening and testing? Social Science Medicine, 54, 339-347. 
Williams, C., Alderson, P., & Farsides, B. (2002) Too Many Choices? Hospital and community 
staff reflect on the future of prenatal screening. Social Science & Medicine, 55, 743-753. 
Yagel, S. (2013).  Non-invasive prenatal testing: more questions than answers. Ultrasound 
Obstet Gynecol , 42, 369–372. 
Zamerowski, S.T., Lumley, M.A., Arreola, R.A., Dukes, K., & Sullivan, L. (2001).Favourable 
attitudes toward testing for chromosomal abnormalities via analysis of fetal cells in maternal 
blood.Genetics in Medicine, 3(4), 301-309. 
 133 
Ziefle, M. & Shaar, M.K. (2011). Gender differences in acceptance and attitudes towards an 
invasive medical stent. Electronic Journal of Health Informatics, 6(2), 13-30. 
Zigmond, A. S., &Snaith, R.P. (1983). TheHospital Anxiety and Depression Scale, Acta 
Psychiatrica Scandinavica, 67, 361-370. 
Zikmund-Fisher, B.J., Fagerlin, A., Keeton, K., & Ubel, P.A. (2007). Does labelling prenatal 
screening test results as negative or positive affect a woman’s responses? American Journal of 
Obstetrics & Gynecology, 197:528.e1-528.e6. (doi: 10.1016/j.ajog.2007.03.076) 
Zlotogora, J. (2002). Parental decisions to abort or continue a pregnancy with an abnormal 
finding after an invasive prenatal test. Prenatal Diagnosis, 22, 1102-1106.  
 134 
6. Appendixes 
6.1. Appendix 1: Original Questionnaire (pilot study) 
 
 135 
 
 
 
 
 
 
 
 136 
 
 
 
 
 
 137 
 
 
 
 
 
 138 
 
 
 
 
 
 139 
 
 
 
 
 
 140 
 
 
 
 
 
 141 
 
 
 
 
 
 142 
 
 
 
 
 
 143 
 
 
 
 
 
 144 
6.2. Appendix 2: Consent Form (pilot study) 
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6.3. Appendix 3: Information Sheet (pilot study) 
 
 
                                               Chief Investigator: Marilena Tzafettas 
                                                                                   London Metropolitan University 
                                                                                   Department of Psychology 
                                                                                   166-220 Holloway Road 
                                   N7 8DB                                   
                                                                                   E-mail: m.tzafettas@londonmet.ac.uk 
 
PARTICIPANT INFORMATION SHEET 
Study Title: Factors implicated in women’s decision-making process 
regarding the uptake of amniocentesis/CVS 
We would like to invite you to take part in a research study. Before you decide we would like 
you to understand why the research is being done and what it would involve for you, so please 
take the time to read the following information carefully. You may also wish to talk to others 
about the study, and please feel free to ask us if there is anything that is not clear to you or if 
you would like more information.  
  
What is the purpose of the study? 
The purpose of the study is to explore the different factors which may impact on a woman’s 
decision to have an amniocentesis/CVS or not. Amniocentesis/CVS are similar tests that may or 
may not be offered to you depending on the results of your first trimester ultrasound scan (your 
doctor will give you more information about this procedure if considered appropriate). Past 
research has shown that when faced with such a decision a woman may be influenced by her 
own feelings and thoughts, and possibly by those of people she is close to. However, previous 
studies have not looked at a combination of these factors which will be the focus of this study. 
We understand that this is a very sensitive issue, and we are hoping that with your help we will 
be able to help women in the future decide whether or not they want to have an 
amniocentesis/CVS. 
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Why have I been invited to take part? 
You have been invited to take part because you are above 18 years of age and have not yet 
had your 1
st
 trimester screening ultrasound (11
th
-14
th
 week of gestation), therefore meeting the 
criteria for the population under study. We are contacting all women in this stage of their 
pregnancy, who are under the care of King’s College Hospital. Being asked to take part does 
not mean you are more likely to need amniocentesis/CVS.  
Do I have to take part? 
No, it is up to you to decide to join the study. If you agree to take part, you will be asked to sign 
a consent form. You are free to withdraw at any time, without giving a reason and this would not 
affect the standard of care you receive. If, at any point after handing in your questionnaire you 
decide that you do not wish to be included in the analysis of the study please contact the Chief 
Investigator at m.tzafettas@londonmet.ac.uk who will immediately remove and manually 
destroy your data. 
What will happen to me if I take part and what will I have to do? 
If you decide to take part in the study, you will be asked to fill out a questionnaire, which should 
take up to 30-40 minutes to complete. You will then be asked to return the completed 
questionnaire to the researcher, together with your signed consent form, using the enclosed 
pre-stamped envelope (or alternatively bring it with you to your scan appointment). 
Please note that after completing the questionnaire your medical records will have to be 
accessed in order to determine whether you had an amniocentesis/CVS or not. This is essential 
for the outcome of this study and will strictly be done by members of your medical team who will 
maintain confidentiality and not disclose any personal information. 
What are the possible disadvantages and risks of taking part? 
This study addresses sensitive issues relating to pregnancy, and therefore carries the risk of 
causing feelings of distress. Information about relevant help-lines is provided on the debrief 
form so that you can access appropriate 24-hour support, but it is still very important for you to 
consider whether this is a sensitive topic for you, before deciding whether to participate or not. 
What are the possible benefits of taking part? 
We cannot promise that the study will help you, but we hope that it will offer you the opportunity 
to reflect on issues that might have not previously occurred to you in relation to your pregnancy 
and that this might help you in the decisions you may have to make regarding prenatal 
screening. In addition, we hope that the results of this study will contribute to a better 
understanding of the factors that mostly influence women in their decision to have an 
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amniocentesis/CVS or not. This information may then be used by health professionals in order 
to support women in their decision. 
What happens when the research study stops?  
When the study is finished and we have analysed all the information, we aim to publish what we 
have found in relevant academic journals. We also hope to present the findings of the study at 
conferences but we will ensure that no individual participants in the study can be identified. You 
may also leave a contact e-mail address, if you wish to be informed of the results personally, 
although this will be a summary of the total results and not your individual score.  
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6.4. Appendix 4: Debrief Sheet (pilot study) 
 
 
DEBRIEF SHEET 
Thank you for taking part in this study which is part of my PhD in the area of Health Psychology 
at London Metropolitan University. The data from this study will be analysed to provide insight 
to the factors that may be implicated in women’s decision making processes regarding the 
uptake of amniocentesis/CVS. Your personal details will not be included in this process. The 
researcher is only interested in group effects rather than data from a single individual.  
By providing evidence for those particular factors which may influence women in the important 
decision of whether they should undergo amniocentesis/CVS, we can further inform health 
professionals who support women during their pregnancy especially in regard to making the 
decision to have an invasive test. 
If you have any questions regarding this study please feel free to contact us at 
m.tzafettas@londonmet.ac.uk and we will be happy to answer any questions or receive any 
comments/feedback. 
We would also like to take this opportunity to remind you that your responses are confidential 
and all results are published anonymously as group data.  However, you still have the right to 
withdraw you responses, as your participation is completely voluntary.  To do this, simply email 
us and we will be happy to remove your data.   
If you would like to talk to someone or find out information about where you can receive help for 
any health related problems or concerns related to your pregnancy, the following registered 
agencies may be useful to you: 
➢ CareConfidential Helpline :    0800 028 2228 
CareConfidential Pregnancy Helpline offers a safe place to talk in confidence about any 
concerns you may have relating to pregnancy, or any difficulties you may be 
experiencing following an abortion, miscarriage, child loss or child separation. 
➢ The National Childbirth Trust – Pregnancy & Birth Line:    0300 330 0772 
Fully qualified antenatal teachers can answer all your questions relating to pregnancy 
or birth. 
➢ The National Childbirth Trust - Shared Experiences Helpline:  0300 330 0774 
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This helpline is run by volunteers who have had challenging experiences of pregnancy, 
birth, and parenthood and can provide a listening ear and support for you. 
If you have any specific concerns about your pregnancy we advise that you also speak to your 
GP, midwife or consultant.  
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6.5. Appendix 5: Voucher for prize draw 
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6.6. Appendix 6: Correlation Matrix 
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6.7. Appendix 7: Oblique Rotation 
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6.8. Appendix 8: Cronbach alpha SPSS output 
 
Scale: Perceived behavioural control 
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Scale: attitude towards chromosomal abnormalities 
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Scale: Benefits of amniocentesis/CVS 
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6.9. Appendix 9: Cronbach alpha SPSS output (previously validate scales) 
 
Scale: HADS - Anxiety scale 
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Scale: Attitudes towards doctors & medicine 
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Scale: HLOC scale 
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6.10. Appendix 10: Amended Questionnaire (main study) 
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6.11. Appendix 11: Information Sheet (main questionnaire study) 
 
 
                                               Chief Investigator: Marilena Tzafettas 
                                                                                   London Metropolitan University 
                                                                                   Department of Psychology 
                                                                                   166-220 Holloway Road 
                                   N7 8DB                                   
                                                                                   E-mail: m.tzafettas@londonmet.ac.uk 
 
PARTICIPANT INFORMATION SHEET 
Study Title: Factors implicated in women’s decision-making regarding the uptake of prenatal 
diagnostic tests 
We would like to invite you to take part in a research study. Before you decide we would like 
you to understand why the research is being done and what it would involve for you, so please 
take the time to read the following information carefully. You may also wish to talk to others 
about the study, and please feel free to ask us if there is anything that is not clear to you or if 
you would like more information.  
What is the purpose of the study? 
The purpose of this study is to explore the different factors which may impact on a woman’s 
decision to have a prenatal diagnostic test or not. Diagnostic tests include the option of amnio / 
CVS or Harmony. Amniocentesis and CVS are tests that may have been offered to you if you 
were found to have an increased risk following your first trimester ultrasound scan (if not 
already, your doctor will give you more information about these procedures if considered 
relevant). Harmony is a blood test and you may have been offered this choice if you were found 
to be at moderate – high risk. Past research has shown that when faced with such a decision a 
woman may be influenced by her own feelings and thoughts, and possibly by those of people 
she is close to. However, previous studies have not looked at a combination of these factors 
which will be the focus of this study. We understand that this is a very sensitive issue, and we 
are hoping that with your help we will be able to help women in the future decide whether or not 
they want to have a prenatal diagnostic test and support them in making the right choice for 
them. 
Why have I been invited to take part? 
You have been invited to take part because you are above 18 years of age and have been 
offered the option of one of the above tests, therefore meeting the criteria for the population 
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under study. We are contacting all women in this stage of their pregnancy, who are under the 
care of King’s College Hospital.  
Do I have to take part? 
No, it is up to you to decide to join the study. If you agree to take part, you will be asked to sign 
a consent form. You are free to withdraw at any time, without giving a reason and this would not 
affect the standard of care you receive. If, at any point after handing in your questionnaire you 
decide that you do not wish to be included in the analysis of the study please contact the Chief 
Investigator at m.tzafettas@londonmet.ac.uk who will immediately remove and manually 
destroy your data. 
What will happen to me if I take part and what will I have to do? 
If you decide to take part in the study, you will be asked to fill out a questionnaire, which should 
take up to 20 minutes to complete. You will then be asked to return the completed questionnaire 
to the researcher, together with your signed consent form, using the enclosed pre-stamped 
envelope. 
What are the possible disadvantages and risks of taking part? 
This study addresses sensitive issues relating to pregnancy, and therefore carries the risk of 
causing feelings of distress. Information about relevant help-lines is provided on the debrief 
form so that you can access appropriate 24-hour support, but it is still very important for you to 
consider whether this is a sensitive topic for you, before deciding whether to participate or not. 
What are the possible benefits of taking part? 
We cannot promise that the study will help you, but we hope that the results of this study will 
contribute to a better understanding of the factors that mostly influence women in their decision 
to have a prenatal diagnostic test or not. This information may then be used by health 
professionals in order to support women in their decision. 
What happens when the research study stops?  
When the study is finished and we have analysed all the information, we aim to publish what we 
have found in relevant academic journals. We also hope to present the findings of the study at 
conferences but we will ensure that no individual participants in the study can be identified. You 
may also leave a contact e-mail address, if you wish to be informed of the results personally, 
although this will be a summary of the total results and not your individual score.  
What if there is a problem? 
We think it is unlikely that anyone will be harmed by taking part in this study. However, if you 
wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal London Metropolitan 
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University complaints mechanisms will be available to you. Please direct concerns to Dr Esther 
Murray, who will be supervising this project, at e.murray@londonmet.ac.uk 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. All questionnaires will remain anonymous, and will be kept separately from the 
consent forms so as not to be linked to individuals. All files will be safely stored in a place where 
no one outside the research team will have access, and will be destroyed after the end of the 
study. 
Who is organising and funding the research? 
The research is being carried out at King’s College Hospital by Marilena Tzafettas, Dr Esther 
Murray, Dr Elizabeth Charman and Dr David Hardman of London Metropolitan University, and 
Professor Kypros Nicolaides of King’s College. They have the responsibility for ensuring that 
this research study is conducted safely, ethically, and according to best practice has no 
financial interest. 
Who has reviewed the study? 
All research in the NHS is looked at by independent groups of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and given a favourable 
opinion by the London – Stanmore National Research Ethics Service Committee. 
Contact for Further Information 
If you are interested in taking part in the study please complete the consent form attached to 
this information sheet, and return it to the researcher together with the completed 
questionnaire using the enclosed pre-stamped envelope. If you have any questions please feel 
free to contact the chief investigator, Marilena Tzafettas at m.tzafettas@londonmet.ac.uk . 
Alternatively you can contact the local principal investigator, Professor Kypros Nicolaides at 
kypros@fetalmedicine.com.  
Thank you for taking the time to read this information sheet. Please find enclosed a box of  
“Pregnacare” vitamin and folic acid supplements which are yours to keep regardless of whether 
you decide to participate in the study or not. 
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6.12. Appendix 12: Consent Form (main questionnaire study) 
 
 
 
CONSENT FORM 
 
Patient Identification Number (to be filled out by the researcher):  _______________ 
 
Title of project: “Factors implicated in women’s decision-making regarding the uptake of 
prenatal diagnostic tests” 
 
Name of researcher: Marilena Tzafettas 
 
Please tick the boxes: 
1. I confirm that I have read and understand the information sheet dated ................ for 
the above study. I have had the opportunity to consider the information, ask questions 
and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected. 
 
3. I agree to take part in the above study.  
 
 
 
__________________________ 
         (name of participant) 
____________ 
        (date) 
   _________________ 
           (signature) 
 
__________________________ 
(name of person taking consent) 
   
_____________ 
       (date) 
  
__________________ 
           (signature) 
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PLEASE RETURN THIS SIGNED FORM TOGETHER WITH YOUR COMPLETED 
QUESTIONNAIRE 
Version 3 – 04/02/2014 
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6.13. Appendix 13: Debrief Sheet (Main questionnaire study) 
 
 
DEBRIEF SHEET 
Thank you for taking part in this study which is part of my PhD in the area of Health Psychology 
at London Metropolitan University. The data from this study will be analysed to provide insight 
to the factors that may be implicated in women’s decision making regarding the uptake of 
prenatal diagnostic tests. Your personal details will not be included in this process. I am only 
interested in group effects rather than data from a single individual.  
By providing evidence for those particular factors which may influence women in the important 
decision of whether they should undergo a prenatal diagnostic test, we can further inform health 
professionals who support women during their pregnancy especially in regard to making the 
decision to have a prenatal diagnostic test. 
If you have any questions regarding this study please feel free to contact me at 
m.tzafettas@londonmet.ac.uk and I will be happy to answer any questions or receive any 
comments/feedback. 
I would also like to take this opportunity to remind you that your responses are confidential and 
all results are published anonymously as group data.  However, you still have the right to 
withdraw your responses, as your participation is completely voluntary.  To do this, simply email 
me and I will be happy to remove your data.   
If you would like to talk to someone or find out information about where you can receive help for 
any health related problems or concerns related to your pregnancy, the following registered 
agencies may be useful to you: 
Ø CareConfidential Helpline :    0800 028 2228 
CareConfidential Pregnancy Helpline offers a safe place to talk in confidence about any 
concerns you may have relating to pregnancy, or any difficulties you may be experiencing 
following an abortion, miscarriage, child loss or child separation. 
Version 3 – 04/02/2014 
Ø The National Childbirth Trust – Pregnancy & Birth Line:    0300 330 0772 
Fully qualified antenatal teachers can answer all your questions relating to pregnancy or birth. 
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Ø The National Childbirth Trust - Shared Experiences Helpline:  0300 330 0774 
This helpline is run by volunteers who have had challenging experiences of pregnancy, birth, 
and parenthood and can provide a listening ear and support for you. 
If you have any specific concerns about your pregnancy we I advise that you also speak to your 
GP, midwife or consultant. 
 
Version 3 – 04/02/2014 
 
